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Abstract 
The emergence of multi and extensively drug resistant tuberculosis (MDRTB and 
XDRTB) has increased the concern of public health authorities around the world. The 
World Health Organization has defined MDRTB as tuberculosis (TB) caused by 
organisms resistant to at least isoniazid and rifampicin, the main first-line drugs used in 
TB therapy, whereas XDRTB refers to TB resistant not only to isoniazid and rifampicin, 
but also to a fluoroquinolone and to at least one of the three injectable second-line 
drugs, kanamycin, amikacin and capreomycin. Resistance in Mycobacterium 
tuberculosis is mainly due to the occurrence of spontaneous mutations and followed by 
selection of mutants by subsequent treatment. However, some resistant clinical 
isolates do not present mutations in any genes associated with resistance to a given 
antibiotic, which suggests that other mechanism(s) are involved in the development of 
drug resistance, namely the presence of efflux pump systems that extrude the drug to 
the exterior of the cell, preventing access to its target. Increased efflux activity can 
occur in response to prolonged exposure to subinhibitory concentrations of anti-TB 
drugs, a situation that may result from inadequate TB therapy. The inhibition of efflux 
activity with a non-antibiotic inhibitor may restore activity of an antibiotic subject to 
efflux and thus provide a way to enhance the activity of current anti-TB drugs.  
The work described in this thesis foccus on the study of efflux mechanisms in the 
development of multidrug resistance in M. tuberculosis and how phenotypic resistance, 
mediated by efflux pumps, correlates with genetic resistance. In order to accomplish 
this goal, several experimental protocols were developed using biological models such 
as Escherichia coli, the fast growing mycobacteria Mycobacterium smegmatis, and 
Mycobacterium avium, before their application to M. tuberculosis. This approach 
allowed the study of the mechanisms that result in the physiological adaptation of E. 
coli to subinhibitory concentrations of tetracycline (Chapter II), the development of a 
fluorometric method that allows the detection and quantification of efflux of ethidium 
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bromide (Chapter III), the characterization of the ethidium bromide transport in M. 
smegmatis (Chapter IV) and the contribution of efflux activity to macrolide resistance in 
Mycobacterium avium complex (Chapter V). Finally, the methods developed allowed 
the study of the role of efflux pumps in M. tuberculosis strains induced to isoniazid 
resistance (Chapter VI). 
By this manner, in Chapter II it was possible to observe that the physiological 
adaptation of E. coli to tetracycline results from an interplay between events at the 
genetic level and protein folding that decrease permeability of the cell envelope and 
increase efflux pump activity. Furthermore, Chapter III describes the development of a 
semi-automated fluorometric method that allowed the correlation of this efflux activity 
with the transport kinetics of ethidium bromide (a known efflux pump substrate) in E. 
coli and the identification of efflux inhibitors.  
Concerning M. smegmatis, we have compared the wild-type M. smegmatis mc2155 
with knockout mutants for LfrA and MspA for their ability to transport ethidium bromide. 
The results presented in Chapter IV showed that MspA, the major porin in M. 
smegmatis, plays an important role in the entrance of ethidium bromide and antibiotics 
into the cell and that efflux via the LfrA pump is involved in low-level resistance to these 
compounds in M. smegmatis.  
Chapter V describes the study of the contribution of efflux pumps to macrolide 
resistance in clinical M. avium complex isolates. It was demonstrated that resistance to 
clarithromycin was significantly reduced in the presence of efflux inhibitors such as 
thioridazine, chlorpromazine and verapamil. These same inhibitors decreased efflux of 
ethidium bromide and increased the retention of [14C]-erythromycin in these isolates. 
Finaly, the methods developed with the experimental models mentioned above allowed 
the study of the role of efflux pumps on M. tuberculosis strains induced to isoniazid 
resistance. This is described in Chapter VI of this Thesis, where it is demonstrated that 
induced resistance to isoniazid does not involve mutations in any of the genes known 
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to be associated with isoniazid resistance, but an efflux system that is sensitive to 
efflux inhibitors. These inhibitors decreased the efflux of ethidium bromide and also 
reduced the minimum inhibitory concentration of isoniazid in these strains. Moreover, 
expression analysis showed overexpression of genes that code for efflux pumps in the 
induced strains relatively to the non-induced parental strains. 
In conclusion, the work described in this thesis demonstrates that efflux pumps play an 
important role in the development of drug resistance, namely in mycobacteria. A 
strategy to overcome efflux-mediated resistance may consist on the use of compounds 
that inhibit efflux activity, restoring the activity of antimicrobials that are efflux pump 
substrates, a useful approach particularly in TB where the most effective treatment 
regimens are becoming uneffective due to the increase of MDRTB/XDRTB. 
 
 
 
 ____________________________________________________________ 
____________________________________________________________ 
 
xvii 
 
Resumo 
O aumento da tuberculose multirresistente e extensivamente resistente (TBMR e 
TBXDR) gerou um agravamento das preocupações por parte das autoridades de 
Saúde Pública em todo o mundo. A Organização Mundial de Saúde (OMS) define 
TBMR como tuberculose (TB) resistente pelo menos à isoniazida e à rifampicina, os 
principais fármacos de primeira-linha utilizados no tratamento da TB, enquanto que a 
TBXDR  refere-se a casos de TB resistente não só à isoniazida e  à rifampicina, mas 
também a uma fluoroquinolona e a pelo menos a um dos três fármacos de segunda-
linha injectáveis canamicina, amicacina e capreomicina. A resistência em 
Mycobacterium tuberculosis deve-se principalmente à ocorrência de mutações 
espontâneas, à qual se segue a selecção de mutantes resistentes durante o 
tratamento. No entanto, algumas estirpes clínicas de M. tuberculosis resistentes não 
apresentam mutação em qualquer um dos genes que se sabe estarem associados à 
aquisição de resistência a um determinado fármaco, o que sugere que outro(s) 
mecanismo(s) deverão estar envolvidos no desenvolvimento de resistência, 
nomeadamente a presença de sistemas de bombas de efluxo que efectuam a extrusão 
do composto para o exterior da célula, evitando que o mesmo atinja o seu alvo. Um 
aumento da actividade de efluxo pode ocorrer devido a uma exposição prolongada a 
concentrações subinibitórias dos antibacilares, uma situação que pode resultar de uma 
terapia inadequada. A inibição da actividade de efluxo com um inibidor que não seja 
um antibiótico poderá restaurar a actividade de um antibiótico que seja substrato de 
bombas de efluxo e desta forma consistir uma forma de aumentar a actividade dos 
actuais fármacos utilizados no tratamento da TB.  
O trabalho descrito nesta dissertação tem como objectivo o estudo dos mecanismos 
de efluxo no desenvolvimento de multirresistência em M. tuberculosis e de como a 
resistência fenotípica mediada por bombas de efluxo se correlaciona com a resistência 
genética. De forma a alcançar este objectivo, foram desenvolvidos vários protocolos 
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experimentais utilizando modelos biológicos, tais como Escherichia coli, 
Mycobacterium smegmatis uma micobactéria de crescimento rápido e Mycobacterium 
avium, antes da sua aplicação ao estudo de M. tuberculosis. Esta abordagem permitiu 
o estudo dos mecanismos que resultam na adaptação fisiológica de E. coli à 
tetraciclina por exposição a concentrações subinibitórias deste antibiótico (Capítulo II), 
o desenvolvimento de um método fluorimétrico que permite a detecção e quantificação 
da actividade de efluxo (Capítulo III), a caracterização do transporte de brometo de 
etídeo em M. smegmatis (Capítulo IV) e a contribuição da actividade de efluxo para a 
resistência aos macrólidos no complexo Mycobacterium avium (Capítulo V). Por fim, 
os métodos desenvolvidos permitiram o estudo do papel das bombas de efluxo em 
estirpes de M. tuberculosis induzidas a resistência à isoniazida. 
Assim, como descrito no Capítulo II, foi possível observar que a adaptação fisiológica 
de E. coli à presença de tetraciclina resulta de uma interacção entre mecanismos a 
nível genético e modificações pós-traducionais a nível da conformação de proteínas 
que diminui a permeabilidade da parede celular e aumenta a actividade das bombas 
de efluxo. Para além disso, o Capítulo III descreve o desenvolvimento de um método 
fluorimétrico semi-automático que permitiu correlacionar esta actividade de fluxo com a 
cinética de transporte do brometo de etídeo (um conhecido substrato de bombas de 
efluxo) em E. coli e também a identificação de inibidores do efluxo.  
Relativamente a M. smegmatis, comparou-se a estirpe selvagem M. smegmatis 
mc2155 com mutantes "knockout" para LfrA e MspA, no que respeita à sua capacidade 
de transportar brometo de etídeo. Os resultados apresentados no Capítulo IV 
demonstraram que MspA, a principal porina de M. smegmatis, desempenha um papel 
importante na entrada de brometo de etídeo e antibióticos na célula e que o efluxo 
através da bomba LfrA está envolvido na resistência de baixo nível a estes compostos 
em M. smegmatis. 
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O Capítulo V descreve o estudo da contribuição de bombas de efluxo na resistência 
aos macrólidos em estirpes clínicas do complexo M. avium. Demonstrou-se que a 
resistência à claritromicina sofreu uma redução significativa na presença dos inibidores 
de efluxo tioridazina, clorpromazina e verapamil. Estes inibidores também diminuíram 
o efluxo de brometo de etideo e aumentaram a retenção de eritromicina marcada com 
14C nestas estirpes. 
Por fim, os métodos desenvolvidos com os modelos experimentais referidos acima 
permitiram o estudo do papel das bombas de efluxo em estirpes de M. tuberculosis 
induzidas à resistência à isoniazida. Este trabalho encontra-se descrito no Capítulo VI 
desta dissertação, onde se demonstra que a indução de resistência à isoniazida não 
resultou da ocorrência de mutações em qualquer um dos genes associados com a 
resistência a este fármaco, mas de um sistema de efluxo que é sensível a inibidores 
do efluxo. Estes inibidores provocaram a diminuição do efluxo de brometo de etídeo e 
também a redução da concentração mínima inibitória da isoniazida nestas estirpes. 
Para além disso, a análise de expressão genética demonstrou a sobre-expressão de 
genes que codificam para bombas de efluxo nas estirpes induzidas comparativamente 
com as estirpes originais não induzidas. 
 Concluindo, o trabalho descrito nesta dissertação demonstra que as bombas de efluxo 
desempenham um papel importante no desenvolvimento de resistência, em particular 
nas micobactérias. Uma estratégia para ultrapassar a resistência mediada por 
mecanismos de efluxo poderia passar pela utilização de compostos que inibem a 
actividade de efluxo, restaurando a actividade de antimicrobianos que são substratos 
de bombas de efluxo, uma abordagem útil particularmente em TB em que os regimes 
de tratamento mais eficazes se estão a tornar ineficazes face ao aumento da 
TBMR/TBXR. 
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 Introduction 
 
I.1 Tuberculosis 
 
I.1.1 The global burden of Tuberculosis  
Tuberculosis (TB) has been part of human history for thousands of years and signs of 
this disease have been found since antiquity with the identification of mycobacterial 
deoxyribonucleic acid (DNA) in Ancient Egypt mummies dated between 3000 and 2400 
years B.C. (Crubezy E. et al, 1998; Donoghue H.D. et al, 2004; Rothschild B. et al, 
2001). In Ancient Greece, Hippocrates described TB as phthysis or consumption, a 
term by which this disease was known until the early 20th century. At the beginning of 
the 17th century and for the next 200 years, the TB epidemic (known as the Great 
White Plague) started in Europe and became the major cause of mortality (Bates J.H. 
et al, 1993). However, despite the long co-existence of TB and mankind, 
Mycobacterium tuberculosis, the agent responsible for this infection in Man, was 
described only in 1882 by Robert Koch (Koch, R. 1882). 
 
In the early 20th century, the general improvement in public health in Europe and in the 
United States of America (U.S.A) helped to reduce the burden of TB. The 
establishment of TB control programmes, along with the introduction of a successful 
anti-TB treatment, resulted in an evident decrease of infection and mortality. In the 
middle of the 20th century, the fact that the disease was considered so close to 
elimination caused a decreased interest of the industrialized countries and, 
consequently, the abandonment of the TB control programmes. In fact, it was 
considered that the recent developments in anti-mycobacterial chemotherapy had 
determined the disappearance of the disease as a public health problem. However, 
despite the decrease of TB cases, the disease never disappeared completely and 
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around 1985, TB began to increase again in industrialized countries (Brudney K. et al, 
1991; Daniel T.M., 2006). The other major factor that contributed for this resurgence, 
along with the decline of the TB control programmes, was the advent of the human 
immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) (Brudney K. 
et al, 1991). Today, TB gained once more the attention of the international community 
and is still without doubt one of the major threats to public health. In 1993, the World 
Health Organization (WHO) declared TB a global health emergency and in 1998, 
together with the International Union Against Tuberculosis and Lung Disease (IUATLD) 
and other international partners, formed the Stop TB Initiative, a new global strategy to 
control TB that has recently evolved into a global partnership, the Stop TB Partnership 
(Stop TB Partnership, 2006). However, despite of these global efforts, TB is still a 
major threat. In fact, the WHO estimates that one third of the world population 
(approximately two billion people) is infected with M. tuberculosis, with eight million 
new cases of TB every year and two million deaths from TB each year (WHO, 2009). 
The higher rates of TB (≥ 300/100 000 inhabitants/year) occur in Sub-Saharan Africa, 
Indonesia and Philippines (Figure I.1). If effective TB control programmes are not 
created, WHO estimates that in 2020 M. tuberculosis will infect approximately 1000 
million people, 150 million will develop the disease and 36 million will die of TB (WHO, 
2009). 
 
The global resurgence of TB is not only related with the higher rates of co-infection with 
HIV, but also with the emergence of M. tuberculosis strains resistant to anti-TB drugs. 
An example was the extensive outbreak of TB in New York City in the early 1990’s. 
This form of TB was resistant to the most effective anti-TB drugs and occurred mainly 
in patients co-infected with HIV. In fact, one in three new cases were found resistant to 
one drug and one in five to more than one drug (Frieden T.R. et al, 1996).  
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Figure I.1. Global incidence of TB. Estimated number of new TB cases per 100 000 population 
for 2007 (Comas I. et al, 2009; WHO, 2009).  
 
WHO defined multidrug resistant TB (MDRTB) as TB cases caused by M. tuberculosis 
strains resistant, simultaneously, to isoniazid (INH) and rifampicin (RIF), two of the first-
line drugs used to treat TB. It is estimated that 50 million people are infected with M. 
tuberculosis strains resistant to anti-TB drugs, with 300 000 news cases of MDRTB 
each year (WHO/ IUATLD, 2008). Recently, a new form of TB has been reported that 
presents resistance not only to first-line drugs, but also to second-line drugs (Figure 
I.2). The WHO has defined this form of TB as extensively drug resistant TB (XDRTB) 
and refers to M. tuberculosis strains that present resistance not only to INH and RIF 
(MDRTB), but also to any fluoroquinolone and at least to one of the three injectable 
second-line drugs kanamycin, amikacin and capreomycin (WHO, 2006). XDRTB can 
develop when these second-line drugs are misused or mismanaged and, consequently, 
become ineffective (Migliori G.B. et al, 2007).  
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Figure I.2. Countries that reported at least one XDRTB case by the end of 2008 (WHO, 2009). 
 
I.1.2 Tuberculosis in Portugal 
Concerning the situation of TB in Portugal, the rates of new TB cases are the highest 
for Western Europe, although small gradual declines were evident in recent years. In 
2003, the Portuguese Health Authorities reported 34.4 cases of TB per 100 000 
inhabitants, with 1.8% cases of MDRTB (DGS, 2008). In Lisbon, the rates of MDRTB 
were as high as 28% in 2003 and declined to less than 8% by 2006 (new cases plus 
re-treatments) (DGS, 2003; DGS, 2007). However, in Porto, the second largest city of 
Portugal, the rates of MDRTB continue to escalate (DGS, 2003; DGS, 2007).  
In Portugal, the majority of the MDRTB strains circulating in the Lisbon Health Region 
belong to family Lisboa, a particular family of strains genetically related. This family 
was involved in an outbreak of MDRTB, mainly in HIV patients, 10 years ago (Portugal 
I. et al, 1999). Over the past years, this family of strains has been associated almost 
exclusively to MDRTB, with a prevalence of about 50% in 2001-2002, 56% in 2003 and 
88% in 2004-2006 (Perdigão J. et al, 2008). Recently, MDRTB has progressed to 
XDRTB, representing in Lisbon about 50% of the MDRTB strains (Perdigão J. et al, 
2008). The use of the mycobacterial inter-spersed repetitive units–variable number of 
tandem repeats (MIRU–VNTR) technique showed that XDRTB strains are clustered in 
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two different, but related profiles that belong to family Lisboa, and are probably a result 
of more than 10 years of family Lisboa MDRTB strains circulating in Portugal. These 
strains while mainly detected in the Lisbon Region, disseminated to other regions of the 
country, turning family Lisboa into a threat to the control of TB in Portugal. 
 
I.2 Mycobacterium sp - General Characteristics 
Mycobacterium is the only genus of the Family Mycobacteriaceae, included in Order 
Actinomycetales, Phylum Actinobacteria and it is presumed to have originated more 
than 150 million years ago (Daniel T.M., 2006; Gutierrez C. et al, 2005). Mycobacteria 
are straight or slightly curved rods between 0.2-0.6 µm wide by 1.0-10 µm long, aerobic 
with optimum growth temperatures that vary according to the species and range from 
25°C to 37ºC. Mycobacteria also have a genomic DNA with a high guanine plus 
cytosine (G+C) content (61-71%) and a characteristic cell-wall that will be described in 
Section I.2.2.  
 
I.2.1 Classification of mycobacteria 
Mycobacteria can be separated into different groups according to their phenotypic 
characteristics. The most used classification system was created by Runion in 1959 
and establishes four groups based on culture characteristic, the incubation period 
required for growth and the development of pigmentation in the presence/absence of 
light (Runyon E.H. 1959; Eisenstadt J. et al, 1995). The first three groups include                                                                      
slow growth mycobacteria that require longer periods of incubation (e.g. M. 
tuberculosis) and the fourth group comprises rapid growth mycobacteria that form 
colonies within seven days of incubation (e.g. M. smegmatis): 
o Group 1 (Photochromogens) – mycobacteria that produce nonpigmented colonies 
when grown in the dark and pigmented colonies only after exposure to light (e.g.: 
M. kansasii, M. marinum);  
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o Group 2 (Scotochromogens) – mycobacteria that produce yellow to orange 
colonies when grown in the dark (e.g.: M. gordonae, M. xenopi); 
o Group 3 (Non-chromogens) – mycobacteria nonpigmented in the light or dark. 
However, older cultures can develop a yellow pigmentation  (e.g. M. tuberculosis, 
M. avium, M. bovis, M. ulcerans); 
o Group 4 – rapid growth mycobacteria that have a slight yellow pigment that does 
not intensify after light exposure (e.g. M. fortuitum, M. chelonae).  
 
The majority of mycobacteria identified until now are environmental and/or commensal 
to Man (non-pathogenic mycobacteria). However, there are some species that are 
strictly pathogenic to Man and/or animals (strictly pathogenic mycobacteria). There is 
also a group of mycobactera usually commensal to Man, but they can become 
pathogenic in certain circumstances (potentially pathogenic mycobacteria) (table I.1). 
The number of cases of infection by this group of mycobacteria has increased in recent 
years due to opportunistic infections in HIV patients.   
 
The several species that comprise the Mycobacterium genus can be grouped in 
different complexes whose members have similar genetic and phenotypic 
characteristics. The M. tuberculosis complex, which includes M. tuberculosis, 
Mycobacterium bovis, M. bovis BCG, Mycobacterium africanum, Mycobacterium 
microti and the three recent newcomers Mycobacterium canetti, Mycobacterium caprae 
and Mycobacterium pinnipedii, comprises slow growth mycobacteria with generation 
periods of approximately 24 hours (Brosch R. et al, 2001). All of the species included in 
this complex are known to cause TB in humans. 
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Table I.1.Classification of mycobacteria according to the risk of infection (Brosch R. et al, 2001; 
David H.L.,1989) 
Rarely pathogenic 
Potentially 
pathogenic 
Strictly 
pathogenic 
M. smegmatis M. aurum M. avium M. tuberculosis 
M. phlei M. chitae M. intracellulare M. bovis 
M. fallax M. duvalii M. chelonae M. africanum 
M. thermoresistibile M. gadium M. fortuitum M. ulcerans 
M. parafortuitum M. gilvum M. kansasii M. microti 
M. gastri M. komossense M. malmoense M. canetti 
M. triviale M. lepraemurium M. marinum M. caprae 
M. nonchromogenicum M. neoaurum M. scrofulaceum M. pinnipedii 
M. gordonae M. terrae M. simiae M. leprae 
M. flavescens M. vaccae M. szulgai  
M. farcinogenes M. agri M. xenopi  
M. senegalense M. aichiense M. asiaticum  
M. paratuberculosis M. austroafricanum M. haemophilum  
M. porcinum M. chubuense M. shimoidei  
M. diernhoferi M. obuense   
M. pulveris M. rhodesiae   
M. tokaiense M. moriokaense   
M. poriferae    
 
The M. avium complex (MAC) comprises, among other environmental species, M. 
avium subsp. avium (responsible for disease in birds, but also for disseminated disease 
in patients with AIDS, cervical lymphadenitis, and chronic lung disease), M. avium 
subsp. paratuberculosis (the etiologic agent of Johne’s disease or paratuberculosis, a 
chronic granulomatous enteric disease of ruminant livestock and wildlife), M. avium 
subsp. silvaticum (causes TB-like lesions in wood pigeons) and M. intracellulare 
Chapter I – Introduction 
_____________________________________________________________________ 
____________________________________________________________ 
 
10 
 
(associated with MAC-associated pulmonary infections in immunocompetent or non-
HIV patients) (Turenne C.Y. et al, 2007).  
The Mycobacterium fortuitum complex includes the rapid growth mycobacteria 
Mycobacterium fortuitum, Mycobacterium peregrinum, Mycobacterium abcessus and 
Mycobacterium chelonae. These organisms have generation periods of 20-30 minutes 
and are frequently responsible for abscess formation in local injection or surgical 
wounds. They can also be associated with pulmonary disease, usually M. abcessus, 
particularly in the case of imunossupression of the host, and are resistant to the anti-TB 
drugs currently in use (Griffith D.E. et al, 2007).  
 
I.2.2 The mycobacterial cell-wall 
The mycobacterial cell-wall, shown schematically in Figure I.3, is a complex structure, 
rich in high molecular weight lipids (Brennan P. et al, 1995; Christensen H. et al, 1999; 
Daffé M. et al, 1998; Draper P., 1998; Jarlier V. et al, 1994). The basic structural 
skeleton of the cell-wall is formed by peptidoglycan linked to a second polysaccharide 
polymer, the arabinogalactan. The mycolic acids are covalently linked to the 
arabinogalactan polymer, forming the inner region of a thick waxy coat surrounding the 
peptidoglycan-arabinogalactan skeleton. These long chain length branched fatty acids 
(70–90 carbon) are characteristic of mycobacteria and account for up to 60% of the 
whole cell dry weight (Brennan P. et al, 1995; Daffé M. et al, 1998; Draper P., 1998). 
The outer surface of this layer contains other complex lipids, including 
glycopeptidolipids, trehalose containing lipooligosaccharides, sulpholipids, phthiocerol 
dimycocerosate and phenolic glycolipids. Spanning the outer layer are porin proteins 
which have similar properties to those found in the Gram-negative outer membrane, 
providing a pathway for low molecular weight hydrophilic nutrients (Niederweis M., 
2003). Lipoarabinomycolate (LAM) is thought to be anchored via phosphatidylinositol to 
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the outer region of the cytoplasmic membrane and protrude through the wall to the 
outer cell surface (Brennan P. et al, 1995; Daffé M. et al, 1998; Draper P., 1998). 
 
 
Figure I.3. Schematic representation of the mycobacterial cell-wall (Park S.H. et al, 2000; Lee 
R.E. et al, 1996). LAM, lipoarabinomannans; LM, lipomannans; PIM, phosphatidylinositol 
mannosides. 
 
Recently, several studies have suggested the presence of a periplasmic space and an 
outer membrane in mycobacteria (Niederweis M. et al, 2010; Hoffmann C. et al, 2008; 
Zuber B. et al, 2008). The periplasm would include the peptidoglycan-arabinogalactan 
polymer that may correspond to an unidentified structure that has been observed by 
cryo-electron microscopy (Hoffmann C. et al, 2008). Relatively to the outer membrane 
organization, it can be represented by two models that differ in the conformation of  the 
mycolic acids. One model suggests that the mycolic acids have an elongated 
conformation that would span the complete hydrophobic matrix, leaving space for free 
lipids to intercalate (Nikaido H. et al, 1993; Hong, X. et al, 2004), whereas a second 
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model, based on results of monolayer experiments and simulation data, suggests a 
folded conformation for the mycolic acids. This folded conformation may be stabilized 
by keto or methoxy groups that were recently proposed to interact with lipid head 
groups (Zuber B. et al, 2008).  
 
The composition of the cell-wall confers a highly impermeable character to 
mycobacteria. In fact, they are resistant to a wide variety of disinfectants and dyes 
used in most staining techniques like Gram and Giemsa. The expression “acid-
fastness” describes the resistance of these microorganisms to stain removal with acid-
alcohol solutions after staining with alkaline dyes such as carbol fuchsin. This feature 
became the basis for the staining technique developed by Paul Ehrlich that evolved 
into the protocol used today to detect acid-fast bacillus bacillus by microscopy (Ziehl-
Neelsen staining) (Brennan P., 1995; Nikaido H., 2001). The cell-wall also provides an 
important contribution to the resistance of these microrganisms to most antimicrobial 
drugs and this subject will be addressed in detail in section I.5.1 "Intrinsic Resistance". 
 
I.2.3 The cord factor 
In general, M. tuberculosis bacilli produce rough textured colonies on solid media and 
are arranged in serpentine cords on microscopic smears. The recognition of these two 
characteristics allows an experienced microbiologist to separately identify M. 
tuberculosis from other mycobacteria in cultured specimens. These characteristics 
have been attributed to the glycolipid trehalose 6, 6’-dimycolate, also known as cord 
factor, which is present in the mycobacterial cell-wall (Hunter N. et al, 2006a). It is 
responsible for: (i) inducing animal granulomas similar to those characteristic of TB 
infection (Hunter N. et al, 2006b); (ii) increasing cytokine production (Ryll R. et al, 
2001); (iii) inhibiting the transfer of phagocytosed bacteria to acidic compartments in 
macrophages (Indrigo J. et al, 2003.); and (iv) influencing the morphology of 
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mycobacterial colonies (Hunter N. et al, 2006a). In liposomes, trehalose dimycolate 
inhibits vesicle fusion, which could explain its role in preventing the phagosome-
lysosome fusion in vivo (Spargo B.J. et al, 1991). However, the role that trehalose 
dimycolate may play outside the host environment remains to be completely clarified. 
 
I.2.4 The mycobacterial genome  
The complete sequencing of the M. tuberculosis H37Rv genome has provided more 
information concerning the characteristics of this organism, such as its slow growth, 
cell-wall complexity and adaptation to environmental conditions (Cole S.T. et al, 1998). 
The genome of M. tuberculosis H37Rv presents a sequence of 4411529 bp and a 
characteristically high guanine plus cytosine (G+C) content (65.5 %). Genome analysis 
revealed an efficient DNA repair system with nearly 45 genes related to DNA repair 
mechanisms, including three copies of the mutT gene, which encodes the enzyme 
responsible for removing oxidized guanines whose incorporation during replication 
causes base-pair mismatching (Mizrahi V. et al, 1998). Concerning transcriptional 
regulation, M. tuberculosis codifies for 13 putative sigma factors and more than 100 
regulatory proteins. The presence of a single ribosomal ribonucleic acid (rRNA) operon 
(rrn), contrary to most eubacteria that have more than one rrn operon, has been 
pointed to be a factor contributing to the slow growth of M. tuberculosis (Brosch R. et 
al, 2000). 
From the genome sequence it is clear that M. tuberculosis has the potential to switch 
from one metabolic route to another, including aerobic (e.g. oxidative phosphorylation) 
and anaerobic respiration (e.g. nitrate reduction). This flexibility is useful for survival 
within the human host environment that can range from high oxygen tension in the lung 
alveolus to microaerophilic/anaerobic conditions within the tuberculous granuloma.  
There are also genes encoding for 250 distinct enzymes involved in fatty acid 
metabolism that allow the synthesis and degradation of several lipids from simple fatty 
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acids to complex molecules such as mycolic acids (Cole S.T. et al, 1998). Moreover, 
the genome of M. tuberculosis H37Rv codes for multiple putative efflux proteins, of 
which the majority have not yet been characterized (Cole S.T. et al, 1998; Louw G.E. et 
al, 2009).   
Altogether, the presence of a permeability barrier established by the outer membrane, 
metabolic versatility, high fidelity replication machinery and multidrug efflux 
compensate for the slow growth of these organisms by allowing M. tuberculosis to 
successfully adapt to challenging environments, namely host defense mechanisms and 
antibiotic pressure. 
 
I.3 Pathogenesis of tuberculosis 
M. tuberculosis is a mainly intracellular pathogen that enters the body via the 
respiratory pathway. However, most people infected by M. tuberculosis do not develop 
the disease during their lifetime. The risk of developing the disease increases when an 
imunossupression takes place, such as co-infection with HIV. This shows that the 
immune response plays a crucial role in the outcome of M. tuberculosis infection (Flynn 
J.L. et al, 2001). The first event in the host-pathogen relationship is the phagocytosis of 
M. tuberculosis by alveolar macrophages. This is followed by cell-mediated immunity, 
with a flow of lymphocytes and activated macrophages into the lesion resulting in 
granuloma formation. This controls the exponential growth of the bacilli and the dead 
macrophages form a caseum. The bacilli are then contained in the caseous centers of 
the granuloma. Then, one of the following scenarios can take place: (i) the bacilli may 
remain forever within the granuloma (latent TB); (ii) the bacilli can be re-activated later; 
and (iii) the bacilli can be discharged into the airways after enormous increase in 
number, necrosis of bronchi and cavitation. Finally, fibrosis develops around the area 
of necrosis in order to contain the infection. This occurs as a final defence mechanism 
of the host when all other mechanisms have failed (Flynn J.L. et al, 2001). 
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HIV infection is a risk factor for TB. Not only does HIV increase the risk of reactivating 
latent M. tuberculosis infection, it also increases the risk of developing TB after 
infection or reinfection. In patients infected only with M. tuberculosis, the risk of 
developing TB during their lifetime ranges between 10% and 20%. However, patients 
co-infected with HIV have their annual risk increase in 10% (Goletti D. et al, 1996; 
Nakata K. et al, 1997). In the co-infected patient, a complex interaction occurs between 
M. tuberculosis and HIV that results in the aggravation of both pathologies. In fact, HIV 
promotes the progression of M. tuberculosis latent infection to disease, whereas M. 
tuberculosis enhances HIV replication, accelerating the progress of HIV infection 
(Goletti D. et al, 1996; Mariani F. et al, 2001; Nakata K. et al, 1997; Rosas-Taraco A.G. 
et al, 2006). HIV infection impairs M. tuberculosis-specific IFN-γ production, which is 
not reversed by anti-retroviral treatment (Sutherland R. et al, 2006). The clinical 
presentation of TB in HIV/AIDS patients is related to the blood level of CD4+ T 
lymphocytes, a measure of the degree of immunossupression of the patient (Jones 
B.E. et al, 1993). A level of 200 CD4+ T cells/µL was established as a threshold for 
severe immunossupression. Above this level, the TB granuloma is produced in 
response to M. tuberculosis infection, including multinucleated giant cells, 
macrophages, CD4+ and CD8+ T lymphocytes and a central caseous necrosis. CD4+ T 
cell counts below 200/µL, cause the progressive impairment of the granuloma. Even in 
the presence of severe immunossupression, pulmonary TB is still the most common 
presentation of the disease, although extrapulmonary and disseminated TB is also very 
frequent in these patients (approximately 50% of cases). 
 
I.4 Treatment 
Treatment of TB is used not only to cure the disease but also to interrupt the 
transmission and to prevent relapse (most relapses occur within 6-12 months after the 
end of therapy) (Böttger E.C. et al, 2008). In 1994, the WHO introduced the Directly 
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Observed Treatment Short Course (DOTS), a strategy for the detection and treatment 
of TB, in which patients are observed to take each dose of anti-TB medication, until the 
end of therapy (WHO, 2001). Monthly sputum specimens are then taken until 2 
consecutive specimens are negative. However, the effectiveness of DOTS is facing 
new challenges due to the increase of MDRTB and the emergence of XDRTB. This 
lead to a new strategy called DOTS-plus, a comprehensive management initiative built 
upon the DOTS strategy with the goal of preventing further development and spread of 
MDRTB (WHO, 2006; WHO/ IUATLD, 2008).  
Treatment can be divided into first-line and second-line drugs: the first-line drugs used 
are INH, RIF, pyrazinamide (PZA), ethambutol (EMB) and streptomycin (STR) and the 
second-line drugs include fluoroquinolones, aminoglycosides such as kanamycin and 
amikacin, cyclic peptides like capreomycin, D-cycloserine, ethionamide, and ρ-amino 
salicylic acid. Each treatment regimen for pulmonary TB caused by susceptible 
organisms has an initial 2 months intensive phase with INH, RIF, PZA and EMB, 
followed by a continuation phase with INH and RIF for 4 to 7 months. STR can be used 
as an interchangeable drug with EMB in the initial phase of treatment. However, STR is 
only recommended to be interchangeable with EMB when the organism is known to be 
susceptible to the drug or the patient is from a community in which STR resistance is 
unlikely (Blumberg H.M. et al, 2003; WHO, 2001). The mechanisms of action of these 
drugs will be discussed in subchapter I.5.2 "Genetic Resistance". 
 
I.5 Resistance to anti-mycobacterial drugs 
In TB, clinical drug resistance is classified as acquired resistance, when drug resistant 
mutants are selected as a result of ineffective treatment, or as primary resistance, 
when a patient is infected with a resistant M. tuberculosis strain (Figure I.4). The 
selection of drug resistant mutants has to do with the long generation time of M. 
tuberculosis, its low metabolic activity and capacity for dormancy (Wayne, L.G. 1994). 
Chapter I – Introduction 
_____________________________________________________________________ 
____________________________________________________________ 
 
17 
 
Furthermore, the compartmentalization of the infection increases the probability of 
exposure to monotherapy, since M. tuberculosis may be located inside pulmonary 
cavities, with difficult antibiotic access (Elliott A.M. et al, 1995). This effect is enhanced 
in the presence of an inadequate dosage of anti-TB drugs, due to inadequate 
prescription by the physician or non-adherence by the patient. In order to prevent drug 
resistance it is necessary to understand the mechanisms by which M. tuberculosis 
becomes resistant. Over the years, several studies have described the mechanisms of 
action of most of the anti-TB agents used in clinical practice. 
 
 
Figure I.4. Development of resistance in TB. Acquired resistance develops due to the selection 
of resistant mutants as a consequence of ineffective treatment and non-compliance. Primary 
resistance occurs through the transmission of the resistant bacteria to a new host (adapted from 
Johnson R. et al, 2006). 
 
I.5.1 Intrinsic resistance 
The intrinsic resistance of mycobacteria to many antimicrobial drugs is mainly 
attributed to the permeability barrier provided by the mycobacterial cell-wall (Jarlier V. 
et al, 1994; Nguyen L. et al, 2006, Niederweiss M. et al, 2010). However, this does not 
fully explain intrinsic drug resistance in mycobacteria, suggesting that there must be 
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other systems, such as enzymatic inactivation (e.g. β-lactamases) or active efflux of 
drugs that work in synergy with the permeability barrier (Jarlier V. et al, 1994). 
 
o Cell-wall impermeability 
The lipid-rich mycobacterial cell-wall establishes a barrier to the entry of antimicrobials 
protecting the cell from toxic compounds (Brennan P.J. et al, 1995; Draper P. et al, 
1998). The peptidoglycan and arabinogalactan layers limit the entry of hydrophobic 
molecules, whereas the mycolic acid layer limits the access of both hydrophobic and 
hydrophilic molecules (Brennan P.J. et al, 1995). Relatively hydrophobic antibiotics 
such as RIF and fluoroquinolones may enter the cell by diffusion through the 
hydrophobic bilayer. However, hydrophilic antibiotics and nutrients that cannot diffuse 
through the cell-wall may use porin channels (Lambert P.A., 2002; Niederweis M., 
2008; Niederweiss M. et al, 2010). The presence of porins in a lipid bilayer supports the 
hypothesis that the mycobacterial cell-wall has an outer-membrane analogous to that 
of Gram-negative bacteria. However, mycobacterial porins are much less abundant 
than in the Gram-negative outer membrane and only allow low rates of uptake for small 
hydrophilic nutrients and antibiotics (Niederweis M., 2008; Trias J. et al, 1992). 
 
o Porins 
Porins are defined as non-specific protein channels in bacterial outer membranes that 
allow the entry of hydrophilic solutes (Nikaido M., 2003; Niederweiss M. et al, 2010). 
Channel-forming proteins that are functionally similar to porins of Gram-negative 
bacteria have been described in many mycobacteria (Niederweis M., 2003). MspA was 
the first porin of M. smegmatis to be described and deletion of mspA reduced the outer-
membrane permeability to cephaloridine and glucose, suggesting that MspA was the 
major diffusion pathway for hydrophilic solutes in M. smegmatis (Niederweis M. et al, 
1999; Stahl C. et al, 2001). Moreover, consecutive deletions of mspA and another porin 
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gene, mspC lowered the permeability for glucose 75-fold and the growth rate of M. 
smegmatis also decreased (Stephan J. et al, 2005). It was demonstrated that deletion 
of MspA and MspC increased resistance of M. smegmatis to β-lactam antibiotics, 
chloramphenicol and norfloxacin. Furthermore, expression of MspA in M. tuberculosis 
and M. bovis BCG promoted glucose uptake, and increased the growth rate and the 
susceptibility to hydrophilic antibiotics such as β-lactams, INH, EMB and STR 
(Mailaender C. et al, 2004). These studies demonstrated that small and hydrophilic 
antibiotics use the Msp porins to enter the cell. 
 
Other studies demonstrated the presence of channel-forming proteins in M. 
tuberculosis and M. bovis BCG (Kartmann B. et al, 1999; Lichtinger T. et al, 1999; 
Senaratne R.H. et al, 1998). An example is the OmpATb of M. tuberculosis. A study 
has shown that uptake of serine, but not of glycine, was reduced in an ompATb mutant 
compared to wild-type M. tuberculosis. This suggested that OmpATb was a porin, 
which was consistent with its apparent channel-forming activity in vitro (Raynaud C. et 
al, 2002). However, the uptake of glicine was higher in the mutant, which is not 
consistent with OmpATb being a major porin. Therefore, it is not clear that OmpATb 
has a significant porin function in M. tuberculosis. Nevertheless, the failure of the 
ompATb mutant to grow at low pH, and the induction of ompATb transcription at low pH 
and in macrophages, suggests that this protein may play a role in the adaptation to low 
pH and in M. tuberculosis survival inside the host’s macrophages (Niederweis M., 
2003; Raynaud C. et al, 2002). 
 
A recent study used a bioinformatic approach to predict outer membrane proteins of M. 
tuberculosis (Song H. et al, 2008). The porin MspA of M. smegmatis provided the basis 
for a secondary structure analysis performed for 587 proteins of M. tuberculosis 
predicted to be exported to the outer membrane. Using this approach, Rv1698 and 
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Rv1973 were identified as outer membrane proteins. Nevertheless, more studies are 
needed to identify porin-channels that can provide a pathway for anti-TB drugs across 
M. tuberculosis cell-wall. 
 
o Efflux pumps 
Along with cell-wall impermeability, active efflux systems can also provide resistance 
by extruding drug molecules that enter the cell. Knowing that the intracellular 
concentration of a given drug depends on the balance between its influx and efflux, it is 
therefore of great importance to increase our understanding of the processes of drug 
influx through porins and drug efflux via efflux pumps, in order to prevent drug 
resistance (Niederweis M., 2003; Nikaido H. 2001.). The M. tuberculosis genome 
encodes many putative drug exporters, and several studies have demonstrated the 
association of protein transporters with resistance to tetracycline (TET), 
aminoglycosides, fluoroquinolones, RIF, INH and chloramphenicol in several 
mycobacteria (Ainsa J. et al, 1998; Banerjee S.K. et al, 2000; De Rossi E. et al, 1998a; 
Li X.Z. et al, 2004; Pasca M.R. et al, 2004; Silva P.E. et al, 2001; Viveiros M. et al, 
2003). This topic will be further adressed in section 1.6 "Efflux Pumps", and in 
particular in 1.6.2 "Efflux Pumps in Mycobacteria". 
 
I.5.2 Genetic resistance 
Genetic resistance to antibiotics in most bacteria can be due to transmissible genetic 
elements, like transposons, integrons and plasmids, acquired by transduction or 
transformation. In M. tuberculosis, genetic resistance occurs mainly through 
chromosomal mutations, although mobile genetic elements, like the insertion sequence 
IS6110, have been associated with resistance through the inactivation of critical genes 
(Gillespie S. 2002; Böttger E.C. et al, 2008; Dale J. W. et al, 1995). This section will 
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address the genetic mechanisms of resistance of each of the anti-TB drugs used in the 
first- and second-lines of treatment.  
 
I.5.2.1 First-line drugs 
 
I.5.2.1.1 Isoniazid 
In the 1950’, it was discovered that isonicotinic acid hydrazide (latter known as INH) 
had a high activity against TB, higher than any other compound used at the time 
(Bernstein J.W.  et al, 1952; Vilchèze C., 2007). Soon INH became one of the major 
first-line anti-TB drugs and its mechanisms of action and resistance have been studied 
for more than 50 years. 
 
o Mechanism of action 
INH is particularly active against slowly growing mycobacteria (Pansy F. et al, 1952). 
The minimum inhibitory concentration (MIC) of INH against M. tuberculosis is 0.05 
mg/L, but is 100-fold higher against the fast-growing M. smegmatis. It is thought that 
INH enters the mycobacteria through passive diffusion through the cell-wall and that it 
is active only against dividing bacteria (Bardou F. et al, 1998; Mitchison D.A. et al, 
1956). The first study regarding the mechanism of action of INH was published in 1970 
by Winder and Collins (Winder F.G. et al, 1970). In this study, the authors use the 
following approach to demonstrate that mycolic acid biosynthesis was inhibited by INH: 
M. bovis BCG and M. tuberculosis H37Ra were exposed to INH and [14C]-glycerol for 
six hours and the mycolic acids were extracted and analyzed by thin layer 
chromatography, showing that inhibition of mycolic acid synthesis occurred after this 
treatment. This effect was absent in INH resistant strains, which suggested that INH 
inhibited an enzyme involved in mycolic acid biosynthesis. Later studies confirmed 
these findings, with the demonstration that inhibition of mycolic acid biosynthesis was 
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correlated with cell death and accumulation of long-chain fatty acids. However, the 
unavailability of genetic tools at the time did not allow further analyses. (Davidson L.A. 
et al, 1979; Takayama K. et al, 1975).  
 
o INH activation by KatG 
INH is a prodrug that needs activation by the catalase-peroxidase KatG and it is the 
activated form of INH that can inhibit mycolic acid biosynthesis. The idea that KatG 
might play a role in activation of INH rose with the first isolation of INH resistant 
mutants, which were catalase-negative (Middlebrook G., 1954). Zhang et al. 
demonstrated that transforming INH resistant M. tuberculosis strains with wild-type M. 
tuberculosis katG restored INH sensitivity (Zhang Y. et al, 1993). Subsequent studies 
demonstrated that KatG coverts INH into a range of activated species, such as an 
isonicotinoyl radical, that can acylate numerous compounds (Johnsson K. et al, 1994; 
Lei B. et al, 2000; Wilming M. et al, 1999).  
 
o INH inhibition of the enoyl-ACP reductase InhA 
InhA is a NADH-dependent enoyl-acyl carrier protein (enoyl-ACP) reductase of the fatty 
acid synthase type II (FASII) system (Figure I.5), involved in mycolic acid biosynthesis 
(Dessen A. et al, 1995; Marrakchi H. et al, 2000).  
 
 
Figure I.5. The fatty acid synthase type I (FASI) and II (FASII) systems (Vilchèze C. et al, 2000). 
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A proposed mechanism of action is that INH is activated by the catalase-peroxidase 
KatG to form an isonicotinoyl radical that binds to nicotinamide adenine dinucleotide 
(NAD+). This INH-NAD adduct inhibits the enoyl-ACP reductase InhA, which causes 
accumulation of long-chain fatty acids, inhibition of mycolic acid biosynthesis and, 
ultimately, cell death (Figure I.6) (Lei B. et al, 2000; Vilchèze C. et al, 2006; Vilcheze C. 
et al, 2007). 
 
 
 
Figure I.6. Proposed model for the mechanism of action of INH (Vilchèze C. et al, 2007). 
 
o KasA, a hypothetical INH target 
The β-ketoacyl ACP synthase KasA, another enzyme of the FASII system, has also 
been proposed as the main target of INH (Mdluli K. et al, 1998; Slayden R.A. et al, 
2000). This enzyme was isolated in an 80 kDa complex that also contained INH and 
the mycobacterial acyl-carrier protein AcpM, after exposure of M. tuberculosis to [14C]-
INH. These results and the presence of mutations in kasA in INH resistant M. 
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tuberculosis clinical isolates suggested that KasA was the main target of INH (Mdluli K. 
et al, 1998). However, later studies have identified mutations in kasA in INH 
susceptible isolates and the transfer of kasA mutations into M. tuberculosis H37Rv and 
M. bovis BCG using specialized transduction did not result in INH resistance (Lee A.S. 
et al, 1999; Piatek A.S. et al, 2000; Ramaswamy S.V. et al, 2003; Vilcheze C. et al, 
2006). Furthermore, the 80 kDa complex described above could also be obtained when 
M. tuberculosis was treated with other InhA inhibitors, but not with KasA inhibitors. This 
demonstrated that INH was not a part of this complex and only inhibition of InhA, but 
not of KasA, induced the formation of this complex (Kremer L. et al, 2003). In 
conclusion, the hypothesis of KasA as a target for INH is still controversial. 
 
o Mechanisms of INH resistance 
 
(i) Loss of catalase-peroxidase (KatG) activity 
Resistance to INH in M. tuberculosis clinical isolates is most frequently associated with 
mutations in katG that result in a decrease or loss of catalase-peroxidase activity and, 
consequently, in a reduced ability to form the INH-NAD adduct that inhibits InhA (Heym 
B. et al, 1995; Zhang Y. et al, 1992). At least 130 mutations in katG (2223 bp) have 
been reported from amino acids 1 to 735. Missense, nonsense mutations, insertions, 
deletions, truncation and full gene deletion have been observed (Ramaswamy S.V. et 
al, 2003; Zhang M. et al, 2005; Zhang Y. et al, 1992). The most common mutation is 
S315T, which results in a high deficiency in forming the INH-NAD adduct (Guo H. et al, 
2006; Hazbon M.H. et al, 2006; Zhang Y. et al, 1992).  
 
(ii) Over-expression or alteration of InhA 
Other mutations associated with INH resistance occur in inhA the gene coding for the 
INH target, InhA. The most common mutation in inhA is mutation S94A, located in the 
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NADH binding site of InhA (Quemard A. et al, 1995). This mutation reduces the affinity 
of the enzyme for its cofactor NADH, resulting in a lower affinity for the INH-NAD 
adduct, leading to resistance to the inhibition by the INH-NAD adduct (Vilcheze C. et al, 
2006). However, mutations in the inhA gene usually co-exist with mutations in the 
promoter region of inhA or katG mutations (Basso L.A. et al, 1998; Guo H. et al, 2006; 
Hazbon M.H. et al, 2006; Zhang M. et al, 2005). Overexpression of inhA is also 
associated with resistance to INH by titration of the drug. Mutation C-15T in the inhA 
promoter is the second most common mutation in INH resistant clinical isolates (Guo 
H. et al, 2006; Hazbon M.H. et al, 2006; Zhang M. et al, 2005). This mutation increases 
the inhA mRNA level, resulting in InhA overexpression and an increase in resistance to 
INH (Vilcheze C. et al, 2006).  
 
(iii) Other mutations associated with INH resistance 
Mutations in the ndh gene coding for NADH dehydrogenase NdhII were identified in 
INH resistant M. tuberculosis clinical isolates (Hazbon M.H. et al, 2006; Lee A.S. et al, 
2001). These mutations result in low NdhII activity, which causes an accumulation of 
NADH, the substrate for NdhII. This NADH accumulation causes a competition 
between NADH and INH-NAD for binding to InhA and protects this enzyme against the 
inhibitory effect of the INH-NAD adduct (Figure I.7) (Vilcheze C. et al, 2005).  
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Figure I.7.  Proposed mechanism of resistance to INH, and structurally similar drug 
ethionamide, by mutations in ndh.  These mutations increase the NADH intracellular 
concentration and cause resistance by competing with the INH-NAD adduct for the binding to 
InhA (Vilchèze C.  et al, 2005). 
 
Other mutations involved in resistance to INH are located in the ahpC-oxyR intergenic 
region. OxyR is a regulatory protein that is an oxidative-stress sensor and activator of 
gene transcription (Farr S.B. et al, 1991). OxyR controls the expression of katG and 
ahpC genes coding for the catalase-peroxidase (KatG) and alkyl hydroperoxidase 
(AhpC), respectively (Farr S.B. et al, 1991). In M. tuberculosis complex, oxyR is 
naturally inactive due to several frameshift mutations and deletions. This inactivation 
confers increased susceptibility to INH, providing an explanation to the high 
susceptibility of M. tuberculosis to this drug (MIC of 0.05 mg/L) (Pagan-Ramos E. et al, 
2006). Mutations in the ahpC promoter sequence were found in INH resistant M. 
tuberculosis with a deficient KatG activity, but not in INH susceptible isolates (Figure 
I.8) (Dhandayuthapani S. et al, 1996; Sherman D.R. et al, 1996; Springer B. et al, 
2001).  
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Figure I.8. Mutations identified in the ahpC-oxyR intergenic region. Sequence polymorphisms 
are designated with one asterisk and sequence variants with two asterisks (Sreevatsan S. et al. 
1997a). 
 
These mutations consist in compensatory alterations that occur as a result of loss of 
catalase-peroxidase activity. This results in a mechanism of resistance since 
organisms INH resistant due to decreased KatG activity require a compensatory 
mutation that results in overexpression of AhpC in order to survive the toxic effects of 
organic peroxides generated by the host macrophage (Sherman D.R. et al, 1996; 
Springer B. et al, 2001). 
 
I.5.2.1.2 Rifampicin 
RIF is one of the most important anti-TB drugs since it has an early bactericidal effect 
on metabolically active M tuberculosis, but also exhibits late sterilizing action on semi-
dormant organisms with short bursts of metabolic activity. This late effect of RIF, 
coupled with the effectiveness of PZA, has allowed the reduction of standard TB 
treatment from 1 year to 6 months (Grosset J., 1978). The mechanism of action of RIF 
is the inhibition of transcription by targeting the DNA-dependent RNA polymerase. 
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Resistance to RIF occurs most often in strains that are also resistant to INH and, 
whereas monoresistance to INH is common, monoresistance to RIF is rare. This 
makes RIF resistance a surrogate marker for MDRTB. More than 96% of the RIF 
resistant strains contain a mutation in a 81 bp (27 codons) central region of the gene 
rpoB that codes for the β-subunit of RNA polymerase (Ramaswamy S. et al, 1998; 
Somoskovi A. et al, 2001; Telenti A. et al, 1993). The most common mutations (65-
86%) are located at codons 526 and 531 and result in high-level resistance to RIF (MIC 
> 32 mg/L). However, alterations in codons 511, 516, 518, and 522 result in low-level 
resistance to RIF (Moghazeh S.L. et al, 1996; Ohno H. et al, 1996). The location of the 
most comon mutations in the 81 bp region of rpoB allows a straightforward approach to 
rapidly detect RIF resistance and/or MDRTB using molecular methods. However, in 
some isolates no mutation was found in the 81 bp region, but rare mutations in the 
amino-terminal region of rpoB have been found instead (Heep M. et al, 2000).  
 
I.5.2.1.3 Pyrazinamide 
PZA is another important first-line drug for the treatment of TB and plays a unique role 
in anti-TB treatment. It has a sterilizing effect on semi-dormant bacilli and, when used 
in combination with INH and RIF, reduces the duration of treatment from 1 year to 6 
months (Grosset J., 1978). 
 
o Mechanism of action 
PZA is a prodrug that is converted to its active form pyrazinoic acid (POA) by the 
mycobacterial enzyme pyrazinamidase. In M tuberculosis, accumulation of intracellular 
POA occurs when the extracellular pH is acidic. Studies suggest that PZA enters M. 
tuberculosis by passive diffusion, is converted into POA by pyrazinamidase and, due to 
a inefficient efflux system, POA accumulates in the bacterial cytoplasm (Salfinger M. et 
al, 1990; Somoskovi A. et al, 2001; Zhang Y. et al, 1999;). This inefficient efflux system 
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is thought to be the cause for M. tuberculosis unique susceptibility to PZA, contrary to 
other mycobacteria, such as M. smegmatis, that have an active efflux mechanism that 
rapidly extrudes POA (Zhang Y. et al, 1999). The accumulation of POA lowers the 
intracellular pH to a suboptimal level that can result in inactivation of target enzymes, 
such as the fatty acid synthase I (Zimhony O. et al, 2000). However, other studies 
show that PZA may not have a specific target, but instead the accumulation of POA 
causes the disruption of membrane potential, inhibiting ATP production and membrane 
transporters in M. tuberculosis (Zhang Y. et al, 2003). Moreover, it was also observed 
that inhibition of enzymes responsible for the generation of membrane potential, such 
as proton-ATPase, NADH dehydrogenase and cytochrome c oxidase by N,N'-
dicyclohexylcarbodiimide (DCCD), rotenone and azide, synergizes with PZA activity. 
This further supports the idea that PZA or POA disrupt membrane energetics as a 
mechanism of action (Zhang Y. et al, 2003). 
 
o Mechanism(s) of PZA resistance 
The isolation of the first PZA resistant M. tuberculosis isolates showed the absence of 
pyrazinamidase activity in these organisms (Konno K. et al, 1967). It was demonstrated 
that 72–97% of all PZA resistant clinical isolates tested carried a mutation in the 
structural gene or in the promoter region of pncA coding for the pyrazinamidase 
(Somoskovi A. et al, 2001; Scorpio A. et al, 1996). However, isolates with high-level 
resistance to PZA, but without mutations in the pncA gene have been described, which 
suggests that other mechanisms are also involved in the development of PZA 
resistance (such as deficient PZA uptake, pncA regulation, or POA efflux) (Raynaud C. 
et al, 1999).  
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I.5.2.1.4 Ethambutol 
 
o Mechanism of action 
EMB is especially important when used in drug combinations to prevent the emergence 
of drug resistance or to treat single drug resistant TB. Several studies have suggested 
that EMB interferes with the synthesis of the cell-wall core polymers arabinogalactan 
and lipoarabinomannan, components of the mycobacterial cell-wall, leading to a lack of 
arabinan receptors for the mycolic acids. The targets of EMB are thought to be the 
arabinosyl transferases, encoded by the embCAB operon, which are involved in 
polymerizing arabinose into the arabinan components of arabinogalactan and 
lipoarabinomannan (Lee R.E. et al, 2005.; Telenti A. et al, 1997; Wolucka B.A., 1994).  
 
o Mechanism(s) of EMB resistance 
Resistance to EMB in M. tuberculosis has been associated with mutations in the 
embCAB operon, particularly in the embB gene. Mutations at codon 306 of the embB 
gene (embB306), located in the EMB resistance-determining region (ERDR), are found 
in 28–68% of all EMB resistant clinical isolates (Plinke C. et al, 2006; Rinder H. et al, 
2001; Sreevatsan S. et al, 1997b). However, there is still some controversy about the 
role of these mutations in mediating EMB resistance, since embB306 mutations have 
recently been identified in EMB susceptible M. tuberculosis clinical isolates (Lee A.S. et 
al, 2004; Mokrousov I. et al, 2002; Perdigão J. et al, 2009). Recent studies showed that 
embB306 mutants have an altered EMB susceptibility and that the acquisition of 
mutations in this codon may not necessarily cause clinical EMB resistance. Instead, 
these mutations may represent a first step in the development of resistance and other 
genes may also be involved (Safi H. et al, 2008; Perdigão J. et al, 2009). On the other 
hand, a recent study has demonstrated that EmbC is a more suitable target for EMB in 
M. tuberculosis (Goude R. et al, 2009). In this study, mutations in embC that reduced 
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the arabinosyltransferase activity resulted in increased EMB susceptibility in M. 
tuberculosis and, although overexpression of EmbC was not possible in M. 
tuberculosis, overexpression of EmbC led to EMB resistance in M. smegmatis. 
Moreover, overexpression of embB in M. tuberculosis also resulted in EMB resistance, 
but at a lower level than that caused by EmbC. Overexpression of embA in M. 
tuberculosis had no effect on EMB resistance. These results suggest that, more than 
EmbB or EmbA, EmbC is a direct target of EMB (Goude R. et al, 2009). 
 
I.5.2.1.5 Streptomycin 
 
o Mechanism of action 
STR is an aminoglycoside antibiotic and is one of the first-line drugs used to treat TB. 
Early studies in E. coli demonstrated that STR binds to the 16S rRNA, inhibiting protein 
translation (Moazed D. et al, 1987; Ramaswamy S. et al, 1998). Contrary to other 
bacteria that have multiple copies of rRNA genes, members of M. tuberculosis complex 
have only one copy, which means that single nucleotide changes can result in antibiotic 
resistance (Bercovier H. et al, 1986).  
 
o Mechanism(s) of STR resistance 
Mutations associated with STR resistance in M. tuberculosis have been identified in the 
rrs and rpsL genes coding for the 16S rRNA and ribosomal protein S12, respectively 
(Douglass J. et al, 1993; Meier A. et al, 1996a). Mutations in rrs are most frequently 
found in two regions around nucleotides 530 and 915. In secondary structure models, 
the 530 loop of 16S rRNA is highly conserved and is located adjacent to the 915 
region. Several nucleotides in both regions interact with the ribosomal S12 protein 
(Stern S. et al, 1988) and previous studies in E. coli showed that STR interacts directly 
with 530 loop and 915 region of 16S rRNA, providing further evidence that mutations at 
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these sites result in STR resistance (Moazed D. et al, 1987). In the 530 loop, the most 
common mutations are CT transitions at positions 491, 512, and 516, and 
transversions (AC/T) at position 513. In the 915 region, the most frequent mutations 
are CA/G alteration at position 903 and AG at position 904. However, the majority 
of mutations associated with STR resistance occur in rpsL and the most common 
mutation is an AAGAGG substitution in codon 43 (Ramaswamy S. et al, 1998).  
 
I.5.2.2 Second-line drugs 
When the recommended short-course treatment with first-line drugs fails due the 
emergence of MDRTB, management of TB in these cases is based on the use of 
second-line drugs (WHO, 2001). However, these drugs are more toxic and less 
effective than first-line drugs and treatment is more prolonged and expensive (Figure 
I.9).  
 
 
 
Figure I.9. Effectiveness and tolerability relation of first- and second-line drugs used in TB 
treatment (Dorman S.E. et al, 2004). 
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There are six classes of second-line drugs used for the treatment of TB: 
aminoglycosides, such as amikacin and kanamycin; cyclic peptides, such as 
capreomycin; fluoroquinolones, such as ciprofloxacin, levofloxacin and moxifloxacin; 
thioamides, like ethionamide; D-cycloserine; and p-aminosalicylic acid. The increased 
use of these drugs has contributed to the emergence of XDRTB strains and, therefore, 
it is important to understand the mechanisms by which M. tuberculosis becomes 
resistant to these drugs.  
 
I.5.2.2.1 Kanamycin, amikacin and capreomycin 
The aminoglycosides kanamycin and amikacin and the cyclic peptide capreomycin are 
important second-line drugs used to treat patients with MDRTB. Despite not belonging 
to the same group of antibiotics, aminoglycosides and cyclic peptides have the same 
mechanism of action, which consists in the inhibition of protein synthesis. These drugs 
interfere with several ribosomal functions including the formation of the 30S subunit 
initiation complex, by blocking tRNA translocation from the A to the P site (Harms J.M. 
et al, 2003). Unlike STR resistance, which is associated with alterations of the 
ribosomal target site resulting from mutations in the rpsL gene (coding for S12 
ribosomal protein) or in a specific region of the rrs gene of the 16S rRNA, kanamycin 
and amikacin resistance is associated with mutations in the 1400 region of the rrs gene 
(Alangaden G.J. et al, 1998; Douglass J. et al, 1993; Meier A. et al, 1996a). Mutations 
in the rrs gene associated with resistance to kanamycin and amikacin in M. 
tuberculosis include A1401G (MIC > 128 mg/L), C1402T and G1484T (Jugheli L. et al, 
2009; Suzuki Y. et al, 1998). 
In the case of capreomycin, several studies suggest that it interacts at the 
aminoglycoside site within helix 44 of 16S rRNA and with 23S rRNA, although the site 
of action on the larger rRNA remains unclear (Maus C.E. et al, 2005a). Resistance to 
capreomycin is associated not only to mutations in the 16S rRNA gene (rrs) like the 
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A1401G alteration, but also to mutations in the tlyA gene, encoding a putative rRNA 
methyltransferase (Johansen S.K. et al, 2006; Maus C.E. et al, 2005b). Thus, 
capreomycin resistance in mycobacteria is due to the loss of the ability of the drug to 
bind to and inhibit ribosomes, because of the lack of methylation of rRNA (tlyA 
mutation) or changes in the 16S rRNA (rrs mutation).  
 
I.5.2.2.2 Fluoroquinolones 
Fluoroquinolones are part of the drug regimens recommended for treatment of MDRTB 
(Blumberg H.M. et al, 2003). Fluoroquinolones inhibit the bacterial type II 
topoisomerase DNA gyrase and topoisomerase IV. These ATP-dependent enzymes 
act by a transient double-stranded DNA break and cooperate to facilitate DNA 
replication (Levine C. et al, 1998). In particular, DNA gyrase catalyzes the negative 
supercoiling of DNA and is essential for efficient DNA replication, transcription and 
recombination, whereas topoisomerase IV has a specialized role in chromosome 
segregation. DNA gyrase is a tetrameric A2B2 protein. The A subunit carries the 
breakage-reunion active site, whereas the B subunit promotes ATP hydrolysis. Genes 
coding for DNA gyrase were identified in the M. tuberculosis genome as gyrA and gyrB 
that code for the A and B subunits, respectively (Madhusudan K. et al, 1994). However, 
there is no evidence of the topoisomerase IV parC and parE gene homologs in the 
genome of M. tuberculosis (Cole S.T. et al, 1998). Thus, it appears that DNA gyrase is 
the only topoisomerase target for fluoroquinolones in M. tuberculosis.  
Resistance to fluoroquinolones is thought to occur mainly by mutations in the quinolone 
resistance-determining region (QRDR) of the gyrA gene. However, resistance 
associated with mutations in the gyrB gene was only observed in in vitro selected 
strains and to date only mutations in the QRDR of gyrA were described in clinical 
isolates of M. tuberculosis (Guillemin V. et al, 1998; Kocagoz T. et al, 1996; Takiff H.E. 
et al, 1994). The association between mutations in this region and fluoroquinolone 
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resistance is attributed to the conservation of the region and its involvement in the 
interaction between fluoroquinolones and DNA gyrase (Alangaden G.J. et al, 1995; 
Ginsburg A.S. et al, 2003; Williams K.J. et al, 1996).  
 
I.5.2.2.3 Ethionamide 
Ethionamide is structurally similar to INH and also inhibits mycolic acid biosynthesis 
(Winder F.G. et al, 1971). It was demonstrated that a single aminoacid mutation of 
inhA, S94A, as well as overexpression of inhA confered resistance to both ethionamide 
and INH in M. smegmatis, M. bovis and M. tuberculosis (Banerjee A. et al, 1994; 
Larsen M.H. et al, 2002; Vilcheze C. et al, 2006; Wilson T.M. et al, 1995). Several M. 
tuberculosis clinical isolates resistant to INH contain mutations in the inhA gene, and 
have been found to be cross-resistant to ethionamide (Morlock G.P. et al, 2003). This 
demonstrated that the primary target of INH and ethionamide was InhA, the enoyl-acyl 
ACP reductase involved in mycolic acid biosynthesis. Like INH, ethionamide is also a 
prodrug that requires activation in order to have anti-TB activity. However, KatG mutant 
strains resistant to INH are suscepible to ethionamide, suggesting that ethionamide has 
a different activator (Morlock G.P. et al, 2003). Mutations in the ethA gene were found 
in clinical isolates resistant to ethionamide (De Barber A.E. et al, 2000; Morlock G.P. et 
al, 2003). Like katG and INH, the overexpression of ethA in M. smegmatis resulted in 
increased susceptibility to ethionamide (Baulard A.R. et al, 2000). This suggested that 
the product of ethA, a membrane associated flavin mono-oxygenase enzyme, plays a 
crucial role in the activation of ethionamide (Vannelli T.A. et al, 2002). The active form 
of ethionamide has never been isolated in vitro, although some inactive metabolites 
produced by the catalytic oxidation of ethionamide by EthA have been studied by thin 
layer chromatography and high performance liquid chromatography (De Barber A.E. et 
al, 2000).  
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I.5.2.2.4 D-Cycloserine 
D-Cycloserine is an analog of D-alanine and inhibits peptidoglycan biosynthesis in M. 
tuberculosis. Peptidoglycan contains the aminoacids D-alanine, D-glutamate and 
diaminopimelate. D-Alanine is one of the central molecules of the cross-linking step of 
peptidoglycan assembly and three enzymes are involved in the D-alanine branch of 
peptidoglycan biosynthesis: the pyridoxal phosphate-dependent D-alanine racemase 
(Alr); the ATP-dependent D-alanine:D-alanine ligase (Ddl); and the ATP-dependent D-
alanine:D-alanine-adding enzyme (MurF) (Feng Z. et al, 2003; Walsh C.T., et al 1989). 
Previous studies demonstrated that D-cycloserine inhibits M. tuberculosis Alr and Ddl 
enzymes (David H. et al, 1969; Strych U. et al, 2001). It was suggested that D-
cycloserine resistance in M. tuberculosis is primarily due to mutations in the ddl gene 
and that inhibition of Alr plays only a minor role in the mechanism of action of D-
cycloserine (David H. et al, 1969; David H., 1971). However, another study showed 
that a strain overexpressing both the alr and ddl genes presented an increased level of 
resistance to D-cycloserine and that Ddl was not significantly affected by D-cycloserine 
at the concentration that inhibits Alr (Feng Z. et al, 2003). The authors suggested that 
Alr overproduction contributed to the maintenance of the internal D-alanine pool, 
antagonizing the inhibition of Ddl by D-cycloserine. In fact, D-cycloserine treatment in 
M. smegmatis decreased the intracellular level of D-alanine in strains with wild-type Alr 
activity, and overproduction of Alr maintained a relatively abundant level of D-alanine. It 
was also demonstrated that overexpression of the ddl gene confered D-cycloserine 
resistance, but at lower levels than those for strains overproducing Alr (Feng Z. et al, 
2003).  
However, M. smegmatis alr null mutants are not dependent on D-alanine for growth, 
indicating that there is another pathway for D-alanine biosynthesis (Chacon O. et al, 
2002). A hypothesis could be that Alr is a high-affinity D-cycloserine binding target that 
would protect Ddl, a low-affinity target from drug inhibition. According to this 
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hypothesis, the major mechanism of resistance to D-cycloserine is the overproduction 
of the high-affinity but otherwise non essential target, while the bactericidal effect is due 
to the inhibition of the low-affinity lethal target (Feng Z. et al, 2003). However, one can 
not exclude the possibility that the bactericidal effect of D-cycloserine may result from 
the inhibition of a different target(s). In conclusion, more studies are needed in order to 
identify the exact target(s) of D-cycloserine. 
 
I.5.2.2.6 ρ-aminosalicylic acid 
ρ-aminosalicylic acid was one of the first antibiotics found to be effective in the 
treatment of TB in the 1940’s and was used later with INH and STR in combination 
chemotherapy against M. tuberculosis (Lehmann J., 1946; Murray J.F., 2004.). 
However, ρ-aminosalicylic acid caused gastrointestinal toxicity leading to poor patient 
compliance (Pugh D.L. et al, 1952). Consequently, the use of ρ-aminosalicylic acid 
decreased as more easily tolerated antibiotics became available. Recently, ρ-
aminosalicylic acid has been reintroduced in anti-TB therapy due to a new formulation 
of the drug that has fewer side effects and the emergence of MDRTB that required 
alternatives to the first-line anti-TB agents (WHO, 2000). However, despite the long 
history of ρ-aminosalicylic acid use in therapy, its mechanism of action remains to be 
clarified. ρ-aminosalicylic acid has structural similarities to sulphonamides, structural 
analogues of ρ-amino benzoic acid (PABA), which suggests that it might compete with 
PABA for dihydropteroate synthase (DHPS), an enzyme involved in folate biosynthesis. 
However, unlike sulphonamides, ρ-aminosalicylic acid appears to be a poor inhibitor of 
DHPS in vitro, raising the possibility that it may have a different target (Nopponpunth V. 
et al, 1999). However, the lack of inhibition in vitro does not prove that DHPS is not the 
in vivo target. One possibility is that ρ-aminosalicylic acid accumulates in the bacterial 
cells, leading to inhibition of DHPS activity in vivo. Other hypothesis is that ρ-
aminosalicylic acid might be converted to an active form inside bacterial cells, like INH 
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and PZA (Somoskovi A. et al, 2001). It is known that mutations on thyA that codes for 
thymidylate synthase A, an enzyme required for thymine biosynthesis, are associated 
with resistance to folate antagonists (Rengarajan J. et al, 2004). Thymidylate synthase 
A catalyzes the reductive methylation of dUMP to dTMP, required for de novo dTTP 
synthesis (Kunz B.A. et al, 1991). Since thymidylate synthase A is a major consumer of 
reduced folate in bacteria, when enzyme activity decreases or is inhibited, utilization of 
THF derivatives is also diminished. Thus, more reduced folate becomes available for 
other essential reactions allowing the bacteria to survive in the presence of a folate 
antagonist, such as ρ-aminosalicylic acid (Rengarajan J. et al, 2004).  
 
A recent study investigated the mutations associated with ρ-aminosalicylic acid 
resistance in M. tuberculosis clinical isolates and ρ-aminosalicylic acid resistant 
spontaneous mutants (Mathys V. et al, 2009). The following genes were analyzed: 
thyA, dfrA, folC, folP1, and folP2 that code for enzymes of the folate pathway; thyX, 
encoding an alternative thymine biosynthetic enzyme; and three N-acetyltransferase 
genes (nhoA, aac(1), and aac(2)) possibly associated with the modification of ρ-
aminosalicylic acid. Sixty-three percent of the ρ-aminosalicylic acid resistant isolates 
had no mutations in the studied genes, suggesting that ρ-aminosalicylic acid resistance 
mechanism in M. tuberculosis is associated with others than those involved in the 
biosynthesis of thymine nucleotides. 
 
I.5.3 The relation between intrinsic resistance and genetic resistance 
It has now become generally accepted that the overall bacterial resistance to 
antimicrobial agents is due not just to one resistance mechanism, but to a synergy 
between intrinsic resistance and genetic resistance (Nikaido H., 2009). As an example, 
it has been shown that efflux mechanisms appear prior to acquisition of target gene 
mutations and that overproduction of efflux pumps results in an increase in antibiotic 
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resistance (Baucheron S. et al, 2004; Quinn T. et al, 2006). Moreover, it has been 
suggested that the combination of a diminished outer membrane permeability, due to 
porin alterations, and an increased activity of efflux pumps, decrease the antibiotic 
concentration in the cell (Davin-Regli A et al, 2008; Mallea M. et al, 1998; Viveiros M. et 
al, 2007). This allows the bacteria to survive for a longer period of time than what may 
have been expected according to the minimum inhibitory concentration for that 
organism in the presence of that antibiotic, conferring a low-level resistance phenotype. 
It is possible that this prolonged survival under antibiotic pressure may increase the 
probability of spontaneous mutants, which contain mutations in genes encoding the 
target protein, to emerge from this subpopulation of bacteria presenting a high-level 
resistance phenotype (Pagès J.M. et al, 2009; Piddock L., 2006a; Quinn T. et al, 2006). 
This fact may be particularly relevant in the case of the long-term therapy such as that 
used in TB treatment, where a sustained pressure of sub-inhibitory concentrations of 
an antibiotic can result in an increased efflux activity and allow the selection of 
spontaneous mutants, thus rendering the organism resistant to that antibiotic. 
A way to prevent these events from occurring could be the inhibition of efflux pumps, 
which would restore the activity of antibiotics that are subject to efflux. If efflux pumps 
play, indeed, a role on the selection/stabilization of mutants, these should appear with 
decreased frequency in the presence of an efflux inhibitor than in its absence. By this 
manner, it is necessary to understand the organization of efflux pumps and the 
mechanisms behind efflux-mediated resistance. 
 
I.6 Efflux Pumps 
Bacterial efflux pumps are known for their association with antimicrobial resistance. 
However, the presence of efflux pumps in bacteria is previous to the development of 
antibiotics. Therefore, their natural physiological role is not related with the use of 
antibiotics, but instead consists in the extrusion of noxious agents from the cell, 
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allowing the bacteria to survive in a hostile environment (Piddock L.J., 2006; Poole K., 
2007). An example of a natural function of efflux pumps is the secretion of intracellular 
metabolites and protection against bile salts and fatty acids in enteric bateria as a 
response to their natural environment.  
 
Antimicrobial resistance due to an increased efflux activity can be caused by the 
genetic overexpression of the efflux pump, or by aminoacid substitutions in the protein 
itself that can render the pump more efficient. Both mechanisms cause the reduction of 
the intracellular concentration of the antimicrobial and, consequently, the organism 
becomes less susceptible to that agent.  
 
Efflux pumps may be substrate-specific or transport a broad range of structurally 
dissimilar compounds (including antibiotics of multiple classes), the latter of which may 
be associated with multiple drug resistance. Genes coding for efflux pumps can be 
found on the bacterial chromosome or on transmissible elements such as plasmids 
(Piddock L.J., 2006; Poole K., 2007). The following sections will address the 
characteristics of efflux pumps, their role on drug resistance and strategies to prevent 
efflux-mediated multidrug resistance. 
 
I.6.1 Classes and Organization of Efflux Pump Systems 
Efflux pump systems can be organized into five different families according to their 
energetic and structural characteristics (Figure I.10): the ATP-binding cassette (ABC) 
superfamily; the major facilitator superfamily (MFS); the multidrug and toxic compound 
extrusion (MATE) family; the small multidrug resistance (SMR) family; and the 
resistance nodulation division (RND) family. Efflux pumps that are included in the ABC 
superfamily are considered primary transporters because they hydrolyze ATP as a 
source of energy, whereas the other families of efflux pumps use the proton (or sodium 
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in the case of MATE family) gradient as an energy source and are thus called 
secondary transporters (Lomovskaya O. et al, 2007; Marquez B., 2005; Piddock L.J, 
2006; Poole K., 2007). 
 
 
Figure I.10. Schematic representation of the different classes of efflux pump systems (Piddock 
L.J., 2006).  
 
o ATP-binding cassette (ABC) superfamily 
ABC transporters are involved in different transport functions such as the efflux of 
toxins, metabolites and drugs. These systems consist of two cytoplasmic domains that 
bind ATP and two hydrophobic transmembrane domains (Davidson A.L. et al, 2008; 
Higgins C.F., 2001). The nucleotide binding domains are highly homologous and 
possess the Walker A and B motifs, common to all ATP-binding proteins, and a 
Signature Motif specific to ABC transporters (Davidson A.L. et al, 2008; Kerr I.A., 
2002). One of the most studied ABC transporters is the mammalian P-glycoprotein (P-
gp) that, when overexpressed, confers resistance to compounds used in cancer 
chemotherapy (Lage H., 2003). Other ABC transporters have been described in Gram-
positive and Gram-negative bacteria (Davidson A.L. et al, 2008; Lubelski J. et al, 
2007). An example is LmrA, a well studied ABC transporter from Lactococcus lactis 
that confers multidrug resistance and presents structural and functional homologies 
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with the human P-gp (Poelarends G.P. et al, 2002; Lubelski J. et al, 2007). Genome 
sequencing revealed putative LmrA homologues in other bacteria such as E. coli, 
Bacillus subtilis, Helycobacter pylori, Haemophillus influenzae, Mycoplasma genitalium 
and Staphylococcus aureus (Davidson A.L. et al, 2008; Lubelski J. et al, 2007).  
 
o Major facilitator superfamily (MFS) 
MFS is a large superfamily of transporters involved in symport, uniport or antiport of 
various substrates. Most proteins are 400-600 aminoacid residues in size and possess 
either 12 or 14 putative transmembrane domains (Fluman N. et al, 2009; Law C.J. et al, 
2008; Saidijam M. et al, 2006). An example of an MFS drug efflux protein in Gram-
negative bateria is the MdfA from E. coli, which can extrude compounds like 
chloramphenicol and various cationic compounds (Bibi E. et al, 2001). MdfA is a typical 
MFS 12 transmembrane helix protein with a large and complex multidrug recognition 
pocket. In addition to its function as a multidrug transporter, other studies revealed that 
MdfA plays a physiological role in alkaline pH homeostasis, possibly through its 
K+/proton antiporter activity (Lewinson O. et al, 2004). EmrD is another MFS 
drug/proton antiporter from E. coli and was first identified as an efflux pump for 
uncouplers of oxidative phosphorylation, which can rapidly inhibit bacterial growth by 
depleting the proton gradient (Naroditskaya V. et al, 1993). It was later discovered that 
EmrD could also transport detergents such as benzalkonium and sodium 
dodecylsulfate (Nishino K. et al, 2001). EmrD is a close homologue to other MFS 
transporters, including MdfA from E. coli, NorA from S. aureus, LmrP from L. lactis and 
Bmr from B. subtilis (Paulsen I.T. et al, 1996a).  
 
o Multidrug and toxic compound extrusion (MATE) family 
Efflux pumps of the MATE family have been described for various bacteria, including 
Vibrio parahaemolyticus (NorM), Vibrio cholerae (VcrM; VcmA), Bacteroides 
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thetaiotaomicron (BexA), Haemophilus influenzae (HmrM), Pseudomonas aeruginosa 
(PmpM), Clostridium difficile (CdeA), and S. aureus (MepA) (McAleese F. et al, 2005; 
Omote H. et al, 2006; Otsuka M. et al, 2005). Most MATE members consist of 400–550 
residues with 12 transmembrane helices. Although no apparent consensus sequence 
is conserved in all MATE proteins, all proteins share 40% sequence similarity. Two 
energy sources have been identified for MATE transporters: the proton motive force 
and the sodium ion gradient. Some MATE transporters, such as NorM of V. 
parahaemolyticus, have been shown to be energetically coupled to the sodium ion 
gradient force across the plasma membrane. This force is established by either a 
primary Na+ pump or a Na+-proton antiporter coupled with respiration. However, in the 
case of AbeM (Acinetobacter baumannii) and PmpM (P. aeruginosa) activity is coupled 
to the proton motive force across the plasma membrane (Omote H. et al, 2006). It was 
demonstrated that these transporters confer resistance against cationic drugs such as 
ethidium bromide (EtBr), tetraphenylphosphonium (TPP), berberine, acriflavine and 
norfloxacin (Omote H. et al, 2006). In particular, MepA from S. aureus has been 
associated with resistance to tigecycline, an antibiotic that shows antimicrobial activity 
against methicillin-resistant S. aureus (MRSA) (McAleese F. et al, 2005). 
 
o Small multidrug resistance (SMR) family 
The smallest secondary transporters belong to the SMR family. These proteins are 
typically around 110 aminoacid residues in length with 4 predicted transmembrane 
helices. SMR transporters can confer resistance to several compounds, such as methyl 
viologen, TPP, benzalkonium, cetyltrimethylammonium bromide, cetylpyridinium 
chloride, EtBr, acriflavine, proflavin, crystal violet, pyronine Y and safranin O (Bay D.C. 
et al, 2008). The most characterized members of this family are the plasmid encoded 
Smr from S. aureus, which confers resistance to EtBr and other quartenary 
compounds, and chromosomal encoded EmrE from E. coli that is now considered the 
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structural archetype of all SMR proteins (Paulsen I.T. et al, 1996b; Schuldiner S., 2007; 
Tate C.G., 2006). EmrE confers resistance to monovalent cations, such as ethidium, 
proflavine, pyronin Y and safranin O, as well as to erythromycin, sulfadiazine, TPP and 
TET.  
 
o Resistance nodulation division (RND) family 
RND transporters have been mostly studied in Gram-negative bacteria, because they 
are involved in intrinsic antibiotic resistance in these microorganisms. However, in 
Gram-positive bacteria their function is still mostly unknown. These transporters 
present a broad range of substrates and can extrude positive, negative or neutral 
charged molecules, hydrophobic and hydrophilic compounds (Piddock L.J., 2006; 
Poole K., 2007). Most RND transporters are composed of a polypeptide chain with 700-
1300 aminoacid residues and are predicted to span the membrane 12 times with two 
large periplasmic domains located between transmembrane helices 1 and 2 and 
between 7 and 8 (Seeger M.A. et al, 2008). Examples of the RND superfamily include 
AcrB and AcrF from E. coli, MexB from P. aeruginosa and MtrD from Neisseria 
gonorrhoeae. Two other putative E. coli proteins, AcrD and YhiV, may also be RND 
multidrug efflux proteins (Piddock L.J., 2006; Poole K., 2007). These transporters 
combine with membrane fusion proteins and outer membrane proteins (also called 
outer membrane factor) to form a tripartite efflux pump system. The most studied 
example of such structure is the AcrAB-TolC system of E. coli (Figure I.11). This 
tripartite efflux system comprises the following components: a RND transporter protein 
in the inner membrane (AcrB), a periplasmic membrane fusion protein (AcrA) and an 
outer membrane protein channel (TolC) (Piddock L.J., 2006; Poole K., 2007). AcrB 
binds the substrate within either the phospholipid bilayer of the inner membrane of the 
bacterial cell-wall or the cytoplasm and transports them to the exterior of the cell using 
TolC. AcrA mediates the cooperation between AcrB and TolC (Piddock L.J., 2006; 
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Seeger M.A. et al, 2008). The AcrAB-TolC system transports a wide range of 
antibiotics such as β-lactams (e.g. oxacillin), macrolides (e.g. erythromycin), 
fluoroquinolones (e.g. ciprofloxacin) and tetracyclines, RIF, novobiocin, fusidic acid and 
nalidixic acid, and also other compounds such as EtBr, acriflavine, bile salts and short-
chain fatty acids (Piddock L.J., 2006; Poole K., 2007). 
 
 
 
Figure I.11.Schematic representation of AcrAB–TolC of E. coli. AcrB is responsible for 
substrate recognition and energy transduction. Drugs are extruded in exchange with protons. 
TolC forms a pore in the outer membrane, which is extended by a long periplasmic channel. 
AcrA mediates the interaction between AcrB and TolC (Seeger M.A. et al, 2008).  
 
 
I.6.2 Efflux pumps in mycobacteria 
Several mycobacterial drug efflux pumps have been identified and characterized to the 
present day (Louw G.E. et al, 2009; Viveiros M. et al, 2003). Table I.2 summarizes 
most of these pumps and the most characterized transporters are discussed bellow: 
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o Genes encoding ABC transporters comprise approximately about 2.5% of the M. 
tuberculosis genome and at least 37 complete and incomplete ABC transporters have 
been identified (Braibant M. et al, 2000). However, only a few of these transporters 
have been characterized and shown to be involved in drug resistance. M. tuberculosis 
contains a putative doxorubicin-resistance operon, drrABC (Choudhuri B.S. et al, 
2002). The DrrAB genes expressed in M. smegmatis confer resistance to a broad 
range of antibiotics, including TET, erythromycin, ethambutol, norfloxacin, STR and 
chloramphenicol. The resistant phenotype is reversed by treatment with reserpine or 
verapamil, compounds known to inhibit efflux (Choudhuri B.S. et al, 2002). Studies 
have suggested that the main role of the Drr proteins of M. tuberculosis may be the 
export of lipids to the exterior of the cell and, in particular, DrrC seems to be involved in 
the transport of phthiocerol dimycocerosates (Camacho L.R. et al, 2001). The M. 
tuberculosis Rv2686c-Rv2687c-Rv2688c operon encodes an ABC transporter 
responsible for fluoroquinolone efflux when produced from a multicopy plasmid. When 
overexpressed in M. smegmatis, this operon increases 8-fold the MIC of ciprofloxacin 
and 2-fold the MIC of norfloxacin. The level of resistance decreases in the presence of 
reserpine, carbonyl cyanide m-chlorophenylhydrazone (CCCP) and verapamil (Pasca 
M.R. et al, 2004).  
 
o The plasmid-encoded TET efflux pump Tet(V) was isolated from M. smegmatis 
and, when overexpressed, increases the MIC of TET from 2- to 4-fold. The distribution 
of the tet(V) gene among the genus Mycobacterium has been investigated by 
polymerase chain reaction (PCR). However, M. smegmatis and M. fortuitum were the 
only species tested that revealed a tet(V) gene (De Rossi E. et al, 1998a). 
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Table I.2. Efflux pump genes and transporters associated with drug resistance in mycobacteria 
(adapted from Louw G.E. et al, 2009). 
Efflux pump Microorganism 
Possible 
substrates 
Family Ref. 
PstB 
M. smegmatis 
M. tuberculosis 
INH, RIF, EMB, CIP ABC Bhatt K. et 
al, 2000 
Rv2686c-Rv2687c-Rv2688c M. tuberculosis CIP ABC Pasca M.R. 
et al, 2004 
Rv1747 M. tuberculosis INH ABC Braibant M. 
et al, 2000 
DrrA-DrrB-DrrC M. tuberculosis TET, STR, EMB ABC 
Choudhuri 
B.S. et al, 
2002  
Tet(V) M. smegmatis TET MFS De Rossi E. 
et al, 1998a 
LfrA M. smegmatis 
Fluoroquinolones, 
EtBr, acriflavine 
MFS Takiff H.E. 
et al, 1996 
Rv1258c 
(Tap homologue) M. tuberculosis INH, RIF, EMB, OFL MFS 
Siddiqi N. et 
al, 2004 
Rv1877 M. tuberculosis TET, KAN, ERY MFS Li X.Z. et al, 
2004 
Rv1634 M. tuberculosis Fluoroquinolones MFS De Rossi E.  
et al, 2002 
EfpA M. tuberculosis Possibly INH MFS Doran J.L. 
et al, 1997 
P55 
M. tuberculosis 
M. bovis 
Aminoglycosides, 
TET, RIF 
MFS Silva P.E. 
et al, 2001 
Tap M. fortuitum 
Aminoglycosides, 
TET 
MFS Ainsa J.A. 
et al, 1998 
MmpL7 M. tuberculosis INH RND Pasca M.R. 
et al, 2005 
Mmr M. tuberculosis 
TPP, EtBr, ERY, 
acriflavine 
SMR De Rossi E. 
et al, 1998b 
IniA-IniB-IniC M. tuberculosis INH 
Membrane 
protein 
Colangeli, 
R. et al, 
2005 
 
ABC, ATP-binding cassette; CIP, ciprofloxacin; INH, isoniazid; EMB, ethambutol; EtBr, ethidium bromide; 
ERY, erythromycin; KAN, kanamycin; MFS, major facilitator superfamily; OFL, ofloxacin; RIF, rifampicin; 
RND, resistance nodulation division; SMR, small multidrug resistance; STR, streptomycin; TET, 
tetracycline; TPP, tetraphenyl phosphonium.  
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o The LfrA protein of M. smegmatis was the first efflux pump to be described in the 
genus Mycobacterium and may be responsible for low-level resistance to 
fluoroquinolones, acridine and quaternary ammonium compounds (Liu J. et al, 1996; 
Sander P. et al, 2000; Takiff H.E. et al, 1996). When overexpressed, LfrA seems to 
play an important role in the resistance to ciprofloxacin in M. smegmatis. However, in 
the absence of overexpression, LfrA is thought to have no effect on the susceptibility to 
fluoroquinolones. In fact, disruption of the lfrA gene decreased 8-fold the MIC of EtBr 
and acriflavine and decreased only 2-fold the MICs of ciprofloxacin, doxorubicin and 
rhodamine (Li X.Z. et al, 2004). This discrepancy of results between EtBr and 
ciprofloxacin can be explained if EtBr is a better substrate for LfrA (Li X.Z. et al, 2004). 
Other explanation resides in the fact that efflux pumps other than LfrA may extrude 
ciprofloxacin in M. smegmatis. The region upstream from the lfrA gene revealed the 
presence of an open reading frame encoding a putative polypeptide of 195 amino 
acids, LfrR, homologous to several transcriptional regulators of the TetR family (Li X.Z. 
et al, 2004). The lfrR and lfrA genes are organized into an operon probably controlled 
by LfrR. It has been demonstrated that deletion of the lfrR gene enhances lfrA 
expression, increasing the resistance to ciprofloxacin, norfloxacin, EtBr and acriflavine 
(Li X.Z. et al, 2004). No known homologue of the lfrA gene as been described in the M. 
tuberculosis genome (De Rossi E. et al, 2002).  
 
o The M. fortuitum Tap efflux pump and its M. tuberculosis homologue Rv1258c 
confer resistance to TET and aminoglycosides, including STR (Ainsa J. et al, 1998). 
When cloned on a plasmid, Tap increased the resistance of M. smegmatis mc2155 to 
gentamicin, STR and TET (Ainsa J.A. et al, 1998). In the case of a clinical strain of M. 
tuberculosis, the expression of rv1258c increased in the presence of RIF and ofloxacin 
(Siddiqi N. et al, 2004). Furthermore, TET accumulation experiments showed that the 
efflux activity of Tap from M. fortuitum is inhibited by CCCP and reserpine, a result 
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consistent with the decrease of the MIC of this antibiotic in the presence of these 
compounds. In addition, CCCP, reserpine and also chlorpromazine reduced the MIC of 
TET in a M. smegmatis strain expressing the Tap protein (Ramon-Garcia S. et al, 
2006). 
 
o Rv1634 is a MFS efflux pump that has been suggested as a new fluoroquinolone 
efflux transporter in M. tuberculosis (De Rossi E. et al, 2002). It was demonstrated that 
this pump decreased susceptibility to various fluoroquinolones when overexpressed in 
M. smegmatis. Furhermore, accumulation assays suggest that Rv1634 is also involved 
in norfloxacin and ciprofloxacin efflux (De Rossi E. et al, 2002). 
 
o The P55 efflux pump from M. bovis and M. tuberculosis has been associated with 
low-level resistance to several drugs including TET, aminoglycosides and RIF (Ramon-
Garcia S. et al, 2009; Silva P.E. et al, 2001). Rv1410c, the gene for P55 in M. 
tuberculosis, forms an operon with Rv1411c, encoding the lipoprotein LprG. It is 
thought that both genes support in vivo growth of M. tuberculosis and studies 
performed in M. smegmatis have shown that this operon is required for survival in the 
presence of EtBr and for normal cell surface composition (Bigi F. et al, 2004; Farrow 
M.F. et al, 2008). A recent study has demonstrated that P55 plays a role in at least 
three important processes: (i) it extrudes and provides resistance to several drugs 
(including rifampicin); (ii) it is part of the oxidative stress response; and (iii) it is needed 
to maintain normal growth characteristics on solid and in liquid media (Ramon-Garcia 
S. et al, 2009). 
 
o The M. tuberculosis putative efflux protein EfpA presents the transporter motifs 
characteristic of QacA of S. aureus, including those associated with proton antiporter 
function and those specific to drug transporters. It was shown that expression of efpA 
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increases in the presence of INH, which could suggest that the protein encoded by this 
gene transports molecules involved in mycolic acid synthesis (Wilson M. et al, 1999). 
The deletion of the efpA homologue in M. smegmatis resulted in a 2-fold increased 
susceptibility to EtBr, gentamicin and fluoroquinolones and an 8-fold increased 
susceptibility to acriflavine. However, it also resulted in a 4-fold decreased susceptibility 
to rifamycins and chloramphenicol and a 2-fold decreased susceptibility to INH and 
erythromycin (Li X.Z. et al, 2004). Moreover, this efpA deleted mutant grew more slowly 
than the wild-type strain, which could mean that its higher susceptibility may be 
because of impaired growth (Li X.Z. et al, 2004). Thus, the role of EfpA in drug 
resistance remains unclear. However, since the deletion of this gene increases 
susceptibility to EtBr, it is pssible that EtBr is a substrate of this pump (Li X.Z. et al, 
2004). 
 
o The genome of M. tuberculosis contains several genes that code for putative 
transport proteins of the RND superfamily. These proteins have been designated 
MmpL (mycobacterial membrane proteins, large) and are thought to be involved in the 
transport of fatty acids (Tekaia F. et al, 1999). In M. tuberculosis, MmpL7 exports 
phthiocerol dimycocerosate (PDIM), a lipid component of the outer membrane 
(Camacho L.R. et al, 2001). Upstream from the mmpL7 gene is the fadD28 gene, 
which encodes an acyl-CoA synthase probably involved in the release and transfer of 
mycocerosic acid from mycocerosic acid synthase to diols. A strain with an insertion in 
mmpL7 produces a dimycocerosate (DIM) molecule that is retained in the cytoplasm or 
the cytoplasmic membrane. The production of MmpL7 in M. smegmatis promotes a 32-
fold increase of the MIC of INH. However, this phenotype is reversed if fadD28 and 
mmpL7 are expressed simultaneously, which suggests that DIM and INH compete for 
the same MmpL7 transporter (Pasca M.R. et al, 2005).  
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o Mmr is the only protein of the SMR family that has been described in M. 
tuberculosis (De Rossi E. et al, 1998b). The chromosomal gene mmr, when inserted 
into a multicopy plasmid, decreases the susceptibility of M. smegmatis to TPP, EtBr, 
erythromycin, acriflavine, safranin O and pyronin Y. Accumulation assays have shown 
that Mmr extrudes TPP, in a process dependent of the proton motive force. The 
presence of mmr-like genes in other Mycobacterium species (M. simiae, M. gordonae, 
M. marinum and M. bovis) has been demonstrated by Southern hybridization (De Rossi 
E. et al, 1998b). 
 
o The operon Rv0341-Rv0342-Rv0343 was demonstrated to be induced by treatment 
with INH (Alland D. et al, 1998). The three genes that form this operon were designated 
as iniB, iniA and iniC (for isoniazid inducible gene) in the order that they appeared in 
the operon. From the three genes the most studied is iniA and it has been shown that it 
may be involved in the development of tolerance to INH and EMB (Colangeli R. et al, 
2005). In fact, deletion of iniA from M. tuberculosis increased the susceptibility to INH, 
whereas the overexpression of this gene in M. bovis allowed the survival of the 
organism for a longer period of time in the presence of INH and EMB and also resulted 
in resistance to EtBr. The exposure of the iniA overexpressing M. bovis BCG strain to 
reserpine reversed both tolerance to INH and resistance to EtBr. The fact that IniA 
forms multimeric structures containing a central pore suggests that this protein could 
be a pump component. By this manner, IniA may function through an efflux pump like 
mechanism, although it does not seem to directly transport INH from the bacterial cell 
(Colangeli R. et al, 2005).  
 
I.6.3 Efflux pump inhibitors and the “helper compound” concept 
The contribution of efflux pumps to the increase of multidrug resistance has made 
these pumps new drug targets for the development of new antimicrobial drugs that can 
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be used in combination with an antibiotic (Martins M. et al, 2008; Pagès J.M. et al, 
2009). Strategies to combat efflux mediated resistance involve the modification of 
antibiotics into derivatives that are minimally affected by efflux and the development of 
therapeutic agents that inhibit the efflux activity (efflux pump inhibitors, EPIs) and can 
be used as adjuvants (also called ‘helper compounds’) to existing antibiotics. However, 
to be strictly definied as an EPI, a compound has to satisfy several criteria: 1) it must 
enhance the activity of multiple substrates of the pump; 2) it must not potentiate 
antibiotics that are not efflux substrates; 3) it must not have activity in strains lacking 
efflux pumps; 4) it must increase accumulation and decrease extrusion of efflux pump 
substrates; and 5) it must not affect the proton gradient across the inner membrane 
(Lomovskaya O. et al, 2001). Although until now no EPI has fully answered these 
criteria nor reached or passed clinical trials for the treatment of bacterial infections, 
several compunds have been used to inhibit efflux activity in vitro. A classic example is 
CCCP, which affects the energy level of the bacterial membrane and is used to 
dissipate the proton motive force and inhibit the efflux of several drugs. However, this 
compound also reduces the viability of the bacterium and cause cell death and, 
therefore, the observed effect on the efflux activity may be due to causes other than 
efflux inhibition. Moreover, this compound is described as highly noxious and cytotoxic 
and is also a substrate of efflux pumps (Krulwich T.A. et al, 1990; Pagès J.M. et al, 
2009). 
 
Phe-Arg-β-naphthylamine (PAβN) is a peptidomimetic that was described to inhibit the 
efflux of quinolones in Pseudomonas aeruginosa (Renau T.E. et al, 2002). This 
molecule has showed an activity against other efflux systems of E. coli, E. aerogenes, 
Klebsiella pneumoniae and Salmonella enterica (Lomovskaya O. et al, 2006; 
Lomovskaya O. et al, 2007; Pagès JM et al, 2005). However, the MexB efflux pump of 
P. aeruginosa recognizes PAβN as a pump substrate (Lomovskaya O. et al, 2007). 
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PAβN acts by competition with an antibiotic that is substrate of an efflux pump system. 
This results in the extrusion of PAβN, while the antibiotic remains in the cell until it 
reaches its target. By this manner, PAβN reduces/reverses resistance to a certain 
antibiotic to which the bacteria were initially resistant (Pagès J.M. et al, 2009). 
 
It has been demonstrated that phenothiazines, such as thioridazine and 
chlorpromazine, reduce or reverse multidrug resistance in bacteria (Amaral L. et al, 
2004; Kristiansen M.M. et al, 2003; Michalak K. et al, 2006; Molnar J. et al, 1997). 
These compounds inhibit the transport of calcium (Ca2+) by preventing its binding to 
Ca2+-binding proteins, such as calmodulin (Martins M. et al, 2008; Weiss B. et al, 
1980). As a consequence, enzyme systems dependent of Ca2+, such as those involved 
in generating cellular energy from hydrolysis of ATP, are inhibited (Garcia J.J. et al, 
1995). Considering that overexpression of efflux pumps is associated with multidrug 
resistance and that most of these systems are driven by the proton-motive force, which 
is dependent of Ca2+-dependent enzyme systems, the inhibition of Ca2+-dependent 
enzymes will render the bacteria susceptible to an antibiotic to which they were initially 
resistant (Bhatnagar K. et al, 2003; Martins M. et al, 2008). Furthermore, it has been 
shown that phenothiazines also enhance the killing of intracellular bacteria. This can be 
due to a concentration effect, as the agent reaches lethal concentrations inside the 
macrophage, or to the inhibition of K+ and Ca2+ transport processes (Wittekindt O.H. et 
al, 2006). Although the concentration effect cannot be ruled out, recent experiments 
have shown that inhibitors of K+ and Ca2+ transport enhance the killing of intracellular 
bacteria, further suggesting that phenothiazines enhance killing by the same 
mechanism (Ahluwalia J. et al, 2004; Martins M. et al, 2008).  
 
Reserpine is a plant alkaloid known to inhibit P-gp in eukaryotic cells (Marquez B., 
2005; Stavri M. et al, 2007). Other studies demonstrated that reserpine increases the 
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activity of fluoroquinolones on multidrug resistant (MDR) Gram-positive bacteria, 
decreases the emergence of resistance in S. aureus and S. pneumoniae in vitro and 
inhibits LmrA, an ABC efflux system of L. lactis (Brenwald N. et al, 1997; Markham P.N. 
et al, 1996; Markham P.N., 1999; Marquez B., 2005). However, bacterial resistance to 
reserpine has already been described (Ahmed M. et al, 1993).  
 
The calcium channel antagonist verapamil, another known inhibitor of P-gp, also 
inhibits several bacterial ABC efflux pumps, including EfrAB of Enterococcus faecalis, 
and Rv2686c-Rv2687c-Rv2688c and DrrAB of M. tuberculosis (Choudhuri B.S. et al, 
2002; Lee E.W. et al, 2003; Pasca M.R. et al, 2004). 
 
In summary, various compounds have been used to inhibit efflux activity in vitro, but 
none of them is used in clinical practice for this purpose. These inhibitors could be 
used as ‘helper compounds’, administered in combination with conventional antibiotics 
to which the organism was initially resistant. However, clinical trials are needed to 
demonstrate the importance of efflux inhibitors in the therapy of drug resistant bacterial 
infections. There is also a concern regarding the selectivity of these compounds, since 
some of them have been shown to inhibit both eukaryotic and bacterial efflux systems 
(Marquez B., 2005; Martins M. et al, 2008). In conclusion, the search for EPIs has 
proven to be a challenge and more studies are required until effective and specific 
inhibitors are found. 
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I.7 Objectives of this thesis 
The main objective is to study the role of efflux mechanisms in the development of 
multidrug resistance in M. tuberculosis and how phenotypic resistance, mediated by 
efflux pumps, correlates with genetic resistance. The concept behind this work consists 
in the fact that increased activity of efflux pumps can occur in response to prolonged 
exposure to subinhibitory concentrations of anti-TB compounds, a common situation 
that results from inadequate TB therapy. This may render an organism increasingly 
resistant to the compound and be the basis for the maintenance of an increased 
mycobacterial population in the patient undergoing therapy. The inhibition of 
mycobacterial efflux would restore activity of an antibiotic subject to efflux and provide 
a way to enhance the activity of current anti-TB drugs.  
In order to evaluate the contribution of efflux to drug resistance in M. tuberculosis, 
several experimental protocols had to be developed and optimized before their 
application to M. tuberculosis. This was performed using biological models such as E. 
coli and the fast growing mycobacteria M. smegmatis, since M. tuberculosis is a slow-
growth mycobacteria and a level III pathogen. By using other microorganisms as 
experimental models, one can thus overcome the biosafety difficulties and time 
consuming aspect associated with this pathogen, and obtain reliable methods that are 
easily applied to M. tuberculosis. By this manner, the following approach has been 
used in this work: 
 
o Development of a protocol that would allow the quantification of the 
expression level of genes coding for efflux pumps (Chapter II) 
 In order to correlate the bacterial phenotypic resistance provided by efflux pumps with 
the genetic expression of genes encoding those pumps, it was necessary to develop 
and optimize a protocol based on the real-time quantitative reverse transcriptase-
polymerase chain reaction (qRT-PCR) methodology. This was performed using E. coli 
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K-12 as a conceptual model, comparing the mRNA levels extracted from E. coli strains 
induced to resistance to TET with the mRNA extracted from the susceptible non-
induced counterparts. The use of E. coli as a model allowed not only the development 
of a protocol that would be applied to M. tuberculosis, but also demonstrated a 
sequence of events concerning the regulation of efflux pumps and porins during the 
TET adaptation process, thus providing more insight to the complex mechanisms of 
regulation of efflux activity (Viveiros M. et al, 2007). 
 
o Development of a fluorometric method that allows the real-time detection of 
efflux pump activity (Chapter III)  
An efflux quantification protocol was developed using real-time fluorometry to measure 
the accumulation and extrusion of EtBr. Using E. coli K-12 AG100 as a model, it was 
possible to study the accumulation of EtBr under conditions that limit energy (i. e. 
absence of glucose, low temperature) and its extrusion under optimum conditions. It 
also allowed the determination of the activity of efflux inhibitors, namely 
chlorpromazine, in the transport of EtBr across the cell-wall. Furthermore, the 
application of this method allowed the development of a mathematical model that 
quantifies EtBr transport across E. coli cell wall (Paixão L. et al, 2009; Viveiros M. et al, 
IJAA, 2008a; Viveiros M. et al, 2010a). 
 
o Application of the fluorometric method to mycobacteria: assessment of EtBr 
transport across the M. smegmatis cell-wall (Chapter IV) 
After the optimization of the main parameters and experimental conditions using E. coli 
K-12 AG100 as a model, the real-time fluorometric method was used for the 
assessment of efflux pump activity in mycobacteria, starting with the adjustment of 
parameters using M. smegmatis mc2155 (a frequently used model in mycobacterial 
research) and mutant strains carrying a deletion of genes coding for an efflux pump or 
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for porins (Li X.Z. et al, 2004; Niederweiss M. et al, 1999) and correlated this 
information with an antibiotic profile. Since many homologous pumps are present in 
both M. tuberculosis and M. smegmatis, studies that use M. smegmatis as a model 
organism can provide data that will help to understand efflux-mediated drug resistance 
mechanisms in other mycobacteria, including M. tuberculosis and M. avium (Li X.Z. et 
al, 2004; Rodrigues L. et al, 2008; Rodrigues L. et al, 2010). 
 
o Study of the role of efflux pumps in antimicrobial resistance: the case of M. 
avium complex and macrolide resistance (Chapter V) 
The study of efflux activity of M. avium complex strains is of interest due to their clinical 
prevalence among HIV-infected patients and will provide data for the selection of the 
most effective EPIs to be used in M. tuberculosis strains. The real-time fluorometric 
method previously developed was used to detect the efflux activity of reference strains 
and clinical isolates of M. avium complex. This efflux activity was correlated with an 
antibiotic profile obtained by the determination of MICs of macrolides in the presence 
and absence of agents such as chlorpromazine, thioridazine and verapamil (Rodrigues 
L. et al, 2008; Rodrigues L. et al, 2009).  
 
o Efflux pumps and isoniazid resistance in M. tuberculosis complex (Chapter 
VI)  
M. bovis BCG strain Pasteur, M. tuberculosis H37Rv (ATCC27294) and M. tuberculosis 
clinical strains, susceptible to INH, were induced to resistance by a gradual, step-wise 
increase of antibiotic concentration over a prolonged period of time (Viveiros M. et al, 
2002). Evaluation of efflux pump activity as the cause of INH induced resistance was 
performed using the real-time fluorometric method and the expression of genes coding 
for efflux pumps was conducted by qRT-PCR. This data coupled with the determination 
of the MIC of INH in the presence and absence of efflux inhibitors, such as 
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chlorpromazine, thioridazine, verapamil and reserpine, provided information concerning 
the role of efflux pumps in the development of INH resistance in M. tuberculosis 
complex.   
 
In summary, this thesis aimed to increase the understanding of the mechanisms of 
efflux-mediated bacterial resistance, using a working algorithm based on the 
development of techniques that allow the detection and quantificaton of efflux activity 
on a real-time basis. The ultimate objective consists in the application of these 
techniques, and data obtained with experimental bacterial models, to M. tuberculosis in 
order to clarify the role of efflux pumps in the mechanism(s) by which this organism 
becomes resistant to INH and one step closer to multidrug resistance. Moreover, the 
clarification of how intrinsic resistance, provided by the increased activity of efflux 
pumps, correlates with the emergence of genetic resistance, by the occurrence of 
mutations, will provide further insight on the mechanims behind the emergence of 
MDR/XDRTB. By this manner, a possible strategy to prevent the emergence of such 
resistant strains could be the use of efflux inhibitors that would restore the activity of 
the antibiotic(s) subject to efflux by inhibiting the efflux pump. Furthermore, it has been 
shown that inhibitors of K+ and Ca2+ efflux pumps enhance the killing of intracellular M. 
tuberculosis by nonkilling macrophages. This double effect wielded by these inhibitors 
(inhibition of bacterial efflux activity and enhancement of killing activity by the 
macrophage) may be a potential strategy to be used in the control of MDR/XDRTB 
(Viveiros M. et al, 2010b). 
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Antibiotic Stress, Genetic Response and Altered Permeability of  
Escherichia coli 
 
II.1 Summary 
Membrane permeability is the first step involved in resistance of bacteria to an 
antibiotic. The number and activity of efflux pumps and outer membrane proteins that 
constitute porins play major roles in the definition of intrinsic resistance in bacteria that 
is altered under antibiotic exposure.  
In this work we describe, with the aid of real-time qRT-PCR and western blot detection, 
the genetic regulation of porins and efflux pumps of E. coli, used as a working model 
for the mycobacteria work in the forthcoming chapters, during prolonged exposure to 
increasing concentrations of TET. This study demonstrates that, in addition to the 
transcriptional regulation of genes coding for membrane proteins, the post-translational 
regulation of proteins involved in the permeability of bacteria also plays a major role in 
the physiological adaptation to antibiotic exposure. A model is presented that 
summarizes the events that occur during the physiological adaptation of E. coli to TET. 
This work also allowed for the development of an qRT-PCR protocol that would be 
latter adapted to M. tuberculosis (Chapter VI). 
 
II.2 Introduction 
Intrinsic antibiotic resistance in Gram-negative bacteria (without chromosomal mutation 
or acquisition of mobile genetic elements encoding resistance determinants) can be 
increased by preventing the antibiotic from entering the cell. This can be achieved by 
the control of the outer membrane permeability and by the efflux of antibiotics (Gootz 
T.D., 2006; Nikaido H., 2001; Piddock L.J., 2006). Intrinsic resistance to antibiotic 
agents is mainly attributed to the outer membrane of Gram-negative bacteria that acts 
as a barrier and delays the influx of various antibiotics, detergents and dyes, and to 
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efflux pumps, which extrude the drug to the exterior of the cell, enabling the bacteria to 
survive in the presence of these noxious agents (Davin-Regli A. et al, 2006; Nikaido H., 
2001). Additional resistance is afforded by overexpressed efflux pumps that extrude a 
wide variety of unrelated antibiotics. Overexpressed efflux pumps of Gram-negative 
bacteria result in a MDR phenotype known to be a prevalent form of clinical resistance 
(Piddock L.J., 2006; Viveiros et al, 2007). It was previously demonstrated that it is 
possible to induce high-level resistance to TET in susceptible E. coli K-12 by a gradual, 
step-wise increase in the exposure to the antibiotic (Viveiros M. et al, 2005). The 
induction process took about 110 days and this resistance was reversed by transfer to 
drug free medium or by the use of PAβN, an inhibitor of the AcrAB efflux pump system 
(Davin-Regli A. et al, 2006; Piddock L.J., 2006; Viveiros M. et al, 2005). The major 
inner membrane transporter genes of E. coli K-12 were overexpressed after prolonged 
exposure to TET, with acrB being the most expressed transporter gene and a clear 
connection between the induced activity of the AcrAB system and TET induced 
resistance was demonstrated (Viveiros M. et al, 2005). Besides becoming resistant to 
TET, the induced strain became resistant to a variety of other antibiotics, detergents 
and dyes that are not substrates of the AcrAB system (Davin-Regli A. et al, 2006; 
Piddock L.J., 2006; Viveiros M. et al, 2005). The development of this MDR phenotype 
led us to explore and analyse the interplay between the major efflux pump systems 
present in E. coli and the control of the outer membrane permeability through the 
regulation of porin channels. In E. coli, outer membrane permeability is regulated by 
the balance of porin proteins, the diffusion channels that are the major route for 
passage of small hydrophilic compounds (Nikaido H., 2001; Nikaido H., 2003; Pagès 
J.M. et al, 2005). The two major outer membrane proteins in E. coli are OmpC and 
OmpF, consisting of three 16-stranded β-barrels defining a transmembrane pore in the 
outer membrane (Basle A. et al, 2006; Cowan S.W. et al, 1992). Highly expressed 
under optimal environmental conditions, their level of expression is adjusted when it is 
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necessary to minimize penetration of noxious compounds or maximize access to 
nutrients (Ferenci T., 2005; Liu X. et al, 2001; Nikaido H., 2003). It has been 
demonstrated that the level of expression of porins OmpC and OmpF not only controls 
the permeability of the outer membrane to glucose and nitrogen uptake under nutrient 
limitation (Ferenci T., 2005; Liu X. et al, 2001), but may also be differentially regulated 
by the concentration of certain antibiotics in the environment (Castillo-Keller M. et al, 
2006; Davin-Regli A. et al, 2006; Randall L.P. et al, 2002;). The OmpC and OmpF 
coding genes are transcriptionally regulated by a two-component signal transduction 
regulatory system consisting of the OmpR and EnvZ proteins (Hall M.N. et al, 1981). 
Recently, it has been shown that the overexpression of OmpX, structurally related to 
the eight β-strand OmpA (a major outer membrane protein  involved in the stabilization 
of the bacterial membrane), leads to a decrease in the expression of OmpC and OmpF 
porins and a decreased susceptibility to β-lactams and other antibiotics in E. coli 
(Dupont M. et al, 2004).  
Besides porins, efflux pumps also play an important role in the control of bacterial 
permeability that contributes to the development of an MDR phenotype. 
E. coli has been shown to have at least nine distinct proton dependent efflux pump 
systems that bestow resistance to two or more antibiotics (MDR). The genes coding for 
each of these efflux pumps are emrE, acrEF (formerly envCD), emrAB, emrD, acrAB-
tolC, mdfABC, tehA, acrD (an acrB homologue) and yhiUV (Edgar R. et al, 1995; 
Kawamura-Sato K. et al, 1999; Lomovskaya O. et al, 1992; Ma D. et al, 1995; 
Naroditskaya V. et al, 1993; Nishino K. et al, 2001; Purewal A.S., 1991; Rosenberg 
E.Y. et al, 2000; Turner R.J. et al, 1997). These transporters belong to one of three 
efflux pump families: MFS (emrD, mdfA, emrB), RND (acrB, acrF, acrD, yhiV) and SMR 
(emrE, tehA) (Davin-Regli A. et al, 2006; Piddock L.J., 2006). The tripartite AcrAB-TolC 
system is the most well-studied MDR pump system consisting of an inner membrane 
efflux transporter (AcrB) that removes antibiotics from the cytoplasm to the periplasm, 
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where the linker protein (AcrA) directs the inter-membrane transport of the antibiotic 
through the outer membrane channel (TolC) to the environment (Nikaido H., 2001; 
Pagès J.M et al., 2005; Piddock L.J., 2006). The major efflux pump systems in E. coli 
are from the RND family and have broad substrate specificity. Their expression is 
controlled by transcriptional activators like the MarA, encoded by the multiple antibiotic 
resistance operon marRAB, and homologs like SoxS and Rob (Cohen S.P. et al, 1993; 
Davin-Regli A. et al, 2006; Martin R.G. et al, 2001). MarA not only controls the 
expression of efflux systems, but is also involved in the control of porin expression (by 
decreasing it) through the activation of micF, a small antisense RNA that binds with 
ompF mRNA preventing its translation, and activates the expression of the porin 
expression down-regulator OmpX (Dupont M. et al, 2004; Barbosa T.M. et al, 2000). 
These global activators, when induced by oxidative stress or the presence of noxious 
compounds in the environment, enhance resistance of enterobactereaceae to a variety 
of antibiotics, hence an MDR phenotype (Davin-Regli A. et al, 2006; Delihas N. et al, 
2001; Nakajima H. et al, 1997). Moreover, they control the degree of intrinsic 
resistance of enterobactereaceae and increase the level of efflux pump expression. 
The regulation of porin level and expression of multidrug resistance efflux pumps has 
been suggested to occur by a common pathway and/or a cascade of events (Davin-
Regli A. et al, 2006; Li X.Z. et al, 2004). Studies of step-wise induction of resistance, 
like the gradual exposure of E. coli K-12 to TET, may afford an understanding of the 
genetic regulation of multidrug resistance efflux pumps, their interplay and relationship 
to the permeability barrier (Viveiros M. et al, 2005). Therefore, with the aid of real-time 
qRT-PCR and western blot detection we have analysed and correlated the activity of: 
(i) regulatory genes that affect the MDR phenotype, (ii) genes that code for efflux 
pumps; (iii) genes that encode outer membrane proteins; and (iv) the level of outer 
membrane proteins during the process of induced resistance of E. coli K-12 to 
increasing concentrations of TET.  
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II.3 Results 
 
II.3.1 Inducement of resistance to tetracycline 
The TET susceptible E. coli K-12 AG100 parent strain (MIC of 2.0 mg/L) was induced 
by gradual stepwise increase of TET to significant levels of resistance to the antibiotic 
(Figure II.1) (Viveiros M. et al, 2005). Repeated serial transfer of the TET induced 
strain to drug-free medium restored the level of susceptibility to that initially present in 
E. coli K-12 AG100 after 40 days (Figure II.1). 
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Figure II.1. Time course of inducement of TET resistance in E. coli K-12 AG100 and reversal of 
induced resistance by transfer to drug-free medium. The strain was induced to TET resistance 
by serial transfer of the bacteria to media containing increasing concentrations of the antibiotic 
(+ TET). Reversal of resistance was achieved by serial transfer to drug-free medium (- TET). 
MICs were periodically determined and confirmed in solid media by the TET E-test (AB Biodisk, 
VIVA Diagnostica, Huerth, Germany) according to the manufacturer’s instructions (Viveiros M. 
et al, 2005). 
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The MICs of a panel of antibiotics were determined for E. coli K-12 AG100 and for the 
TET induced strain, designated as E. coli AG100TET. As shown by the data presented 
in Table II.1, susceptibility of AG100TET is significantly decreased, with the exception of 
kanamycin and erythromycin. The MICs of EtBr and efflux inhibitors against the above 
mentioned strains are presented in Table II.2 
 
Concerning the effect of known efflux inhibitors, used at ½ of their MIC, to prevent any 
direct effect on the growth of E. coli K-12 AG100 and AG100TET (Viveiros M. et al, 
2005), chlorpromazine, CCCP and PAβN reduced the MIC of TET against AG100 from 
2.0 to 0.5 mg/L (Table II.3). With respect to the effects of the above inhibitors on the 
susceptibility of AG100TET to TET, CPZ and PAβN reduced the susceptibility of this 
from 12 to 0.5 mg/L. 
 
Table II.1. MIC of antibiotics against E. coli K-12 AG100 and AG100TET. 
Antibiotic 
MIC (mg/L) 
E. coli AG100 E. coli AG100TET 
Tetracycline 2.0 12 
Kanamycin 15 10 
Erythromycin 100 100 
Ofloxacin 0.12 0.48 
Ciprofloxacin 0.03 0.12 
Chloramphenicol 8.0 >16 
Penicillin 16 64 
Oxacillin 256 >512 
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Table II.2. MICs of EtBr and efflux inhibitors against E. coli AG100 and AG100TET. 
Compound 
MIC (mg/L) 
E. coli AG100 E. coli AG100TET 
EtBr 150 300 
CPZ 60 140 
CCCP 10 20 
PAβN >200 >200 
EtBr, ethidium bromide; CCCP, carbonyl cyanide m-chlorophenylhydrazone; CPZ, chlorpromazine; PβAN, 
Phe-Arg-β-naphtylamide. 
 
Table II.3. MICs of TET in the presence and absence of and efflux inhibitors against E. coli 
AG100 and AG100TET. 
Compound 
MIC (mg/L) 
E. coli AG100 E. coli AG100TET 
TET 2 12 
TET + CPZ 0.5 3 
TET + CCCP 0.5 12 
TET + PAβN 0.5 0.5 
CCCP, carbonyl cyanide m-chlorophenylhydrazone; CPZ, chlorpromazine; PβAN, Phe-Arg-β-
naphtylamide; TET, tetracycline. 
 
II.3.2 Evaluation of gene expression by qRT-PCR 
The step-wise induction of TET resistance in E. coli K-12 afforded an understanding of 
the genetic regulation of multidrug efflux pumps and their interplay with the permeability 
barrier (Viveiros M. et al, 2005). By this manner, real-time qRT-PCR was used to 
analyse the activity of genes that code for transcriptional regulators, efflux pumps and 
outer membrane proteins that may be involved in this process of induced resistance by 
prolonged exposure to increasing concentrations of TET. This analysis was performed 
at the end of four stages of the induction process; control culture (no TET added); the 
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initial stage where the cells are first exposed to 1.5 mg/L of TET (MIC 2 mg/L); half-way 
of the induction process where they grew at 4.0 mg/L of TET (MIC 6 mg/L) and at the 
end of the induction process where they grew at 10 mg/L of TET (MIC 12 mg/L). The 
results obtained are presented by Figure II.2 and discussed bellow in terms of 
relationships that have been established for regulatory and responding genes. 
 
II.3.2.1 Genes responding to stress: 
 
(i) soxS and rob  - After resistance to TET has been established at the highest initial 
concentration of the antibiotic (i.e. 1.5 mg/L), the response of the soxS gene is 2.8 
times more active than that of the unexposed control. This response is further 
increased to 3.5 times after resistance to 4 mg/L has been achieved. However, by the 
time the strain has become resistant to 10 mg/L of TET, the response of the gene has 
been reduced to a level below that initially observed, suggesting that the stress gene 
soxS performs its functions quite early under conditions of antibiotic pressure. The 
activity of the rob gene during the process of TET induced resistance is significantly 
increased after the bacteria become resistant to 4 mg/L of TET. As was the case of the 
other stress-response gene soxS, the increased activity noted is apparently not 
required for higher levels of resistance (i.e. 10 mg/L). Although rob has been reported 
to respond to exposure to solvents, detergents and metals (Ariza R.R. et al, 1995; 
Nakajima H. et al, 1995), an antibiotic response is included in this study. Moreover, the 
parallel response of both stress-responding genes noted in the current study supports 
the conclusions of Michan et al. (Michan C. et al, 2002). 
 
(ii) marA, marB and marR  - The regulatory product of gene marR is known to down-
regulate the activity of genes marA and marB by binding to the promoter region of the 
operator marO. TET is known to bind to the product of marR, causing a MDR 
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phenotype (Martin R.G. et al, 1995). Once the repressor activity is inhibited, there is an 
increase of the activity of the universal regulator marA. This is confirmed by the data in 
Figure II.2. In fact, of all of the regulator genes, it is marA which is increased to the 
highest level (9.7 fold) at the time that the organism has developed resistance to 10 
mg/L of TET.  
Although nothing is known of the role of marB during MDR phenotypic expression, its 
expression is increased along with marA. However, their precise relationship during the 
development of induced resistance to TET remains to be clarified.  
 
(iii) micF - micF codes for an antisense small RNA that has been shown to down-
regulate outer membrane proteins (Pratt L.A. et al, 1996) and is activated by marA, rob 
and sox (Guillier M. et al, 2006). In this study, the increase of activity of micF reaches 
its maximum level when the organism has become resistant to 10 mg/L of TET and 
parallels the rise of activity of marA. This behaviour of micF was also found in other 
studies (Barbosa T.M. et al, 2000). The overproduction of MicF has been previously 
reported to decrease the amount of ompF mRNA (Guillier M. et al, 2006). In fact, a 3-
fold decrease of porin mRNA was observed after resistance to 4 and 10 mg/L of TET 
had been induced (Figure II.2). This variation may be caused by the MicF effect on 
ompF mRNA. Similarly MicC may have the same effect on ompC mRNA stability. In 
contrast, it is important to note that the level of ompF mRNA and ompC mRNA of TET 
exposed cells remained, at least, similar to that observed for the untreated control (ratio 
of 1 at 10 mg/L of TET). 
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Figure II.2. Relative expression of outer membrane proteins, transcriptional regulators and 
inner membrane transporter genes. Data from three independent total mRNA extractions of E. 
coli AG100TET (physiologically adapted to increasing concentrations of TET) compared to its 
parental non-induced strain (E. coli K-12 AG100) grown in the absence of antibiotic. A ratio of 1 
corresponds to no alterations in expression compared with the untreated control cells. Values 
were corrected for standard deviation range.  
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II.3.2.2 Efflux pump genes 
 
acrAB and the other efflux pump transporter genes - The response of the acrAB-
tolC when the organism is initially exposed to a concentration of TET of 1.5 mg/L (MIC 
of 2 mg/L) is marginal. This suggests that the activity of this system under initial 
conditions of stress imposed by the exposure to low levels of TET is sufficient for the 
organism to escape from harm. With further exposure to increasing concentrations of 
TET, the expression of acrAB-tolC increases as the organism becomes more and more 
resistant to the antibiotic.  
The response of the other efflux pump transporter genes is one of increased activity. 
However, with the exception of the yhiV efflux transporter gene, an RND type efflux 
pump in E. coli with significant homology to AcrB (Bohnert J.A. et al, 2007), the level of 
activity expressed by the other efflux systems is much less than that evident for the 
acrB and yhiV. In addition, the other efflux pump genes express the highest level of 
activity when the organism has reached a level of resistance of 4 mg/L and with further 
increase of resistance, their level decreases. This suggests that the stress imposed 
during the early stages of exposure to TET requires the cooperation of all of the efflux 
pumps and, as the level of activity of the two main efflux pumps of the bacterium is 
increased, there is a reduction in activity of the other pumps. The increased activity of 
acrAB-tolC parallels the increased activity of the regulator marA, a relationship that has 
been proposed in other studies (Barbosa T.M. et al, 2000). 
 
II.3.2.3 Stress regulator genes of outer membrane proteins  
 
ompR and envZ - The ompR and envZ genes are regulators of outer membrane 
proteins that permit hydrophilic compounds to enter the cell. These regulators belong to 
the two-component signalling family and modulate gene activities of ompF and ompC, 
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the two major outer membrane protein genes that code for tri-barrel porins (Nikaido H., 
2003). When E. coli is under stress, a cascade of gene activities is initiated, involving 
several global regulators such as MarA and MicF, which result in the down-regulation 
of porins (Ferenci T., 2005; Martin R.G. et al, 2001; Pratt L.A. et al, 1996). This down-
regulation results in decreased activity of ompF and ompC. As shown in Figure II.2, 
whereas the increase in the expression of the ompR and envZ genes is maintained for 
the duration of exposure to increasing concentrations of TET, the response of the 
ompA, C and F genes is transiently increased and subsequently reduced to levels 
comparable to those of the E. coli cells that were not exposed to TET. 
Since micF is considered to be a post-transcriptional regulator of porins, the activity of 
ompF and ompC may be a result of the expression of this gene. A high increase in the 
micF expression was observed in TET induced cells (Figure II.2). MicF binds the ompF 
mRNA generating an RNA duplex that alters the translation and mRNA stability. Since 
over-production of MicF is observed in TET induced cells, a decrease of ompF mRNA 
would be expected as described with OmpC (Chen S. et al, 2004). In contrast, the 
porin mRNA level is similar to that produced in untreated cells.  
 
The analyses of genes involved in the increased resistance to TET suggest that the up-
regulation of efflux pump genes is accompanied by a decrease of OmpF and OmpC 
synthesis. As shown by an immunoblot analysis presented in Figure II.3, OmpC is 
reduced and OmpF is significantly reduced in the strain that has become resistant to 10 
mg/L of TET. The observed alterations in porin content were confirmed by the use of 
the antibody that recognizes the specific internal loop domain of general porins (Figure 
II.3). These results are consistent with the notion that when the bacterium is placed 
under antibiotic stress, in conditions that permit it to adjust (namely slow exposure to 
sub-lethal concentrations of the antibiotic and nutrient availability), resistance is 
increased by the upregulation of efflux pumps and down-regulation of porins.  
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Figure II.3. Immunodetection of outer membrane proteins. The detections were carried out 
using antisera prepared against OmpC porin (A), OmpF porin (B), antigenic peptide located 
inside the internal loop 3 porin (C), OmpA (D) and OmpX (E), respectively. Immunodetection 
were carried out with total cell extracts from non-induced E. coli K-12 AG100 (1, 2) and E. coli 
AG100TET induced to 10 mg/L of TET (3, 4). Strains were grown in LB and MH media (odd and 
even lanes, respectively). 
 
OmpA and OmpX - OmpA is considered to be a structural outer membrane protein 
that contributes to the integrity of the cell envelope as a tri-barrel structure (Ruiz N. et 
al, 2006). In this study, there was a transient increase of ompA expression when the 
organism became resistant to 4 mg/L of TET (Figure II.2). An explanation could be that 
the exposure to increasing concentrations of TET reduces protein synthesis and thus 
the need for structural strengthening of the cell envelope takes place. However, with 
the increased activity of efflux pumps and down-regulation of OmpC and F, fewer 
molecules of antibiotic reach their ribosomal targets even when resistance to TET has 
increased to 10 mg/L, and the extra need for OmpA is obviated. 
 
OmpX is an outer membrane protein whose over-production is described to induce a 
reduction of the porin level in E. aerogenes (Dupont M. et al, 2004). In the results 
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presented in Figure II.2, the activity of ompX is the highest of all of the genes 
evaluated. Since the level of OmpX detected is also increased in TET induced strains 
(Figure II.3), the regulatory role of this outer membrane protein may involve a direct 
effect on porin assembly. Two hypotheses may be proposed: (i) OmpX alters the 
normal synthesis of outer membrane proteins; and (ii) a component such as a 
chaperone is required for the construction of nascent porin (Ruiz N. et al, 2006). 
Concerning the first hypothesis, no modification of OmpA synthesis was noted in TET 
induced strains (Figure II.3) suggesting a more specific effect of OmpX on the porin 
expression. In this respect, the overproduction of OmpX and TolC in the strain induced 
to 10 mg/L of TET may induce a saturation of outer membrane protein chaperones, 
such as YaeT and YfiO, that are necessary for the insertion of stably folded proteins 
into the outer membrane and subsequent construction of the tri-barrel porin (Ruiz N. et 
al, 2006; Wu T. et al, 2005). The increase of OmpX may then impair the normal 
assembly of porins. The unstable unfolded porin monomers will then be degraded by 
Deg proteases, serine-type proteases that play an important role in the proteolysis of 
misfolded and damaged proteins, to avoid toxic accumulation of abortive membrane 
protein (Castillo-Keller M. et al, 2006), leading to drastic decrease of porin content as 
has been observed in the TET induced cells. This hypothesis is supported by recent 
data showing competition between TolC and porins during assembly and by the role of 
DegP protease that removes the misfolded membrane proteins accumulated within the 
periplasm (Castillo-Keller M. et al, 2006; Charlson E.S. et al, 2006). In addition, the 
degradation of misassembled unfolded forms of porin occurs very rapidly due to their 
unstable conformation (Bolla J.M. et al, 1988). Moreover, an increased activity of genes 
that code for proteases in E. coli (Charlson E.S. et al, 2006; Douchin V. et al, 2006) 
was noted in this study (Figure II.4). The activity of degP, clpP, rseP and degS was 
increased from 2 to 4-fold after the organism has become resistant to 10 mg/L of TET 
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and may account for the large reduction of porins due to the degradation of unfolded 
forms of OmpC and OmpF (Figure II.4). 
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Figure II.4. Relative quantification of the expression level of the protease genes. Data from 
three independent total mRNA extractions of E. coli AG100 physiologically adapted to 
increasing concentrations of TET compared to its parental non-induced strain grown in absence 
of TET. A ratio of 1 corresponds to no alterations in expression compared with untreated control 
cells. Values were corrected for standard deviation range.  
 
II.4 Conclusions 
In this study, E. coli K-12 AG100 becomes increasingly resistant to TET when 
exposure to TET is gradually increased. The increased expression of efflux pumps is 
not the only mechanism involved in the physiological adaptation processes to TET 
pressure, there is a well-regulated and coordinated interplay between events at the 
genetic level and protein folding that decrease permeability of the cell envelope and 
increase efflux pump activity. In the presence of initial non-lethal concentrations of TET, 
the wild-type E. coli reacts through the activation of early stress responses as seen by 
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the immediate increase of the global regulators like MarA, SoxS, Rob and the 
activation of membrane and periplasmic proteases that release sigma factors in order 
to regulate the two major outer membrane proteins OmpC and OmpF. Following this 
initial stress response, a long-term adaptative response becomes noticeable with a 
sustainable increase of MarA that is not followed by the other two global regulators 
(SoxS and Rob) and, instead, is followed by two specific down-regulators of OmpC and 
OmpF expression, MicF and OmpX. Concomitantly, the over-expression of MarA leads 
to the transcriptional activation of AcrAB-TolC expression, the major efflux pump 
system of E. coli along with an increased expression of the other efflux systems. This is 
the basis for the development of an MDR phenotype (Baquero F. et al, 2001; Gambino 
L. et al, 1993). The gradual step-wise physiological adaptation of E. coli to TET forces 
the cell to answer to a constant stressful environment by the activation of a cascade of 
long-term events that are summarized in Figure II.5.  
 
The results and conclusions obtained in this chapter were summarized in the 
publication Viveiros M. et al, 2007. The results and conclusions of this chapter were the 
basis upon which the scientific rational was designed and implemented for the 
evaluation of the role of mycobacterial porins and efflux pumps in the development of 
MDR phenotypes, and will be presented in chapters IV, V and VI of this thesis. 
Although we have been able to demonstrate in this chapter that increased antibiotic 
pressure induces permeability changes in bacteria that promotes an MDR phenotype 
through the decrease of the porin level and overexpression of efflux pumps, which was  
put in evidence by the use of immuneblot and a qRT-PCR, there was still the need to 
develop an efficient technique to monitor and quantify the transport of porin and efflux 
pump substrates across the cell-wall of bacteria that could be correlated with multidrug 
resistance.  
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Figure II.5. TET activation cascade of E. coli resistance physiological adaptation. Broken 
arrows indicate the activation in 1 and 2 over-expression of specific gene (direct TET pressure 
effect), in 3, the regulation by induced regulators (second level of control), in 4 the effect of 
activated genes coding for membrane proteins (third level of effect). Thick arrows (5) illustrate 
the effect of over-production of outer membrane proteins and proteases. 
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II.5 Materials and Methods 
 
Materials 
The antibiotics TET, kanamycin, erythromycin, ofloxacin, ciprofloxacin, 
chloramphenicol, penicillin and oxacillin and the following compounds, EtBr, CCCP, 
chlorpromazine, and PAβN were purchased from Sigma Aldrich Quimica SA, Madrid, 
Spain. All solutions, except TET and CCCP, were prepared in distilled sterile water, 
and filtered with 0.2 µm syringe filters. TET solutions were prepared in methanol 
whereas CCCP was prepared in 50% methanol. All solutions were prepared on the day 
of the experiment. E. coli cultures were grown in solid (2% agar) or liquid Luria Bertani 
(LB) medium, purchased from Difco, Detroit, Mi, USA, which was supplemented when 
necessary at the given concentrations of the tested compounds. Mueller-Hinton (Oxoid, 
Hampshire, UK) was employed for the determination of the TET MIC by the E-test strip 
(0.016–256 mg/L), purchased from AB Biodisk (VIVA Diagnostica, Huerth, Germany). 
 
Bacterial Strains 
Wild-type E. coli K-12 AG100 strain (argE3 thi-1 rpsL xyl mtl delta (gal-uvrB) supE44) 
(Okusu H. et al, 1996), was kindly offered by Hiroshi Nikaido, Department of Molecular 
and Cell Biology and Chemistry, University of California, Berkely, California, USA. 
Growth conditions, preparation of inoculum and determination of the MIC by the broth 
macrodilution method in LB for each compound employed, and TET MIC by the E-test 
have been previously described (Eliopoulos G.M. et al, 1991; Okusu H. et al, 1996; 
Viveiros M. et al, 2005). The process by which the resistance of E. coli K-12 AG100 to 
TET was increased from 2.0 to 12.0 mg/L has been previously described (Viveiros M. 
et al, 2005). Briefly, the MICs of TET for the parental AG100 strain was initially 
determined as 2.0 mg/L (Okusu H. et al, 1996). The tubes employed for the 
determination of susceptibility to TET that would normally be discarded after a 
Chapter II - Antibiotic stress, genetic response and altered permeability of E. coli 
____________________________________________________________________________________ 
_____________________________________________________________________________ 
 
79 
 
maximum of 18 h were retained in the incubator. By the end of additional 24–48 h the 
tubes corresponding to concentration just above the MIC yielded evidence of growth. 
These cultures were tested for purity and TET susceptibility by the broth macrodilution 
method in LB and E-test (Eliopoulos G.M. et al, 1991; Viveiros M. et al, 2005). These 
new cultures were used to inoculate media containing increasing concentrations of TET 
that ranged from that from which the inoculae were prepared to higher concentrations 
and incubated at 37ºC until evidence of full growth was present. New inoculae were 
prepared from the cultures that contained the highest concentration under which the 
strains grew. This cycle was repeated until significant increase in the resistance of the 
strain to TET was evident and yielded E. coli AG100 that were capable of growing in 
LB broth containing a concentration of TET as high as 10 mg/L (MIC of 12 mg/L) 
(Viveiros M. et al, 2005).  
 
Expression analyses of the membrane efflux transporter genes, outer membrane 
proteins and regulators, by the use of real-time qRT-PCR 
The TET sensitive E. coli K-12 AG100 parent strain (MIC 2.0 mg/L) was induced to 
significant levels of resistance to TET by gradual step-wise exposure to the antibiotic. 
Transcript levels of the inner membrane efflux transporter genes of the major E. coli 
efflux pump systems proton dependent genes (acrB, acrF, acrD, mdfA, tehA, yhiV, 
emrB, emrD and emrE), the linker proteins AcrA and AcrE, the outer membrane 
channel TolC, the outer membrane proteins OmpC, OmpF, OmpA, the transcriptional 
regulators encoded by the multiple antibiotic resistance operon, marRAB, and 
homologs SoxS and Rob, porin transcription regulators ompR and envZ, the regulators 
micF and ompX, as well as the protease genes degP, clpP, rseP and degS were 
determined by real-time qRT-PCR at the end of four stages of the induction process; 
control culture (no TET added); the initial stage where the cells are first exposed to 1.5 
mg/L of TET (MIC 2 mg/L); half-way of the induction process where they grew at 4.0 
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mg/L of TET (MIC 6 mg/L) and at the end of the induction process where they grew at 
10 mg/L of TET (MIC 12 mg/L). Gene transcript levels were normalized against the E. 
coli house-keeping gene D-glyceraldehyde-3-phosphate-dehydrogenase (GAPDH). 
The change of the expression levels of these transporter genes, membrane proteins 
and regulators is presented by Figure II.2 as the relative quantification of the 
expression level in the TET induced strains relative to wild-type E. coli K-12 AG100 
grown in the absence of TET at each stage of the induction process. Each result 
represents the average of three independent cultures grown at its respective TET 
resistance induction level. A ratio of 1.00 corresponds to no change of expression of 
the transcript levels to the parental strain. To prevent the degradation of extracted RNA 
after cell lysis that might alter the expression profile of each sample at the time of 
harvesting, required for assuring reliable gene expression analyses, total RNA was 
isolated in an RNase-free environment with the aid of the RNeasy Protect Mini Kit 
(Qiagen, Hilden, Germany) according to the manufacturer’s instructions. The integrity, 
purity and concentration of the extracted RNA templates were assessed by 
spectrophotometery at 260 nm and agarose gel (1.5%). Purified RNA was stored in 
RNase-free water in microtubes and maintained at -20ºC until quantification was 
performed. The real-time quantification of the RNA templates by quantitative real-time 
one-step RT-PCR was performed in a Rotor-GeneTM 3000 thermocycler (Corbett 
Research, Sydney, Australia) strictly adhering to manufacturer recommendations of the 
QuantiTect SYBR Green RT-PCR Kit (QIAGEN, Hilden, Germany). Briefly, each 0.2 ml 
standard microtube contained, in a final volume of 25 ml, 12.5 ml of the 2× QuantiTect 
SYBR Green RT-PCR master mix, 0.25 ml of 10× QuantiTect RT mix, 900 nM of each 
primer and approximately 20 ng of total RNA in RNase free water. The primers used for 
real-time RT-PCR quantification of expression of each gene are described in Table II.3. 
These were designed using Primer Express 1.5 Software (Applied Biosystems, CA, 
USA) based on the sequence entries in the GenBank for E. coli K-12 complete genome 
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(accession number NC_000913). Primer design and PCR experimental conditions 
were optimised to minimise amplification of contaminating E. coli genomic DNA 
potentially present in the total RNA sample, as well as for the prevention of nonspecific 
primer annealing. The house-keeping GAPDH gene (Branlant G. et al, 1985) was 
chosen as the endogenous reference RNA for relative quantification since it revealed 
consistent expression levels under the experimental conditions with the primers 
presented in Table II.4.  
 
Table II.4. Primers used in this study 
Efflux transporter gene and 
house-keeping gene 
Primer sequence (5’-3’) Length of 
amplicon 
marA 
CATAGCATTTTGGACTGGAT 
TACTTTCCTTCAGCTTTTGC 
187 bp 
marB 
ATAGCAGCTGCGCTTATTC 
ACTTATCACTGCCAGTACCC 
154 bp 
marR 
AGCGATCTGTTCAATGAAAT 
TTCAGTTCAACCGGAGTAAT 
170 bp 
acrA 
CTTAGCCCTAACAGGATGTG 
TTGAAATTACGCTTCAGGAT 
189 bp 
acrB 
CGTACACAGAAAGTGCTCAA 
CGCTTCAACTTTGTTTTCTT 
183 bp 
acrD 
GATTATCTTAGCCGCTTCAA 
CAATGGAGGCTTTAACAAAC 
187 bp 
acrE 
GCCCTCCTTTATTCTGATCT 
GGCTATACGATAAGCATTGG 
166 bp 
acrF 
TAGCAATTTCCTTTGTGGTT 
CCTTTACCCTCTTTCTCCAT 
247 bp 
micF 
TCATCATTAACTTTATTTATTACCG 
GCATCCGGTTGAAATAGG 
70 bp 
soxS 
CCATTGCGATATCAAAAATC 
ATCTTATCGCATGGATTGAC 
210 bp 
rob 
GTCGTCTTTATCCTGACTCG 
TTTGTCACCCTGGAAGATAC 
189 bp 
envZ 
CGTTGAGGTCAACAAAAGTT 
GTCGGTTCTGGATACGAATA 
185 bp 
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Table II.4. (cont.) 
emrB 
ATTATGTATGCCGTCTGCTT 
TTCGCGTAAAGTTAGAGAGG 
196 bp 
emrD 
TGTTAAACATGGGGATTCTC 
TCAGCATCAGCAAATAACAG 
243 bp 
emrE 
GGATTGCTTATGCTATCTGG 
GTGTGCTTCGTGACAATAAA 
156 bp 
mdfA 
TTTATGCTTTCGGTATTGGT 
GAGATTAAACAGTCCGTTGC 
182 bp 
tehA 
TGCTTCATTCTGGAGTTTCT 
TCATTCTTTGTCCTCTGCTT 
232 bp 
yhiV 
GCACTCTATGAGAGCTGGTC 
CCTTCTTTCTGCATCATCTC 
203 bp 
ompF 
GAACTTCGCTGTTCAGTACC 
CGTACTTCAGACCAGTAGCC 
209 bp 
ompC 
CTTCAAAGGTGAAACTCAGG 
GTTGTCAGAACCGTAGGTGT 
241 bp 
ompA 
ACGACTGGTTAGGTCGTATG 
ACGTTGGATTTAGTGTCTGC 
166 bp 
ompX 
ACCTGAAATACCGCTATGAA 
TCAGTGGTCTGGAATTTACC 
208 bp 
ompR 
GACGTCTTCGTAGTCAGAGC 
TTGAACTTACCGAAAGCAAT 
229 bp 
degP 
TGGTAGTGAACAACGTGAAA 
AACAGGTAGATGGTGCTGTC 
184 bp 
clpP 
CAAAAGGTAAACGTTTTTGC 
AATGATTGACCCGTATGAAG 
163 bp 
rseP 
TTGTTTATTACCTGCCGTTT 
ATTAACAGCACCAGCAGAAT 
190 bp 
degS 
TTCCAGTTAGCAACCAAAAT 
TGACACTTCATTAACCACGA 
153 bp 
GAPDH 
ACTTACGAGCAGATCAAAGC 
AGTTTCACGAAGTTGTCGTT 
170 bp 
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Amplification efficiencies of the target genes and reference gene were determined 
through the amplification of one-step RT-PCR template dilution series and PCR 
conditions were optimised until comparable amplification efficiencies were obtained for 
identical amounts of template RNA (absolute slope values less then 0.1) from 
calibration curve plots (Langmann T. et al, 2003). Amplification of GAPDH and other 
genes of interest were then run in separate tubes using the same amount of total RNA 
retrieved from the same sample. Thermal cycling conditions consisted of an initial 
reverse transcription step at 50ºC during 30 minutes, an initial PCR activation step at 
95ºC for 15 minutes followed by 35 cycles of denaturation (94ºC, 60 seconds), 
annealing (51ºC–53ºC for 60 seconds, depending on optimised conditions for the 
primers used) and extension (72ºC for 60 seconds). The relative quantities of the 
mRNA of each gene of interest were determined by the use of the comparative 
threshold cycle (CT) method. Taking advantage of the fact that samples with higher 
initial mRNA template concentration reach the significant threshold level for real-time 
detection at lower PCR cycle numbers than samples containing lower initial template 
concentrations, it is possible to obtain a quantitative measure of the expression 
magnitude (∆CT) of each gene of interest, normalized by the house-keeping gene 
(GAPDH) expression in each sample to correct variation in RNA content and 
amplification efficiencies between samples. The equation 2-∆∆CT allows the relative 
quantification of differences of each gene expression level between two samples, the 
sample of interest (the TET induced AG100 strain) and a calibrator or reference strain 
(the parental AG100 strain). Briefly, from three independent total mRNA extractions 
form E. coli AG100 and AG100TET strains, grown under the described conditions, ∆CT 
of the reference and samples for each gene tested was obtained by subtracting the CT 
value of the GAPDH gene from the CT value obtained for each gene. ∆∆CT was 
calculated by subtracting the average ∆CT values of the reference strain (AG100) from 
the corresponding TET induced ∆CT for each gene tested. The relative quantifications 
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were then calculated by the equation 2-∆∆CT as the number of fold of mRNA quantity 
differences relative to the calibrator or reference strain (Langmann T. et al, 2003; Livak 
K.J et al, 2001). All data was collected and analysed with the aid of the Rotor-GeneTM 
3000 real-time analysis software.   
 
SDS-PAGE analyses and immunoblotting 
Bacteria in exponential growth phase were pelleted and solubilised as previously 
described (Malléa M. et al, 1998). Proteins were analysed on 10% SDS polyacrylamide 
gel system for OmpC, OmpF, OmpA and AcrA detection and 12% SDS-PAGE gel for 
OmpX, (Dupont M. et al, 2004; Malléa M. et al, 1998). Gels were stained with 
Coomassie Brillant Blue R-250 to standardized protein samples. For western blots, 
proteins were electrotransfered onto nitrocellulose membranes (Schleicher & Schlull, 
Keene, NH, USA) in transfer buffer (20 mM Tris, 150 mM glycine, 20% isopropanol, 
0.05% SDS). An initial saturating step was performed overnight at 4ºC with Tris-
buffered sodium (TBS: 50 mM Tris- HCl, 150 mM NaCl, pH 8) containing skimmed milk 
powder (10%). The nitrocellulose membranes were then incubated in TBS containing 
skimmed milk powder (10%) and Triton X-100 (0.2%) for 2 hours at room temperature 
in the presence of polyclonal antibodies directed against denatured OmpC, OmpF, 
OmpA and OmpX, or with F4 polyclonal antibody directed against the L3 internal loop 
of E. coli porins (Dé E. et al, 2001). The detection of antigenantibody complexes was 
performed with alkaline phosphatase conjugated AffinitiPure goat anti-rabbit IgG 
antibodies (Jackson ImmunoResearch, West Grove PA, USA). 
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Fluorometric determination of ethidium bromide efflux kinetics in E. coli 
 
III.1 Summary 
In the previous chapter, a protocol to analyze the expression levels of efflux pumps 
was developed by qRT-PCR using E. coli as a model. The methodology employed 
allowed the demonstration of events involved in the regulation of porins and efflux 
pumps during the adaptation of E. coli to increased concentrations of TET. However, 
there is still the need to correlate this genetic information with the physiological 
detection and quantification of efflux pump activity. The development of methods for 
the early detection and quantification of drug transport across the bacterial cell-wall is a 
tool essential to understand and overcome efflux-mediated drug resistance. This 
chapter describes the development of a protocol for the quantification of efflux 
developed by the use of real-time fluorometry to assess the accumulation and 
extrusion of fluorescent compounds by efflux pumps. E. coli was once again used as a 
model in the development of the protocol that will be applied latter to mycobacteria 
(chapters IV, V and VI). 
EtBr transport across the cell envelope of E. coli K-12 and derivatives was analysed by 
a real-time fluorometric method. Accumulation and efflux of EtBr was studied under 
limiting energy supply (absence of glucose and low temperature) and in the presence 
and absence of the efflux inhibitor, chlorpromazine. The bulk fluorescence variations 
were also observed by flow cytometry analysis, revealing that once inside the cells, 
leakage of EtBr does not occur and its efflux is mediated by active transport. The 
importance of AcrAB-TolC, the main efflux system of E. coli, in the extrusion of EtBr 
was put in evidence by comparing strains with different levels of AcrAB expression. An 
experimental model was developed to describe the transport kinetics in the three 
strains. The model integrates passive entry (influx) and active efflux of EtBr, and 
discriminates different degrees of efflux between the studied strains that vary in the 
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activity of their efflux systems (AG100 – wild-type, AG100A – AcrAB deleted, AG100TET 
– AcrAB overexpressed), as evident from the calculated efflux rates: − 100AGk = 0.0173 
± 0.0057 min-1; 
−
AAGk 100 = 0.0106 ±  0.0033 min-1; and 
−
TETAGk 100 = 0.0230 ± 0.0075 min-
1
.  
The combined use of a semi-automated fluorometric method and an experimental 
model allowed quantifying EtBr transport in E. coli strains that differ in their overall 
efflux activity. This methodology can be used for the early detection of differences in 
the drug efflux capacity in bacteria accounting for antibiotic resistance, as well as for 
expedite screening of new drug efflux inhibitors libraries and transport studies across 
the bacterial cell wall. 
 
III.2 Introduction 
Efflux pumps are major defensive components of the bacterial cell wall that actively 
extrude noxious compounds from the periplasm and/or cytoplasm, thereby decreasing 
their intracellular concentration (Li X.Z. et al, 2004; Piddock L.J., 2006). Active efflux of 
antibiotics by bacteria was first described in 1978 in E. coli resistant to TET (Levy S.B. 
et al, 1978) and, since then, it has been proven that the constitutive or inductive 
expression of these systems is responsible for the intrinsic and acquired resistance of 
many bacterial species to antimicrobials (Bambeke F.V. et al, 2006; Pagès J.M. et al, 
2005).  
Several methods have been used to detect and quantify the activity of bacterial efflux 
pump systems using radio-labeled, metal-labeled or fluorescent substrates to monitor 
their efflux in bacterial cells (Greulich K.O., 2004; Jernaes M.W. et al, 1994; Joux F. et 
al, 2000; Kyriacou S.V. et al, 2004; Lomovskaya O. et al, 2006; Martins M. et al, 2006; 
Mortimer P.G. et al, 1991). Bulk measurement techniques that use fluorescence 
spectroscopy yield a general understanding that represents the balance between entry 
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and extrusion of a given substrate, which may result from the efflux activities of one or 
several pumps (Joux F. et al, 2000; Lomovskaya O. et al, 2006), and where cell 
membrane permeability also plays an important role (Davin-Regli A. et al, 2008; 
Viveiros M. et al, 2007). Because the permeability to the substrate may be regulated by 
a decreased number of porins or by an increase of the lipopolysaccharide layer of the 
cell envelope (Davin-Regli A. et al, 2008; Viveiros M. et al, 2007), the demonstration of 
efflux activity invariably involves the use of an agent that promotes a significant 
increase of substrate accumulated (Lomovskaya O. et al, 2006; Viveiros M. et al, 
2008a; Viveiros M. et al, 2008b). Unless the demonstration of the role of a specific 
efflux pump is readily made, i.e. by the quantification of the expression level of a 
specific transporter (Viveiros M. et al, 2005; Viveiros M. et al, 2007), or by the use of 
mutants whose specific efflux pump has been deleted or inactivated (Okuso H. et al, 
1996), very little can be said about the role that any efflux pump system may play in the 
MDR phenotype of bacteria.  
 
A semi-automated fluorometric method was developed for the assessment of efflux 
pump activity in bulk bacterial cells (Viveiros M. et al, 2008a; Viveiros M. et al, 2010a). 
The method uses the common efflux pump substrate EtBr that has been shown to be a 
particularly suitable probe for these studies. In fact it emits weak fluorescence in 
aqueous solution (external to the cell) and becomes strongly fluorescent when its 
concentration within the periplasm exceeds that of the aqueous solution due to its 
binding to cellular components (Jernaes M.W. et al, 1994).  Such binding must be of a 
weak type if the agent is to serve as a useful probe for efflux, since later intercalation 
into DNA results in strong binding that precludes any dissociation of the substrate for 
efflux (Jernaes M.W. et al, 1994; Joux F. et al, 2000). This method can distinguish 
accumulation, which reflects the balance between influx and efflux, from efflux itself 
(Viveiros M. et al, 2008a; Viveiros M. et al, 2010a) and, therefore, has the potential for 
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the study of the kinetics of EtBr transport. The method was developed using the wild-
type E. coli K-12 AG100 as the bacterial model and the accumulation and efflux of EtBr 
was monitored by real-time fluorometry using the Rotor-GeneTM 3000 from Corbett 
Research (Sydney, Australia) (Viveiros M. et al, 2008a; Viveiros M. et al, 2008b; 
Viveiros M. et al, 2010a). The major innovation of this method is the simultaneous 
evaluation of efflux pump activity in vivo and on-line of a large number of samples, with 
the possibility to expose the same cell preparation to different environmental conditions 
in a single assay. 
 
For the objectives of this thesis, the semi-automated fluorometric method has been 
used to define and parameterize a mechanistic experimental model that demonstrates 
the kinetics of EtBr influx and efflux by E. coli strains that differ in their capacity to 
extrude this molecule. The determination of the influx and efflux rates (k+ and k-, 
respectively) of a fluorescent substrate, by the approach proposed, allows the 
quantification of the cell overall efflux capacity. This information can be useful to 
interpret different phenotypes resulting from this efflux activity, including multidrug 
resistance in clinical bacterial strains. 
 
III.3 Results  
 
III.3.1 Detecting EtBr efflux mediated by E. coli efflux pump systems 
Experiments were carried out with EtBr concentrations that did not affect in any way 
the cell viability, i.e., that did not exceed ½ the MIC for EtBr (Table III.1). In this case 
and as previously demonstrated, accumulation of EtBr and its extrusion from E. coli are 
the result of the balance between EtBr entry by passive diffusion (influx) and the 
extrusion activity of efflux pump systems, primarily the AcrAB-TolC (Viveiros M. et al, 
2005; Viveiros M. et al, 2007; Viveiros M. et al, 2010a). As shown by Figure III.1, the 
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accumulation of EtBr under conditions that are considered to maximize efflux, i.e., 
presence of glucose and 37ºC, begins to take place at a concentration of EtBr that 
exceeds 1.0 mg/L for the wild-type E. coli K-12 AG100 (Figure III.1A), 0.250 mg/L for 
AG100A (acrAB inactivated; Figure III.1B), and 1.0 mg/L for AG100TET (acrAB and 
other efflux pump genes overexpressed; Figure III.1C). As expected, the strain that 
over-express efflux systems (AG100TET) accumulates the least amount of EtBr even 
when the maximum concentration of EtBr to which it is exposed is 6 mg/L. On the 
contrary, the AG100A, whose AcrAB efflux pump has been inactivated, accumulates 
approximately 25 times more EtBr when exposed to a far lower concentration of 1.5 
mg/L of EtBr. The importance of the AcrAB-TolC efflux system is further illustrated by 
the comparison of accumulation of EtBr by the wild-type AG100 to that by the AG100A, 
when both strains are exposed to 1 mg/L of EtBr.  
 
Table III.1. MIC values of EtBr and several antibiotics for E. coli AG100, AG100A and 
AG100TET. 
E. coli strains 
MIC (mg/L) 
EtBr KAN CIP OFX CHL ERY TET 
TET + 
CPZ 
AG100 150 15 0.03 0.12 8 100 2.0 0.5 
AG100A 5 >200 0.004 0.015 2 6.25 0.5 0.5 
AG100TET 300 10 0.12 0.48 >16 100 12 3 
 
CHL, chloramphenicol; CIP, ciprofloxacin; CPZ, chlorpromazine; EtBr, ethidium bromide; ERY, 
erythromycin; KAN, kanamycin; OFX, ofloxacin; TET, tetracycline. Kanamycin was included as control for 
the presence of Tn903 in E. coli AG100A (∆acrAB::Tn903 Kanr). The TET MICs were also calculated in the 
presence of 30 mg/L (AG100), 10 mg/L (AG100A) and 70 mg/L (AG100TET) of CPZ (½ MIC). 
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Figure III.1. Accumulation of EtBr at increasing concentrations by E. coli K-12 AG100(A), 
AG100A(B) and AG100TET (C). The bacteria were exposed to increasing concentrations of EtBr 
at 37ºC in the presence of glucose. Note: assays for AG100A were carried out with lowest EtBr 
concentrations (0.125 - 1.5 mg/L) – see text.  
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Accumulation of EtBr inside the bacterial cells can be increased in the presence of an 
efflux inhibitor such as phenothiazines (e.g. chlorpromazine), compounds that have 
been shown to inhibit efflux activity of Gram-negative bacteria (Bambeke F.V. et al, 
2006; Pagès J.M. et al, 2005; Viveiros M. et al, 2008a). Thus, these compounds are 
usually employed for the demonstration of overexpressed efflux pumps of bacteria 
(Lomovskaya O. et al, 2006; Pagès J.M. et al, 2005; Viveiros M. et al, 2008a; Viveiros 
M. et al, 2008b). Because of the real-time capacity and sensitivity of the semi-
automated fluorometric method, the demonstration of the effects of an efflux inhibitor, 
such as chlorpromazine, on the intrinsic efflux system of the wild-type E. coli K-12 
AG100 is readily made. As shown by Figure III.2A (A1 and A2), high concentrations of 
chlorpromazine maximize the amount of EtBr accumulated only when glucose is 
absent from the medium. Similar results were obtained for the strains AG100TET and 
AG100A (data not shown). The effect of chlorpromazine on the accumulation of EtBr by 
wild-type E. coli K-12 AG100 is similarly demonstrated and confirmed with the aid of 
flow cytometry (Figure III.2B). 
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Figure III.2. Effect of chlorpromazine (CPZ) on EtBr accumulation by E. coli K-12 AG100. The 
bacteria were loaded with EtBr at 1 mg/L in the presence of increasing concentrations of 
chlorpromazine for a period of 60 minutes at 37ºC in the presence and absence of glucose and 
accumulation assessed by: (A1 and A2) the semi-automated fluorometric method; (B) flow 
cytometry, represented by an histogram overlay corresponding to the data  selected for analysis  
(2nd gate) for E. coli K-12 AG100 (i) without EtBr or chlorpromazine, (ii) after 60 minutes of 
exposure to EtBr (1 mg/L) and (iii) after 60 minutes of exposure to EtBr (1 mg/L) and 
chlorpromazine (20 mg/L) at 37ºC without glucose. Data in graphics A1 and A2 correspond to 
the same assay and were separated for the sake of figure clarity.  
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The on-line visualization of efflux activity by the EtBr loaded cells requires that 
accumulation of EtBr has previously taken place. Therefore, before performing the 
efflux assays, bacteria are exposed to conditions that promote significant accumulation 
of EtBr (Viveiros M. et al, 2008a; Viveiros M. et al, 2008b). To this extent, the following 
conditions were chosen: a temperature of 25ºC, absence of glucose and presence of 
chlorpromazine (20 mg/L), to promote maximum accumulation, within 60 minutes. 
When maximum accumulation has taken place under these conditions, the bacteria are 
washed free of EtBr and chlorpromazine and resuspended in fresh buffer with and 
without glucose. Fluorescence readings were conducted over a period of 15 minutes at 
37ºC. As shown by Figure III.3, restoration of optimum conditions of glucose, noted to 
prevent accumulation, are required for the extrusion of EtBr. This assay shows that E. 
coli cells need an energy source for efflux to take place.     
Therefore, this methodological approach proved its usefulness for the demonstration of 
active efflux of EtBr in E. coli and the strategy developed allowed to differentiate influx 
(passive diffusion into the cell) from efflux activity (active efflux through pumps).  
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Figure III.3. Detection of EtBr efflux in E. coli K-12 AG100. The bacteria were loaded with EtBr 
at 1 mg/L in the presence of chlorpromazine (20 mg/L) for a period of 60 minutes at 25ºC. After 
replacing the buffer with EtBr-free PBS with or without glucose, the efflux was assessed by: (A) 
the semi-automated fluorometric method, performed at 37ºC for 15 minutes; and (B) flow 
cytometry, represented by an histogram overlay corresponding to the data selected for analysis 
(2nd gate) for E. coli K-12 AG100 immediately after replacing the buffer with EtBr-free PBS (t=0) 
and 15 minutes after incubation at 37ºC with or without glucose. 
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III.3.2 Modeling EtBr transport across E. coli cell wall  
In order to quantify the efflux activity, a mechanistic experimental model that 
establishes a balance related to the intracellular EtBr concentration was developed, as 
described below:  
[ ] [ ] [ ] intextint EtBrkEtBrkdt
EtBrd
−+
−=   (eq. 1.1.) 
 
where [ ] intEtBr is the intracellular EtBr concentration (mg/L); [ ] extEtBr is the external 
EtBr concentration (mg/L); +k is the rate of EtBr entry into the cells (min-1) and 
−k corresponds to the rate of EtBr efflux from the cells (min-1). Therefore,  
 
[ ] [ ] [ ] intEtBrEtBrEtBr extTot +=   (eq. 1.2.) 
 
where [ ] TotEtBr is the total EtBr concentration (mg/L). Replacing equation (1.2) in 
equation (1.1) and solving it for [ ] intEtBr , it is possible to obtain the following equation, 
which describes the EtBr transport across the cell wall of E. coli: 
 
[ ] [ ] [ ] [ ]








+
−=+
+
=
−+
+
−+
+
TotintTotint EtBrkk
k0)(tEtBrEtBr
kk
k(t)EtBr )tk(ke −++−    (eq. 1.3.) 
 
The equation developed herein (eq. 1.3) allied to the technical approach used to 
quantify the intracellular EtBr concentration (Methods) allowed to quantify the degree of 
EtBr efflux activity in the three E. coli strains (AG100, AG100A and AG100TET). This 
strategy is based on the distinct levels of EtBr fluorescence in solution and inside the 
cells. EtBr emits fluorescence when it is free in solution (in this case, PBS) in a 
concentration dependent manner, accurately captured by the photomultiplier detector 
with the 585 nm high-pass filter of the Rotor-GeneTM 3000 that differentiates mg/L 
differences (Viveiros M. et al, 2008a; Viveiros M. et al, 2010a). The high sensitivity of 
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this detector ensue the definition of a calibration curve, which correlates fluorescence 
(FL0) and the initial EtBr concentration in solution, before the cells are added to the 
medium, varying from 0 mg/L to 6 mg/L: 
 
[ ] 0.0373FL0.1201EtBr 0ini +×= ( 0.99R = ) 
 
where [EtBr]initial = [EtBr]Total. When the E. coli cells are exposed to EtBr containing buffer 
(1 to 6 mg/L for AG100 and AG100TET; 0.125 to 1.5 mg/L for AG100A), the cells start to 
accumulate EtBr that enters by passive diffusion, with the efflux pump systems trying to 
balance this entry according to the kinetics presented in Figure III.1. At these low 
concentrations, EtBr does not reach the cellular components in the cytoplasm to which 
it could bind irreversibly, being effluxed from the cytoplasm and periplasm by either 
single- or multi-component efflux systems (Lee A.  et al, 2000; Seeger M.A. et al, 
2008). When the concentration of EtBr within the periplasmic space exceeds 
significantly its extrusion, EtBr is translocated beyond the inner plasma membrane 
where the medial sites of the cell contain nucleic acids to which the EtBr can intercalate 
almost irreversibly, after which extrusion is not possible (Jernaes M.W. et al, 1994; 
Joux F. et al, 2000; Lee A. et al, 2000; Seeger M.A. et al, 2008). 
Using the rationale described in Methods, it is possible to correlate the fluorescence 
readings by the semi-automated fluorometric method in bulk cells to the EtBr 
concentration that remains inside the cells; [ ] 0.06FL0.022EtBr corr exp intint +×=  
(R=0.99). With the assistance of the software Table CurveTM 2D from Jandel Scientific - 
AISN Software STATISTICA, it is then possible to adjust the model (eq. 1.3.) to the 
experimental data and determine the values of the constants k+ and k-, which represent 
a measure of the rate of entry and the rate of efflux of EtBr into and out of the cell, 
respectively (Figure III.4). Table III.2 summarizes the values of k+ and k- obtained for 
the three strains tested. The values obtained show similar influx rates for the three E. 
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coli strains studied, as expected, since this parameter reflects the entry of EtBr by 
passive diffusion. Both the passive influx absolute values and their variation among the 
three strains are negligible when compared to the values obtained for the efflux rates. 
The model proposed accurately describes the behavior of the three strains, showing a 
lower efflux rate for the AG100A strain when compared to the wild-type AG100 (P 
value = 0.0023), as a result of the inactivation of the AcrAB-TolC system in the mutant 
strain. For the AG100TET strain the model revealed a significantly increased efflux rate 
compared to the wild-type strain (P value = 0.0057). This result reflects the higher 
efflux activity in this TET adapted strain due to the overexpression of efflux pumps, 
particularly of the AcrAB-TolC system (Viveiros M. et al, 2005; Viveiros M. et al, 2007). 
 
 
Table III.2. Influx (k+) and efflux (k-) rates for E. coli K-12 AG100, AG100A and AG100TET. 
E. coli strains k+ (min-1) k- (min-1) 
AG100 0.0019 ± 0.0009 0.0173 ± 0.0057 
AG100A 0.0035 ± 0.0012 0.0106 ± 0.0033 
AG100TET 0.0025 ± 0.0009 0.0230 ± 0.0075 
k+ and k- were determined using the software Table CurveTM 2D from Jandel Scientific - AISN Software 
STATISTICA to adjust the model (eq. 1.3.) to the experimental data obtained with the semi-automated 
fluorometric method (Figure III.1). The results represent an average of three independent assays with the 
correspondent standard deviation.  
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Figure III.4. Influx (k+) and efflux (k-) rates of EtBr in the E. coli strains tested. The values shown 
represent averages of three independent experiments and respective standard deviations for 
the three E. coli strains tested: AG100, AG100A and AG100TET. 
 
 
Moreover, the results provided by the model, in terms of EtBr efflux rates, correlate with 
the MIC for EtBr for each of the strains studied (Table III.1). While the wild-type strain, 
E. coli AG100 (MICEtBr = 150 mg/L), showed an EtBr efflux rate of 
−
100AGk = 0.0173 
± 0.0057 min-1, the AcrAB deleted strain, E.coli AG100A (MICEtBr = 5 mg/L), had the 
lowest EtBr efflux rate 
−
AAGk 100 = 0.0106 ±  0.0033 min-1. Conversely, the TET induced 
strain, E. coli AG100TET, overexpressing the AcrAB system, shows a much higher efflux 
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rate 
−
TETAGk 100 = 0.0230 ± 0.0075 min-1, which corresponds to a MIC for EtBr of 300 
mg/L.  MICs of each strain towards several antibiotics known to be efflux pump 
substrates also showed a correlation between efflux activity and resistance level to 
these drugs (Table III.1). The determination of the MICs for TET in the presence of the 
efflux inhibitor chlorpromazine reinforced the role played by efflux on such resistance, 
as the MICs values decreased in the presence of subinhibitory concentrations of this 
efflux inhibitor, according to the efflux activity previously determined for each strain 
(Table III.1).   
This approach allowed to calculate the values of EtBr influx/efflux rates (k+ and k-) for 
E. coli and to construct a predictive model for the accumulation curve of this molecule 
at any concentration by a given E. coli strain, provided that EtBr concentration does not 
affect the cellular viability. An example of such calculation is provided in Figure III.5, for 
three different concentrations of EtBr for the E. coli strains used. When these predictive 
curves are compared to the experimental data a close fit is obtained (Figure III.5), thus 
validating the proposed model. 
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Figure III.5. Examples of model fitting to experimental data. The figures represent the fitting of 
the model to the experimental data for the time course of intracellular EtBr concentration in E. 
coli strains AG100, AG100A and AG100TET, incubated in the presence of different EtBr 
concentrations. In each case, the solid line represents the model fit.  
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III.4 Conclusions 
In this work, the technical advantages of the semi-automated fluorometric method 
(Viveiros M. et al, 2008a; Viveiros M. et al, 2010a) were applied for the development 
and application of an experimental model to describe and quantify the efflux pump 
activity in E. coli. The semi-automated fluorometric method affords the in vivo and on-
line evaluation of the efflux pump activity by real-time fluorometry using the Rotor-
GeneTM 3000, and represents an innovative technique when compared to other 
technologies (Viveiros M. et al, 2008b). Based upon the differences of fluorescence 
that reflect differences on the EtBr concentrations outside and inside the cells, the 
technique provides a powerful tool for the real-time monitoring of efflux kinetics in 
bacterial cells. Moreover, it has potential for the identification of new efflux pump 
substrates, as well as new bacterial EPIs (Viveiros M. et al, 2008b). A more 
fundamental application is the extension of this methodology to understand the 
transport kinetics of EtBr or other fluorescent substrates in bacterial cells.   
 
This approach was used to differentiate and quantify EtBr transport in E. coli, and an 
experimental model was developed which parameterizes passive entry (influx) and 
active efflux of EtBr. The methodology developed allowed to detect differences in the 
EtBr efflux activity among strains that differ in their efflux pump expression, highlighting 
the importance of these systems in the extrusion from the cell of toxic compounds such 
as EtBr (Lomovskaya O. et al, 2007; Okuso H. et al, 1996; Poole K., 2007).  
Although the experimental model presented was designed based upon a set of three 
canonic, isogenic strains, as a way to assess the method´s sensitivity to differentiate 
their singular efflux activities, it can be applied to other E. coli strains or bacteria, since 
it is based on the overall transport of EtBr across the bacterial cell wall, which is 
common among bacteria (Jernaes MW. et al, 1994; Piddock L.J., 2006; Poole K., 2007; 
Viveiros M. et al, 2008a; Viveiros M. et al, 2008b). It should be stressed however that it 
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allows measuring the overall efflux activity rather than efflux related to a specific pump. 
For evaluation of the role played by a pump, a mutant specific for that pump must be 
used. The determination of influx and efflux rates for each of the strains to be analyzed 
opens new insights and opportunities for exploration of cell wall permeability, as well as 
for the control of the efflux activity in bacterial cells, representing a quantitative method 
to determine efflux activity. This approach may be used to elaborate a standardized 
data base for different reference strains relative to efflux activity (efflux rates), providing 
the means by which one can evaluate the resistance due to efflux pump activity in 
standardized conditions between laboratories. It represents a particularly suitable 
procedure for the assessment of efflux pump activity in MDR clinical isolates and 
screening for potential inhibitors of such activity. Such approaches may contribute to a 
better understanding of the bacterial efflux systems as a resistance mechanism and to 
design new therapeutic strategies against MDR bacterial infections (Martins M. et al, 
2008).  
The results and conclusions obtained in this chapter were summarized in the 
publications Viveiros M. et al, 2008a and Paixão L. et al, 2009. It was demonstrated in 
this chapter that the semi-automated fluorometric method is an efficient technique to 
monitor and quantify the transport of substrates across the cell-wall of bacteria, which 
could be correlated with multidrug resistance in any bacteria and will be applied to 
mycobacteria in the following chapters.  
 
III. 5 Materials and methods 
 
Bacteria 
The following bacteria were employed in this study: E. coli K-12 AG100 wild-type strain 
(argE3 thi-l rpsL xyl mtl ∆(gal-uvrB) supE44), containing a fully functional AcrAB-TolC 
efflux pump system; E. coli AG100A (∆acrAB::Tn903 Kanr) with the AcrAB-TolC efflux 
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pump system inactivated due to the insertion of the transposon Tn903 in the acrAB 
operon (Okuso H. et al, 1996); and E. coli AG100TET, a AG100 progeny strain, induced 
to high level of resistance to TET (able to survive in 10 mg/L of tetracycline, with an 
MIC of 12 mg/L), as previously described, and over-expressing several efflux pumps, 
among which acrAB shows the highest expression level when exposed to high levels of 
TET (Viveiros M. et al, 2005; Viveiros M. et al, 2007). E. coli K-12 AG100 and AG100A 
have been previously characterized and were kindly offered by Hiroshi Nikaido 
(University of California, Berkeley, California, USA) (Okuso H. et al, 1996). Bacterial 
cultures were grown in Luria-Bertani (LB) medium at 37ºC with agitation (220 rpm). 
Cultures of AG100A and AG100TET were supplemented with 100 mg/L of kanamycin 
and 10 mg/L of TET, respectively.  
 
Reagents 
PBS, glucose, EtBr, kanamycin, ciprofloxacin, ofloxacin, chloramphenicol, 
erythromycin, TET and chlorpromazine were purchased from Sigma-Aldrich Química 
SA (Madrid, Spain). EtBr solutions were stored at 4ºC and protected from light. TET 
stock solution was prepared in methanol, whereas kanamycin, ciprofloxacin, ofloxacin, 
erythromycin and chlorpromazine were prepared in distilled water and filtered with 0.22 
µm syringe filters (Millipore Corporation, Bedford, USA). Chloramphenicol stock 
solution was prepared in ethanol. All working solutions were prepared in distilled water 
on the day of the experiment. LB medium was purchased from Difco (Detroit, Michigan, 
USA). Mueller-Hinton (MH) broth medium was purchased from Oxoid (Basingstoke, 
Hampshire, UK). 
 
Determination of minimum inhibitory concentrations 
The MICs for EtBr, the efflux inhibitor chlorpromazine, kanamycin, ciprofloxacin, 
ofloxacin, chloramphenicol, erythromycin and TET were determined by the broth 
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microdilution method in 96-well microtitre plates according to the CLSI guidelines 
(CLSI, 2005). Briefly, bacterial strains were incubated overnight in 5 mL of MH broth at 
37ºC with shaking at 220 rpm. Bacterial cultures were then diluted in PBS to a 
McFarland 0.5 turbidity standard. Aliquots of 0.05 mL were transferred to each well of 
the 96-well plate that contained 0.15 mL of each compound at concentrations prepared 
at 2-fold serial dilutions in MH broth medium. The plates were incubated at 37ºC and 
the MIC results registered after 16-18 hours. The MIC was defined as the lowest 
concentration of compound for which no growth was observed. In order to assure that 
the EPI did not compromise the cellular viability, the concentrations used in the 
following work did not exceed ½ of the MIC. The MIC for TET was also calculated in 
the presence of chlorpromazine at ½ MIC. 
 
The semi-automated fluorometric method 
The method was carried out using the real-time thermocycler Rotor-GeneTM 3000 
(Corbett Research, Sidney, Australia) to monitor the accumulation and extrusion of 
EtBr on a real-time basis (Viveiros M. et al, 2008a; Viveiros M. et al, 2008b). The 
instrument allows the selection of the excitation and emission wavelengths that for EtBr 
are 530 nm band-pass and 585 nm high-pass filters, respectively. The fluorescence 
was acquired in cycles of 60 seconds, during the desired time interval, at the required 
temperature (37ºC or 25ºC). An explanatory diagram is provided in Figure III.6. 
 
(i) Accumulation assay. The accumulation of EtBr was carried out as previously 
described (Viveiros M. et al, 2008a). Briefly, the E. coli strains were grown in 10 mL of 
LB medium until they reached a mid-log phase, which corresponded to an optical 
density at 600 nm (OD600) of 0.6. The bacteria were then centrifuged at 13000 rpm for 3 
minutes, the pellet washed twice with the same volume of PBS and the OD600 of the 
cellular suspension adjusted to 0.3. Glucose was added to the cellular suspension to a 
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final concentration of 0.4% (v/v) and aliquots of 0.095 mL were transferred to 0.2 mL 
microtubes. EtBr was added in aliquots of 0.005 mL to obtain final concentrations that 
ranged from 1.0 to 6.0 mg/L for E. coli K-12 AG100 and AG100TET and from 0.125 to 
1.5 mg/L for AG100A. The fluorescence was monitored in the Rotor-GeneTM 3000 at 
37ºC under the conditions described above. The effect of chlorpromazine in the 
accumulation of EtBr was determined under conditions that optimize efflux (presence of 
glucose and incubation at 37ºC). Chlorpromazine was used at concentrations that did 
not exceed ½ the MIC and the fluorescence was measured over a period of 60 
minutes. 
 
(ii) Efflux assay. The assessment of the efflux of EtBr was conducted as previously 
described (Viveiros M. et al, 2008a). Briefly, the E. coli strains were loaded with EtBr 
under conditions that favor accumulation (no glucose, 25ºC and presence of 
chlorpromazine). When the maximum level of EtBr accumulation was reached 
(approximately 60 minutes), the bacteria were centrifuged (13000 rpm for 3 minutes) 
and the medium was replaced by: i) PBS without glucose; ii) PBS containing glucose; 
and iii) PBS without glucose and with chlorpromazine (control of minimum efflux). 
Aliquots of 0.1 mL were transferred to 0.2 mL microtubes and the assay was performed 
at 37ºC with continuous measurement of fluorescence as described above. The efflux 
of EtBr is presented in terms of relative fluorescence, which is obtained from the 
comparison between the fluorescence observed for the bacteria in the presence or 
absence of glucose and the control in which the cells are exposed to conditions of 
minimum efflux (i.e., absence of glucose and presence of chlorpromazine). Each 
experiment was conducted in triplicate and the results obtained did not vary.   
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Figure III.6. Experimental flowchart of the semi-automated fluorometric method. EPI, efflux 
pump inhibitor; EtBr, ethidium bromide; CPZ, chlorpromazine; PBS, phosphate buffered 
solution. 
 
 
Semi-automated fluorometric method 
 E. coli culture (OD600 = 0.6) 
Accumulation assay Step #4: Efflux assay 
Step #1: Cells centrifuged and resuspended in 
PBS to OD600 = 0.3. Add glucose and EtBr: 
AG100 and AG100TET: [EtBr] = 1 – 6 mg/L 
AG100A: [EtBr] = 0.125 – 1.5 mg/L 
Aquisition of fluorescence (530/585 nm 
excitation/detection) at 37ºC 
Step #2: Selection of [EtBr] to be 
tested with the EPI (in this case, CPZ) 
Add CPZ and the selected [EtBr] to bacteria in 
the presence/absence of glucose 
Step #3: Selection of [CPZ] that causes 
maximum accumulation 
Conditions that cause maximum EtBr 
accumulation: [EtBr] selected in #2; [CPZ] 
selected in #3; incubate at 25ºC for 60 min. 
Centrifuge and resuspend in a 
EtBr-free buffer 
Add glucose (0.4%) and CPZ 
Step #5: Analysis of CPZ effect on 
EtBr efflux Aquisition of fluorescence (530/585 nm 
excitation/detection) at 37ºC 
Aquisition of fluorescence (530/585 nm 
excitation/detection) at 37ºC 
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Model to quantify EtBr efflux in E. coli 
 
(i) Quantification of intracellular EtBr concentration. In order to assess the amount 
of EtBr extruded from the cells, one has to quantify the amount retained inside the 
cells. First, a calibration curve is determined that correlates the initial fluorescence of 
the buffer containing EtBr ( oFL ) with the corresponding EtBr concentration (varying 
from 0 to 6 mg/L):  
[ ] 0.0373FL0.1201EtBr 0 +×=initial ( 0.99R = ). 
Then, for each concentration tested, an EtBr accumulation assay was performed, as 
described above. To quantify the intracellular EtBr concentration, at the end of the 
accumulation assay, 0.6 mL of each EtBr containing buffer were separated from the 
cells by centrifugation at 13000 rpm for 10 minutes and the supernatant filtered with 
0.22 µm syringe filters from Millipore Corporation (Bedford, USA). The fluorescence of 
the cell-free buffer was measured in the Rotor-GeneTM 3000 
( corrected nonfiltEtBr)FL(PBS + ). 
Since some EtBr is retained by the filter itself, a correction factor must be used to 
account for this difference. Thus, the corrected fluorescence of the filtered buffer 
corresponds to:   
0.7032
correctednon filt EtBr)FL(PBS1.2289correctedfilt EtBr)FL(PBS ++×=+  
(R=0.99) 
The difference between the initial fluorescence of the EtBr containing buffer ( oFL ) and 
correctedfilt EtBr)FL(PBS +  gives the fluorescence corresponding to the intracellular 
EtBr concentration. However, the fluorescence data from the transport assays 
measured experimentally still contains a component from the EtBr that remains in 
solution. Thus, each value of the experimental accumulation curve can then be 
corrected by subtracting the background corresponding to the fluorescence of the initial 
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EtBr concentration, originating FLint exp corr. By plotting the previously determined EtBr 
intracellular concentration for the final value of FLint exp corr, for each initial EtBr 
concentration tested, a new relation is achieved:  
[ ] 0.06FL0.022EtBr corr expint int +×=  (R=0.99), 
which allows the conversion of the experimental fluorescence data over time into 
intracellular EtBr concentration over time. The correlations shown here were 
determined for the wild-type E. coli K-12 AG100. Similar relations were determined 
specifically for the other two strains used (AG100A and AG100TET). 
 
(ii) Mathematical and statistical analyses. The model was fitted to the experimental 
values ( [ ] tvsintEtBr ) using the software Table CurveTM 2D from Jandel Scientific - AISN 
Software STATISTICA, which allowed the determination of the values of the 
parameters describing the influx and efflux rates, −+ kandk , respectively. Three 
independent assays were conducted and the results shown are the average ± standard 
deviation. P-value from the ANOVA statistical test was calculated. 
 
(iii) Model validation. The predictive model proposed was validated by comparing the 
experimental data obtained using E. coli K-12 AG100, AG100A and AG100TET cell 
suspensions incubated in the presence of different concentrations of EtBr and the 
curves generated by the model, using the −+ kandk constants determined as described 
above. 
 
Flow cytometry 
This methodology was used to corroborate the analysis of the data obtained with the 
semi-automated fluorometric method. Therefore, the samples from the accumulation 
and efflux assays, used in the semi-automated fluorometric method, were also 
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analyzed by flow cytometry, in order to compare the results obtained with these two 
methodologies. Data acquisition and analysis were performed using a FACSCaliburTM 
(BD Biosciences, San Jose, CA, USA). EtBr was excited at 488 nm and the 
fluorescence detected through a 585 nm filter (FL-2 channel).  
(i) Accumulation assay. E. coli strains were cultured in 10 mL of LB medium at 37ºC 
and 220 rpm until an OD600 of 0.6. Aliquots of 1.0 mL were centrifuged at 13000 rpm for 
3 minutes, the supernatant discarded and the pellet washed twice with PBS. The OD600 
of the bacterial suspension was adjusted to 0.3 using PBS without glucose. EtBr was 
added at a final concentration of 1 mg/L and chlorpromazine was added to a final 
concentration of 20 mg/L. Following incubation at 25ºC for 60 minutes, aliquots of 0.5 
mL were taken for fluorescence measurement in the flow cytometer FACSCaliburTM. 
Data was collected for at least 10,000 events per sample.  
(ii) Efflux assay. After loading the bacteria with EtBr (1 mg/L) in the presence of 
chlorpromazine (20 mg/L), the bacterial suspension was centrifuged at 13000 rpm for 3 
minutes. The supernatant was removed and the pellet resuspended in EtBr-free PBS, 
adjusting the OD600 to 0.3. Efflux was assessed in the presence and absence of 
glucose at 0.4% (v/v). Aliquots of 0.5 mL were taken after 2.5, 5, 15, 30 and 60 minutes 
after incubation at 37ºC, for fluorescence measurement in the flow cytometer 
FACSCaliburTM. Analyses were performed with an acquisition of at least 10,000 events 
per sample.  
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Ethidium bromide transport across Mycobacterium smegmatis cell-wall: 
correlation with antibiotic resistance 
 
IV.1 Summary 
This chapter will focus on the application of the semi-automated method, which was 
developed using E. coli as a model, on the assessment of efflux pump activity in 
mycobacteria. In particular, we have compared the M. smegmatis wild-type strain 
mc2155 with knockout mutants for LfrA (the main efflux pump system of M. smegmatis) 
and MspA (the main porin of M. smegmatis) for their ability to transport EtBr. This 
information was then correlated with the determination of MICs of several antibiotics in 
the presence or absence of the efflux inhibitors chlorpromazine, thioridazine and 
verapamil. The results obtained show that, in the absence of MspA, the accumulation 
of EtBr decreased and the cells became more resistant to several antibiotics, whereas 
the mutant for LfrA showed increased accumulation of EtBr and increased susceptibility 
to EtBr, INH, EMB and CIP. Moreover, reduction of the MIC for STR, RIF, amikacin, 
ciprofloxacin, clarithromycin and erythromycin was observed in the presence of the 
tested inhibitors. These results put in evidence that MspA plays an important role in the 
entrance of quaternary ammonium compounds and antibiotics into the cells and that 
active efflux via the LfrA pump is involved in low-level resistance to several 
antimicrobial drugs in M. smegmatis. The methodology described in this study and the 
results obtained with this non-pathogenic mycobacterium will be used in further studies 
as a model for the evaluation of the activity of the same efflux inhibitors on the 
susceptibility of M. tuberculosis to INH (Chapter VI). 
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IV.2 Introduction 
The intrinsic resistance of mycobacteria to most antimicrobial agents is generally 
attributed to their relatively impermeable cell-wall, which provides a barrier to noxious 
compounds and limits drug uptake (Brennan P.J. et al, 1995). This low permeability is 
due to the structure and lipid-rich composition of the mycobacterial cell-wall that 
comprises mycolic acids, long-chain fatty acids covalently bound to a peptidoglycan-
arabinogalactan polymer, and extractable lipids not covalently linked to the 
peptidoglycan-arabinogalactan (Brennan P.J. et al, 1995; Brennan P.J., 2003; 
Niederweis M., 2003). Diffusion of hydrophilic nutrients is mediated by pore-forming 
proteins like the MspA porin of M. smegmatis, which is described as the major diffusion 
pathway for hydrophilic solutes in these mycobacteria (Niederweis M. et al, 1999; Stahl 
C. et al, 2001). Along with the cell-wall impermeability, active efflux systems can also 
provide resistance by extruding compounds that have entered the cell, making the 
intracellular concentration of a given compound a result of the interplay between 
permeability and efflux (Nikaido H., 2001). Therefore, it is crucial to clarify the 
mechanisms of drug efflux via efflux pumps, in order to develop new antimycobacterial 
therapeutic strategies. Several mycobacterial efflux pumps have been identified and 
characterized to date (Ainsa J.A. et al, 1998; Choudhuri B. S. et al, 2002; De Rossi E. 
et al, 2006; Siddiqi N. et al, 2004; Silva P.E. et al, 2001; Takiff H.E. et al, 1996; Viveiros 
M. et al, 2003). However, the role played by these pumps in drug resistance in 
mycobacteria is not completely understood. LfrA, a transporter protein of the major 
facilitator superfamily (MFS) of M. smegmatis, was the first functional efflux pump to be 
described in mycobacteria and it has been associated with resistance to EtBr, 
acriflavine, doxorubicin, rhodamine 123 and fluoroquinolones (Li X.Z. et al, 2004; Liu J. 
et al, 1996; Sander P. et al, 2000; Takiff H.E. et al, 1996). Moreover, it was 
demonstrated that the upstream region of lfrA contains a gene coding for LfrR, a 
putative transcriptional repressor of the TetR family, which represses the transcription 
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of the lfrRA operon by directly binding to the promoter region (Bellinzoni M. et al, 2009; 
Buroni S. et al, 2006).  
In the study to be described, we used the semi-automated fluorometric method to study 
EtBr transport in M. smegmatis, using the wild-type strain mc2155 and mutant strains 
carrying in-frame deletions of genes coding for porins MspA and MspC, the efflux pump 
LfrA and its repressor LfrR, and correlated this information with the corresponding 
antibiotic profile. Since many homologous pumps are present in M. tuberculosis and M. 
smegmatis, the use of M. smegmatis as a model organism can provide data that will 
help to understand efflux-mediated drug resistance in M. tuberculosis and other 
mycobacteria causing infections in humans (Li X.Z. et al, 2004). 
 
IV.3 Results 
 
IV.3.1 MspA plays an important role in EtBr influx in M. smegmatis 
The M. smegmatis strains used in this study are described in Table IV.1. The 
accumulation of EtBr under optimum efflux conditions (presence of glucose and 
incubation at 37ºC) begins to take place at a concentration of 1 mg/L in the case of M. 
smegmatis SMR5 (a mc2155 derivative streptomycin resistant strain, see Table IV.1) 
(Figure IV.1). This concentration of EtBr corresponds to what the intrinsic efflux 
systems of these organisms are capable of extruding. In the case of the SMR5 
derivatives porin mutants MN01 (∆mspA) and ML10 (∆mspA ∆mspC), this 
concentration increased to 2 and 4 mg/L, respectively (Figure IV.1).  
This could be the consequence of a decreased influx rate of EtBr due to the deletion of 
porins in these strains, since mycobacterial porins, namely MspA, are the major 
pathways for hydrophilic molecules (Niederweis M. et al, 2003; Stahl C. et al, 2001). 
Moreover, the efflux inhibitors thioridazine, chlorpromazine and verapamil (used at ½ 
MIC, see Table IV.2) failed to increase accumulation of EtBr at 1 mg/L in strains MN01 
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and ML10, in contrast to what is observed in the parental strain SMR5 (Figure IV.2). 
This excluded the possibility that the decreased accumulation of EtBr in MN01 and 
ML10 was caused by an active efflux system. Altogether, these results suggest a 
decreased permeability of the cell-wall of the mutant strains towards EtBr and 
demonstrate that the presence of MspA is required for EtBr to enter the cell.  
 
Table IV.1: Description of M. smegmatis strains used in this study. 
M. smegmatis 
strains 
Description Ref. 
mc2155 Wild-type  
Snapper S.B. 
et al, 1990 
SMR5 
mc2155 derivative; resistant to streptomycin due to a mutation in 
ribosomal protein S12 (rpsL) 
Sander P. et 
al, 1995 
MN01 SMR5 ∆mspA 
Stahl C. et al, 
2001 
ML10 SMR5 ∆mspA ∆mspC 
Stephan J. et 
al, 2005 
XZL1675 mc2155 ∆lfrA 
Li X.Z. et al, 
2004 
XZL1720 mc2155 ∆lfrR 
Li X.Z. et al, 
2004 
 
Table IV.2. MICs of EtBr and efflux inhibitors against M. smegmatis mc2155 and mutant strains. 
M. smegmatis strain 
MICs (mg/L) 
TZ CPZ VP EtBr 
mc2155 12.5 25 200 6.25 
SMR5 12.5 25 400 6.25 
MN01 25 25 400 6.25 
ML10 25 25 250 12.5 
XZL1675 6.25 25 125 0.4 
XZL1720 12.5 25 200 6.25 
CPZ, chlorpromazine; EtBr, ethidium bromide; TZ, thioridazine; VP, verapamil. 
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Figure IV.1. Accumulation of EtBr at increasing concentrations (0.5-10 mg/L) by M. smegmatis 
SMR5 (A), MN01 (B) and ML10 (C). 
Chapter IV 
Ethidium bromide transport across M. smegmatis cell-wall: correlation with antibiotic resistance 
____________________________________________________________________________________ 
 
_____________________________________________________________________________ 
 
120 
 
0
20
40
60
80
100
0 10 20 30 40 50 60
Time (min)
Fl
uo
re
sc
en
ce
 
(ar
bi
tra
ry
 
un
its
)
VP
TZ
CPZ
No EPI
0
20
40
60
80
100
0 10 20 30 40 50 60
Time (min)
Fl
u
o
re
sc
e
n
ce
 
(ar
bi
tra
ry
 
u
n
its
) VP
TZ
CPZ
No EPI
0
20
40
60
80
100
0 10 20 30 40 50 60
Time (min)
Fl
u
o
re
sc
e
n
ce
 
(ar
bi
tra
ry
 
u
n
its
)
VP
TZ
CPZ
No EPI
A
B
C
Fl
uo
re
sc
en
ce
 
(ar
bi
tra
ry
 
un
its
)
Fl
u
o
re
sc
e
n
ce
 
(ar
bi
tra
ry
 
u
n
its
)
Fl
u
o
re
sc
e
n
ce
 
(ar
bi
tra
ry
 
u
n
its
)
 
Figure IV.2.Effect of efflux inhibitors on the accumulation of EtBr (1 mg/L) in M. smegmatis 
SMR5 (A), MN01 (B) and ML10 (C). CPZ, chlorpromazine; TZ, thioridazine; VP, verapamil.  
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III.3.2 LfrA is the main efflux system involved in EtBr extrusion in M. smegmatis 
Concerning the knockout mutant for the efflux pump LfrA (strain XZL1675), EtBr started 
to accumulate at a concentration of 0.25 mg/L (Figure IV.3). Since in the wild-type M. 
smegmatis mc2155, accumulation took place at a concentration of 1 mg/L of EtBr 
(Figure IV.3), these results demonstrate an increased susceptibility of the mutant 
strains to EtBr due to a decreased efflux activity. In the case of the lfrR mutant 
XZL1720, EtBr accumulation started at a concentration of 2 mg/L, a higher 
concentration than the observed for the wild-type M. smegmatis mc2155. This could be 
due to the constitutive expression of LfrA in this strain as a consequence of the deletion 
of the repressor LfrR (Buroni S. et al, 2006; Li X.Z et al, 2004). These results are in 
agreement to what has been previously reported regarding LfrA as the main efflux 
system involved in EtBr extrusion (Li X.Z. et al, 2004; Liu J. et al, 1996; Sander P. et al, 
2000; Takiff H.E. et al, 1996). In order to determine the effect of the inhibitors 
thioridazine, chlorpromazine and verapamil on EtBr efflux activity, efflux assays were 
performed for M. smegmatis mc2155, XZL1675 and XZL1720. As shown by Figure 
IV.4, all strains presented efflux of EtBr at 37ºC in the presence of glucose and this 
efflux activity was inhibited in the presence of thioridazine, chlorpromazine and 
verapamil. However, it must be noted that the concentration of EtBr used for the lfrA 
mutant was 15-fold lower than the concentration used for the wild-type and lfrR deleted 
strains (0.2 mg/L for XZL1675 vs 3 mg/L for mc2155 and XZL1720 – ½ MIC for each 
strain, see Table IV.2). This further demonstrates that the deletion of lfrA hinders the 
cell's ability to efflux EtBr, resulting in a low MIC for this fluorochrome and a decreased 
EtBr efflux activity when compared to mc2155 and XZL1720.  
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Figure IV.3. Accumulation of EtBr at increasing concentrations (0.25-8 mg/L) by M. smegmatis 
mc2155 (A), XZL1675 (B) and XZL 1720 (C). 
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Figure IV.4. Efflux of EtBr by M. smegmatis mc2155 (A), XZL1675 (B) and XZL1720 (C). Efflux 
takes place at 37ºC in the presence of glucose and is inhibited by thioridazine, chlorpromazine 
and verapamil. CPZ, chlorpromazine; EPIs, efflux pump inhibitors; TZ, thioridazine; VP, 
verapamil.  
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III.3.3 Effect of efflux inhibitors on the antibiotic resistance of M. smegmatis  
The effect of the efflux inhibitors on the reduction of MICs of antibiotics against M. 
smegmatis mc2155 and mutant strains is presented in Table IV.3.  In the case of wild-
type M. smegmatis mc2155, thioridazine, chlorpromazine and verapamil promoted a 
significant (at least 4-fold) reduction of the MIC of STR, RIF, amikacin, ciprofloxacin, 
clarithromycin and erythromycin. The mutants SMR5, MN01 and ML10 present an MIC 
for streptomycin above 256 mg/L due to the presence of a mutation in the rpsL gene 
that confers resistance to this antibiotic. Deletion of porins MspA (MN01) and MspC 
(ML10) caused a decreased susceptibility to INH, RIF, clarithromycin and erythromycin, 
and MIC reduction was observed for amikacin (SMR5 and MN01), RIF, ciprofloxacin, 
clarithromycin and erythromycin (SMR5, MN01 and ML10). Deletion of lfrA (XZL1675) 
increased the susceptibility to INH, EMB, and ciprofloxacin, which suggests that LfrA 
might contribute to the intrinsic resistance of M. smegmatis to these drugs, as already 
reported by other studies (Li X.Z. et al, 2004). In the LfrA mutant XZL1675, a significant 
reduction of the MIC was observed for STR, RIF, amikacin, clarithromycin and 
erythromycin, which suggests that other efflux pumps are at work in this strain. The 
same efflux inhibitors also had an effect in increasing the susceptibility of the lfrR 
mutant (XZL1720) to the tested antibiotics, with the exception of INH and EMB. 
 
However, some of the results obtained were discrepant with the ones found in the 
literature. In the particular case of RIF, there is a decrease of the MIC in this strain that 
also occurs in the lfrR deleted mutant. Thus, the observed decrease of the MIC may 
not be a result of the deletion of the pump, but could be due to other causes. The 
previous characterization of these strains by Li and Nikaido (Li X.Z. et al, 2004) showed 
that there is no difference between the mutant strains and the wild-type concerning the 
MIC for RIF (authors reported an MIC of 1 mg/L for each strain). Also, our results show 
that the MIC for ciprofloxacin in the case of the lfrR mutant is the same observed for 
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the lfrA mutant, whereas in the literature the deletion of lfR is reported to increase the 
ciprofloxacin MIC from 0.25 mg/L (wild-type M. smegmatis mc2155) to 4 mg/L (M. 
smegmatis XZL1720). The discrepancy between our results and the ones reported in 
the literature could be due to the different methods used for the determination of 
theMICs: microdilution method in Middlebrook 7H9 medium supplemented with oleic 
acid-albumine-dextrose-catalase (OADC) (this study) or microdilution method in 7H9 
medium supplemented with OADC and Tween 80 in combination with drug gradient 
plates (Li X.Z. et al, 2004).  
 
Table IV.3. Effect of efflux inhibitors on the MICs of antibiotics for wild-type and mutant strains 
of M. smegmatis.  
MICs (mg/L) 
Antibiotic/EPI 
M. smegmatis strains 
mc2155 SMR5 MN01 ML10 XZL1675 XZL1720 
STR 
No EPI 0.5 >256 >256 >256 0.5 0.5 
TZ 0.125 >256 >256 >256 0.125 0.25 
CPZ 0.125 >256 >256 >256 0.032 0.063 
VP 0.25 >256 >256 >256 0.25 0.125 
INH 
No EPI 8 128 128 128 4 8 
TZ 8 128 128 128 4 4 
CPZ 8 128 128 128 4 4 
VP 8 128 128 128 4 4 
RIF 
No EPI 4 4 8 8 0.5 0.5 
TZ 2 2 4 4 0.125 0.125 
CPZ 1 1 2 2 0.125 0.125 
VP 2 2 4 4 0.125 0.25 
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Table IV.3. (cont.) 
EMB 
No EPI 1 1 1 1 0.5 1 
TZ 1 1 1 1 0.5 1 
CPZ 1 1 1 1 0.5 1 
VP 1 1 1 1 0.5 1 
AMK 
No EPI 0.5 0.5 0.5 0.5 0.5 0.5 
TZ 0.063 0.063 0.125 0.25 0.063 0.063 
CPZ 0.125 0.125 0.125 0.25 0.063 0.063 
VP 0.125 0.125 0.125 0.25 0.125 0.125 
CIP 
No EPI 0.25 0.25 0.25 0.25 0.125 0.125 
TZ 0.063 0.063 0.063 0.063 0.032 0.032 
CPZ 0.063 0.063 0.063 0.063 0.063 0.063 
VP 0.063 0.063 0.063 0.063 0.063 0.063 
CLT 
No EPI 2 2 8 8 2 2 
TZ 0.25 0.25 1 1 0.25 0.25 
CPZ 0.25 0.25 0.5 1 0.25 0.25 
VP 0.5 0.5 0.5 1 0.5 0.5 
ERY 
No EPI 32 32 64 64 32 32 
TZ 4 4 16 16 4 4 
CPZ 4 4 8 8 4 4 
VP 8 8 8 8 8 8 
AMK, amikacin; CIP, ciprofloxacin; CLT, clarithromycin; CPZ, chlorpromazine; EPI, eflux pump inhibitor; 
ERY, erythromycin; ETB, ethambutol; INH, isoniazid; RIF, rifampicin; STR, streptomycin; TZ, thioridazine; 
VP, verapamil. Data in bold type represents significant (at least 4-fold) reduction of the MIC produced by 
the presence of an EPI. 
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IV.4 Conclusions 
The detection of EtBr influx and efflux can be used to anticipate transport-mediated 
antibiotic resistance in bacteria since these compounds use similar channels to enter 
and leave the cell. In this study, we have compared the wild-type M. smegmatis 
mc2155 with knockout mutants for LfrA and MspA for their ability to transport EtBr. It 
was observed that in the absence of MspA, the major porin of M. smegmatis, 
accumulation of EtBr decreased and the mycobacteria became more resistant to 
several antibiotics. This is in accordance with previous studies that demonstrated MspA 
as the major general diffusion pathway for hydrophilic solutes in M. smegmatis, 
mediating the uptake of small and hydrophilic nutrients such as sugars and phosphates 
across the outer membrane (Niederweis M. et al, 1999, Stephan J. et al, 2005 
Wolschendorf F. et al, 2007). However, this does not necessarily mean that EtBr uses 
MspA as a direct pathway into the cell. In fact, one cannot rule out the possibility that 
the deletion of porins alters the structure and composition of the cell-wall, thus making 
it more impermeable. Studies have demonstrated that deletion of the mspA gene 
increased the resistance of M. smegmatis not only to hydrophilic molecules, but also to 
hydrophobic antibiotics, such as erythromycin (Stephan J. et al, 2004). It was 
suggested that mspA deletion causes the alteration of lipid arrangement in the 
mycobacterial outer membrane. This was supported by the finding that the mspA 
mutant presented a decreased rate of uptake of the hydrophobic agent 
chenodeoxycholate compared to that by the wild-type. Decreased permeability to this 
agent was also observed in a mutant of M. tuberculosis lacking oxygenated mycolic 
acids, which shows that the lipid arrangement is important for the permeability of the 
mycobacterial outer membrane (Dubnau E. et al, 2000; Stephan J. et al, 2004).  
 
The mutant for the LfrA pump showed increased accumulation of EtBr and also an 
increased susceptibility to INH, EMB and ciprofloxacin. This is also in agreement to 
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what has been demonstrated in other studies that showed that disruption of the lfrA 
gene decreased the MIC of EtBr, acriflavine ciprofloxacin, doxorubicin and rhodamine 
(Liu J. et al, 1996; Takiff H.E. et al, 1996). Moreover, resistance to these antibiotics 
decreased in the presence of the efflux inhibitors in the wild-type strain and the mutant 
strain for the LfrA repressor, further demonstrating that active efflux by LfrA plays an 
important role in the extrusion of a broad range of substrates. Altogether these results 
show that MspA plays an important role in the entrance of quaternary ammonium 
compounds and antibiotics into the cells and that active efflux via the LfrA pump is 
involved in low-level resistance to several antibiotics and quaternary ammonium 
compounds in M. smegmatis.  
The results and conclusions obtained in this chapter were summarized in the 
publication Rodrigues L. et al, 2010. We have been able to demonstrate in this chapter 
that in the absence of the porin MspA, M. smegmatis became more resistant to several 
antibiotics and EtBr, whereas the mutant for the efflux pump LfrA showed increased 
accumulation of EtBr and increased susceptibility to EtBr, INH, EMB and ciprofloxacin. 
In addition, MIC reductions for STR, RIF, amikacin, ciprofloxacin, clarithromycin and 
erythromycin were observed in the presence of efflux inhibitors. Therefore, the porin 
MspA plays an important role in the entrance of quaternary ammonium compounds and 
antibiotics into the cells and the LfrA pump is involved in the extrusion and, 
consequently, in low-level resistance to several antimicrobial drugs. The rational and 
methodology applied in this chapter to non-pathogenic mycobacteria will be used for 
the evaluation of the activity of the same efflux inhibitors on the susceptibility of M. 
avium complex reference and clinical strains to macrolides (Chapter V) and to M. 
tuberculosis complex strains to INH (Chapter VI). 
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IV.5 Materials and Methods 
 
Materials 
EtBr, glucose, PBS, chlorpromazine, thioridazine, verapamil, STR, INH, RIF, EMB, 
amikacin and ciprofloxacin were purchased from Sigma Aldrich Química SA (Madrid, 
Spain). Clarithromycin was obtained from Abbott Laboratories (Abbott Park, IL, USA). 
Middlebrook 7H9 broth and OADC supplement were purchased from Difco (Detroit, MI, 
USA). All solutions were prepared on the day of the experiment. 
 
Bacteria 
The M. smegmatis strains used in this work are described in Table IV.1. M. smegmatis 
strains SMR5, MN01 and ML10 were kindly provided by Michael Niederweis 
(Department of Microbiology, University of Alabama at Birmingham, Birmingham, 
U.S.A); strains XZL1675 and XZL1720 were kindly provided by Hiroshi Nikaido 
(Department of Molecular and Cell Biology, University of California, Berkeley, 
California, U.S.A). Mycobacteria were grown at 37ºC in Middlebrook 7H9 broth or 
Middlebrook 7H11 solid medium, supplemented with 10% (v/v) of OADC.  
 
Determination of Minimum Inhibitory Concentrations  
The determination of MICs of EtBr, the efflux inhibitors thioridazine, chlorpromazine 
and verapamil and of antibiotics studied alone and in the presence of an efflux inhibitor, 
was performed by the broth microdilution method according to the Clinical Laboratory 
Standards Institute (CLSI) guidelines (CLSI, 2003). Briefly, mycobacterial strains were 
grown at 37ºC in Middlebrook 7H9 broth supplemented with 10% OADC until an 
O.D.600 of 0.8. The bacterial cultures were diluted in PBS to equal the McFarland No. 
0.5 standard and the final inoculum was prepared by diluting the bacterial suspension 
at 1:100. Aliquots of 0.1 mL were transferred to each well of a 96-well plate that 
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contained 0.1 mL of each compound at concentrations prepared from 2-fold serial 
dilutions in 7H9/OADC medium. The inoculated plates were incubated at 37ºC until 
growth in the agent-free control-well was evident (2-3 days). The MIC was defined as 
the lowest concentration of compound that inhibited visible growth 
 
Semi-automated fluorometric method 
The assessment of accumulation and extrusion of EtBr in the studied M. smegmatis 
strains was performed using the semi-automated fluorometric method, previously 
developed as described in Chapter III.  
(i) Accumulation assay. M. smegmatis strains were grown in 5 mL of 7H9/OADC 
medium at 37ºC until an O.D.600 of 0.8. The culture was centrifuged at 13000 rpm for 3 
minutes, the supernatant discarded and the pellet washed in PBS (pH 7.4). The O.D.600 
was adjusted to 0.4 with PBS and glucose was added at final concentration of 0.4%. 
Aliquots of 0.095 mL of bacterial suspension were distributed to 0.2 mL PCR 
microtubes and EtBr was added at concentrations that ranged from 0.25 to 10 mg/L. 
The fluorescence was measured in the Rotor-GeneTM 3000 (Corbett Research, 
Sydney, Australia), using the 530 nm band-pass and the 585 nm high-pass filters as 
the excitation and detection wavelengths, respectively. Fluorescence data was 
acquired every 60 seconds for 60 minutes at 37ºC. 
The effect of thioridazine, chlorpromazine and verapamil on the accumulation of EtBr 
was determined by adding 0.005 mL of each compound to aliquots of 0.095 mL of 
EtBr-containing bacterial suspension previously distributed to 0.2 mL PCR microtubes. 
The fluorescence was measured every 60 seconds for 60 minutes at 37ºC in the Rotor-
GeneTM 3000.  
(ii) Efflux assay. Mycobacteria were exposed to conditions that promote accumulation 
of EtBr: no glucose; presence of the efflux inhibitor that caused maximum 
accumulation, in this case verapamil; and incubation at 25ºC (Viveiros M. et al, 2008; 
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Rodrigues L. et al, 2008). The EtBr loaded cells were centrifuged at 13000 rpm for 3 
minutes and resuspended in EtBr-free PBS containing 0.4% glucose. After adjusting 
the O.D.600 to 0.4, aliquots of 0.095 mL were transferred to 0.2 mL microtubes. 
Fluorescence was measured in the Rotor-GeneTM 3000 as described for the 
accumulation assay. The efflux activity was quantified by comparing the fluorescence 
data obtained under conditions that promote efflux (presence of glucose and absence 
of efflux inhibitor) with the data from the control in which the mycobacteria are under 
conditions of no efflux (presence of an efflux inhibitor and no energy source). Thus, the 
relative fluorescence corresponds to the ratio of fluorescence that remains per unit of 
time, relatively to the EtBr-loaded cells. 
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The role of efflux pumps in macrolide resistance in Mycobacterium avium 
complex 
 
V.1 Summary 
M. avium complex (MAC) is clinically important since it can cause severe infections in 
immunocompromised individuals such as patients with AIDS. The use of the 
macrolides clarithromycin and azithromycin has improved the outcome of MAC 
infections, but therapeutic failure is still a major problem. Along with the objectives of 
this thesis and following the evidences previously gathered, we have studied, in this 
chapter, the contribution of efflux pump activity in macrolide resistance in MAC clinical 
strains. Eighteen clinical strains isolated from AIDS patients were evaluated for 
macrolide resistance in the presence and absence of the efflux inhibitors thioridazine, 
chlorpromazine and verapamil. The efflux activity of these strains was then assessed 
by the semi-automated fluorometric method that detects extrusion of EtBr, as 
demonstrated in Chapter III and IV. Resistance to clarithromycin was significantly 
reduced in the presence of thioridazine, chlorpromazine and verapamil. The same 
efflux inhibitors were effective in decreasing the efflux of EtBr from MAC cells. 
Moreover, increased retention of [14C]-erythromycin in the presence of these efflux 
inhibitors further demonstrated that active efflux contributes to MAC resistance to 
macrolides. This study demonstrates that efflux pumps play an important role in MAC 
resistance to antibiotics and can now be extended to highly pathogenic mycobacteria.  
  
V.2 Introduction 
MAC comprises a heterogeneous group of environmental mycobacteria whose clinical 
relevance has acquired greater significance in recent decades because it causes 
severe infections in AIDS patients and other immunocompromised individuals (Field 
S.K. et al, 2004; Griffith D.E. et al, 2007; Guthertz L.S. et al, 1989; Primm T.P. et al, 
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2004). The classic definition of MAC includes the genetically distinct species 
Mycobacterium avium and Mycobacterium intracellulare (Inderlied C.B., 1993). M. 
avium is more prevalent in clinical and environmental samples and is mainly 
responsible for disseminated MAC disease in HIV patients, whereas M. intracellulare is 
an important contributor to MAC-associated pulmonary infections in immunocompetent 
or non-HIV patients (Guthertz L.S. et al, 1989; Tsang A.Y. et al, 1992; Turenne C.Y. et 
al, 2007; Yakrus M.A. et al, 1990). MAC infections are difficult to treat owing to the 
intrinsic multidrug resistance of the organism, which is assumed to be a consequence 
of decreased permeability of the cell wall, mainly due to the composition of the thick 
arabinogalactan–peptidoglycan–mycolic and, in MAC strains, this layer is surrounded 
by a second electrondense layer of serovar-specific glycopeptidolipids (Inderlied C.B. 
et al, 1993). Thus, the wide range of resistance shown by MAC isolates to most 
antimicrobial drugs has been ascribed to the composition of its unique cell wall, the 
integrity of which, when affected, results in increased susceptibility to a variety of drugs 
(Griffith D.E.l, 2007; Guthertz L.S. et al, 1989; Jarlier V. et al, 1994; Tomioka H., 2004). 
The only antimicrobial agents for which a correlation has been demonstrated between 
in vitro susceptibility results and clinical outcome in controlled clinical trials are the 
macrolides clarithromycin and azithromycin. Because susceptibility to clarithromycin 
predicts susceptibility to azithromycin, CLSI guidelines state that clarithromycin should 
be the only drug routinely evaluated for activity against MAC (CLSI, 2003). There are 
no CLSI interpretive guidelines for other drugs since in vitro results are not predictive of 
clinical outcome and may be misleading (CLSI, 2003). Nevertheless, other drugs such 
as rifabutin, EMB, amikacin, clofazimine, linezolid and the fluoroquinolones are 
relatively effective in controlling MAC bacteraemia as long as they are able to reach 
their internal target and the target has not mutated (Griffith D.E., 2007; Tomioka H., 
2004). It is now known that efflux pumps contribute to intrinsic resistance of 
mycobacteria to antibiotics. Moreover, when these efflux pumps are overexpressed 
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they extrude a wide variety of chemically and structurally unrelated noxious compounds 
from the cell, thereby preventing them from reaching their intended targets (Amaral L. 
et al, 2007; De Rossi E. et al, 2006; Doucet-Populaire F. et al, 2002; Silva P.E. et al, 
2001; Viveiros M. et al, 2003). Although overexpressed activity of efflux pumps may 
account for MDR phenotypes of some MAC and M. tuberculosis clinical strains, 
evidence in support of this possibility is essentially absent. It has been previously 
demonstrated that the activity of efflux pumps in M. tuberculosis responsible for 
induced high-level resistance to isoniazid can be inhibited by efflux inhibitors such as 
reserpine (De Rossi E. et al, 2006; Viveiros M. et al, 2001; Viveiros M. et al, 2003). In 
this chapter, we intend to demonstrate the presence of an intrinsic efflux system in M. 
avium reference strain ATCC25291T and to correlate efflux pump activity with 
macrolide resistance in MAC clinical strains (Rodrigues L. et al, 2008, Rodrigues L. et 
al, 2009). 
 
V.3 Results 
 
V.3.1 Effect of efflux inhibitors in macrolide resistance in reference and clinical 
isolates of MAC  
The MICs for clarithromycin and erythromycin against the identified strains are 
summarized in Table V.1. Among the clinical strains tested, M. avium 47/07, M. avium 
386/08, M. intracellulare 253/07 and M. intracellulare AL2 presented clinically 
significant resistance to clarithromycin (breakpoints according to CLSI guidelines: S ≤ 
16 mg/L; I = 32 mg/L; R ≥ 64 mg/L) and a high MIC for erythromycin. This high-level 
clarithromycin/erythromycin resistance is invariably associated with a mutation in 
adenine 2058 or 2059 in domain V of the 23S rRNA gene and is the main mechanism 
of resistance accounting for this phenotype (Griffith D.E. et al, 2006; Meier A. et al, 
1996b; Nash K.A. et al, 1995).  
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In order to determine if the drug susceptibility phenotype of these strains was affected 
by the presence of an efflux inhibitor, the MIC for each antibiotic was determined in the 
absence and presence of ½ of the MICs of thioridazine, chlorpromazine and verapamil 
(Table V.1).  
 
Table V.1. Effect of thioridazine, chlorpromazine and verapamil on the MICs of clarithromycin 
and erythromycin against MAC strains. 
Strain 
MICs (mg/L) 
Clarithromycin Erythromycin 
No EPI TZ CPZ VP No EPI TZ CPZ VP 
M. avium ATCC25291T 4 2 2 2 16 0.5 0.5 4 
M. avium 104 8 8 8 8 256 256 256 256 
M. avium HSB1 8 2 2 4 256 256 256 256 
M. avium HSB2 8 2 2 8 256 256 256 256 
M. avium HSB3 8 2 2 8 256 64 16 128 
M. avium HSB4 8 1 1 8 256 128 128 256 
M. avium HSB5 8 2 2 2 256 256 256 256 
M. avium HSB6 8 2 2 8 256 256 256 256 
M. avium AL1 8 2 1 1 128 64 16 16 
M. avium 47/07 1024 1024 1024 512 512 256 512 128 
M. avium 386/08 512 512 128 512 1024 256 256 512 
M. intracellulare ATCC13950T 0.25 0.25 0.25 0.25 0.06 0.06 0.06 0.06 
M. intracellulare 101/07 8 8 4 8 256 256 256 64 
M. intracellulare 278/07 8 8 8 8 256 16 16 256 
M. intracellulare 308/07 1 0.5 0.5 1 256 256 256 16 
M. intracellulare 421/07 1 0.5 0.5 1 256 256 256 256 
M. intracellulare 30/08 1 0.25 0.5 0.25 256 256 256 64 
M. intracellulare 92/08 2 0.5 1 0.125 256 256 128 256 
M. intracellulare 253/07 1024 1024 256 1024 2048 1094 512 256 
M. intracellulare AL2 2048 256 2048 1024 2048 256 1094 256 
TZ, thioridazine; CPZ, chlorpromazine; VP, verapamil. EPIs were used at ½ the MIC. A 4-fold reduction 
was considered to denote significant synergistic effect between the antibiotic and the EPI and is identified 
in bold. Breakpoints for clarithromycin MIC determination by microdilution in 7H9/pH 6.8: S ≤ 16 mg/L; I = 
32 mg/L; R ≥ 64 mg/L (CLSI, 2003). 
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The MICS determined for each efflux inhibitor tested are shown in Table V.2, and it is 
important to note that ½ the MIC of each of the agents listed has no effect on the 
viability of the organisms (data not shown). This is a condition that must be satisfied if 
the effect of the efflux inhibitor on the MIC of an antibiotic is to be exclusively that 
against the efflux system itself (Rodrigues L. et al, 2008; Viveiros M. et al, 2008a). As 
shown by the results presented in Table V.1, the efflux inhibitors chlorpromazine and 
thioridazine reduced the MIC of clarithromycin for 12 of the 20 isolates tested, including 
the M. avium reference strain. The effects of these efflux inhibitors on the MIC of 
erythromycin were also evident for 7 strains. Verapamil promoted significant reduction 
of the MICs for clarithromycin and erythromycin in 4 and 8 strains, respectively. These 
results suggest that MAC strains have one or more chlorpromazine and thioridazine 
sensitive efflux pump(s) that recognise clarithromycin as a substrate. However, in the 
particular case of the strains with high-level resistance to clarithromycin, the reduction 
of the MICs promoted by the efflux inhibitors does not reach a level of susceptibility, i.e. 
an MIC ≤ 16 mg/L. 
 
Screening for mutations in  the domain V of the 23S rRNA gene revealed the presence 
of point mutations in position 2058 in three strains that presented high-level resistance 
to clarithromycin (M. avium 47/07 AG; M. intracellulare 253/07 AC; M. intracellulare 
AL2 AC). Substitutions of the adenine at position 2058 by guanine or cytosine has 
been described in association with high-level resistance to clarithromycin (Griffith D.E. 
et al, 2006; Jamal M.A. et al, 2000; Nash K.A. et al, 1995). The other isolate showing 
phenotypic resistance to clarithromycin albeit at a lower level (M. avium 386/08), 
presented a wild-type sequence in this region of the 23S rRNA gene. This phenotype 
could result from mutation(s) located outside this region, or due to a different resistance 
mechanism(s), including efflux. 
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Table VI.2. MICs of EtBr and efflux inhibitors determined for MAC clinical and reference strains. 
Strain 
MIC (mg/L) 
TZ CPZ VP EtBr 
M. avium ATCC25291T 20 25 800 6.25 
M. avium 104 25 25 500 6.25 
M. avium HSB1 25 25 1000 16 
M. avium HSB2 25 25 500 8 
M. avium HSB3 25 25 1000 16 
M. avium HSB4 25 25 1000 16 
M. avium HSB5 6.25 25 1000 8 
M. avium HSB6 25 25 500 8 
M. avium AL1 10 25 500 6.25 
M. avium 47/07 12.5 12.5 500 12.5 
M. avium 386/08 25 12.5 1000 12.5 
M. intracellulare ATCC13950T 12.5 50 1000 2 
M. intracellulare 101/07 12.5 12.5 500 12.5 
M. intracellulare 278/07 12.5 12.5 500 6.25 
M. intracellulare 308/07 12.5 12.5 500 12.5 
M. intracellulare 421/07 12.5 12.5 500 12.5 
M. intracellulare 30/08 12.5 12.5 500 12.5 
M. intracellulare 92/08 12.5 12.5 500 12.5 
M. intracellulare 253/07 6.25 12.5 500 4 
M. intracellulare AL2 6.25 12.5 500 4 
TZ, thioridazine; CPZ, chlorpromazine; VP, verapamil; EtBr, ethidium bromide. 
 
V.3.2 Detection of efflux activity by real-time fluorometry 
The efflux activity of MAC reference and clinical strains was assessed by the semi-
automated fluorometric method in the presence and absence of the efflux inhibitors, 
following the procedures explained in the previous chapters. As shown by Figure V.1, 
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efflux of EtBr was detected in both reference and clinical strains (represented by M. 
avium 386/08 and M. intracellulare AL2) at 37ºC in the presence of glucose. Moreover, 
this efflux activity decreased in the presence of verapamil and thioridazine (Figure V.1). 
A similar effect was observed with chlorpromazine (data not shown). Whilst both M. 
avium strains showed similar EtBr efflux activity, for M. intracellulare, efflux was more 
evident in the clinical strain, while only a basal efflux activity was registered for M. 
intracellulare ATCC13950T. These results provide further evidence that efflux activity is 
involved in the resistance to macrolides in both M. avium and M. intracellulare clinical 
strains. 
 
V.3.3 Retention of [14C]-erythromycin 
Evidence for such activity was also provided by studying the retention of radiolabelled 
erythromycin in order to compare the intracellular accumulation of this antibiotic in the 
presence or absence of an efflux inhibitor. As shown in Figure IV.2, the presence of 
thioridazine and verapamil promotes the intracellular retention of [14C]-erythromycin, in 
accordance with the results obtained for MIC determination for erythromycin in the 
presence and absence of these efflux inhibitors (Table V.1). These results confirm the 
previous assumption that at least one active efflux system is involved in the extrusion 
of macrolides and contributes to the resistance of MAC to these drugs. 
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Figure V.1. Efflux of EtBr by M. avium ATCC25291T, M. intracellulare ATCC13950T, and clinical 
strains M. avium 386/08 and M. intracellulare AL2. The assays were conducted at 37ºC, with or 
without an efflux pump inhibitor (EPI). Relative fluorescence was obtained by normalization of 
data against the conditions of no efflux (presence of efflux inhibitor and no glucose). Efflux of 
EtBr was inhibited by verapamil (VP) and thioridazine (TZ) used at ½ MIC.  
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Figure V.2. Retention of [14C]-erythromycin by MAC reference and clinical strains. The 
intracellular accumulation of [14C]-erythromycin (Ery) was determined in the presence and 
absence of verapamil (VP) or thioridazine (TZ) at ½ MIC. Values (expressed as counts per 
minute, CPM) are the average of three replicate tubes. Error bars indicate standard deviations.  
 
V.4 Conclusions 
Mycobacteria belonging to MAC are still the most frequent cause of opportunistic 
bacterial infection in patients with AIDS. Treatment of MAC disease remains difficult 
and requires months of multiple therapy, although it has been greatly improved with the 
introduction of the extended-spectrum macrolides clarithromycin and azithromycin, 
which are far more effective than other antimicrobial agents against MAC infections 
(Field S.K. et al, 2004; Griffith D.E., 2007; Guthertz L.S et al., 1989; Primm T.P et al., 
2004).  However, cross-resistance between clarithromycin and azithromycin has been 
detected and, although monotherapy with clarithromycin (or azithromycin) significantly 
reduced levels of MAC bacteraemia, it is usually followed by relapses from macrolide-
resistant strains. Consequently, other antimycobacterial drugs must be used in 
combination with clarithromycin to prevent the emergence of macrolide resistance 
(Heifets LB., 1996). 
Efflux of antibiotics has been identified as a relevant contributor to bacterial resistance 
in clinical practice and is now recognised as an important cause of intrinsic antibiotic 
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resistance in mycobacteria (Rodrigues L. et al, 2008; Rodrigues L. et al, 2009; Viveiros 
M. et al, 2003). In this chapter, we investigated the contribution of active efflux to 
macrolide resistance in reference and clinical MAC strains isolated from AIDS patients. 
In this work, we have also shown that these efflux inhibitors effectively reduce the MIC 
of clarithromycin for most strains tested. The same efflux inhibitors were effective in 
decreasing efflux from MAC cells loaded with EtBr. These efflux assays highlighted the 
efflux activity in the four high-level resistant MAC strains identified in this study (two M. 
avium and two M. intracellulare strains), demonstrating that besides the presence of 
mutations in the 23S rRNA gene in three of these strains, this high-level resistance also 
results from efflux activity, as already suggested by the reduction of MICs for 
clarithromycin and erythromycin in the presence of the efflux inhibitors (Table V.1). 
Retention of [14C]-erythromycin by the same inhibitors further demonstrated that active 
efflux contributes to MAC resistance to macrolides. Prolonged exposure to 
antimycobacterial compounds, such as in MAC therapy, may render the mycobacterial 
population increasingly resistant by means of increased efflux activity, from which 
mutants emerge with an increased probability, explaining the relapses from macrolide-
resistant strains in patients subjected to monotherapy, especially in AIDS patients 
where the immune system is weakened; there is thus the need to add other 
antimycobacterial drugs (Heifets LB., 1996; Tomioka H., 2004). Therefore, agents that 
inhibit mycobacterial efflux pumps not only render the organism more susceptible to an 
antibiotic but also reduce the probability of selection of spontaneously arising mutants 
and may become important antimycobacterial therapy adjuvants and a source of new 
antimycobacterial compounds.  
The results and conclusions obtained in this chapter were summarized in the 
publications Rodrigues L. et al, 2008 and Rodrigues L. et al, 2009. We have been able 
to demonstrate in this chapter that efflux pump activity play an important role in MAC 
resistance to antibiotics, in particular to macrolides, and this scientific and 
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methodological approach can now be extended to highly pathogenic mycobacteria 
such as M. tuberculosis complex strains resistant to INH (Chapter VI). 
 
V.5 Materials and Methods 
 
Materials 
Middlebrook 7H9 broth and OADC supplement were purchased from Difco (Detroit, 
MI). EtBr, glucose, PBS, potassium phosphate, lithium chloride, chlorpromazine, 
thioridazine, verapamil and erythromycin were purchased from Sigma-Aldrich Química 
SA (Madrid, Spain). Clarithromycin was obtained from Abbott Laboratories (Abbott 
Park, IL). [N-Methyl-14C]-erythromycin and the liquid scintillation cocktail ULTIMA 
GOLD F were purchased from PerkinElmer (Waltham,MA). All solutions were prepared 
on the day of the experiment.  
 
Bacteria 
The following MAC strains were used in this study: the reference strains M. avium 
subsp. avium ATCC 25291T and M. intracellulare ATCC 13950T; M. avium 104, a 
common MAC representative whose genome is sequenced; and 17 clinical strains 
isolated from respiratory specimens from AIDS patients, received in our laboratory from 
hospitals of the Greater Lisbon area for routine mycobacterial isolation and 
identification. All specimens were processed by the conventional mycobacteriological 
NaOH-NALC method (Kent P.T., 1985) and aliquots were collected for acid-fast 
staining (Ziehl–Neelsen) and inoculation of MGIT tubes of the BACTECTM MGITTM 960 
system (Becton-Dickinson Diagnostic Instrument Systems, Towson, MD). MAC strains 
present in full-grown cultures were identified as M. avium or M. intracellulare by the 
AccuProbe® system (Gen-Probe Inc., San Diego, CA) according to the manufacturer’s 
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instructions. For the following studies the strains were grown at 37ºC in Middlebrook 
7H9 broth or Middlebrook 7H11 solid media, both supplemented with 10% OADC. 
 
Determination of minimum inhibitory concentrations 
MICs for the efflux inhibitors thioridazine, chlorpromazine and verapamil and for the 
antibiotics clarithromycin and erythromycin, alone and in the presence of an efflux 
inhibitor, were determined by the broth microdilution method according to CLSI 
guidelines (CLSI, 2003). Briefly, MAC strains were grown in 7H9/OADC medium at 
37ºC to an OD600 of 0.8. Bacterial cultures were diluted with PBS to McFarland No. 0.5 
standard and the inoculum prepared with an aliquot of the suspension was diluted to 
1:100. Aliquots of 0.1mL of the inoculum were transferred to wells of a 96-well plate 
containing 0.1mL of 7H9/OADC medium with two-fold serial dilutions of each agent. 
The inoculated plates were incubated at 37ºC until growth in the agent-free control well 
was evident (5–7 days). The MIC was defined as the lowest concentration of 
compound that inhibited visible growth. 
 
Ethidium bromide efflux assay by a semi-automated fluorometric method 
EtBr extrusion from MAC cells was assessed by a semi-automated fluorometric method 
as described previously (Rodrigues L. et al, 2008; Viveiros M. et al, 2008a; Viveiros M. 
et al, 2010a). Briefly, mycobacterial cells were grown in 7H9/OADC medium at 37ºC 
until an OD600 of 0.8. The culture was centrifuged at 13000 rpm for 3 minutes, the 
supernatant was discarded and the pellet was washed once and re-suspended in PBS. 
After adjusting the OD600 to 0.4, mycobacteria were exposed to conditions that 
promoted maximum accumulation of EtBr: EtBr at ½ the MIC for each strain; no 
glucose; presence of verapamil at ½ the MIC; and incubation at 25ºC for 60 minutes. 
EtBr-loaded cells were centrifuged at 13 000 rpm for 3 minutes and re-suspended in 
EtBr-free PBS. After adjusting the OD600 to 0.4, glucose was added at a final 
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concentration of 0.4%, aliquots of 0.095 mL were transferred to 0.2 mL microtubes and 
EPIs were added. Fluorescence was measured in a Rotor-GeneTM 3000 real-time 
thermocycler (Corbett Research, Sydney, Australia) using 530 nm band-pass and a 
585 nm high-pass filters as the excitation and detection wavelengths, respectively. 
Fluorescence data were acquired every 60 seconds for 30 minutes at 37ºC. 
Efflux activity was quantified by comparing the fluorescence data obtained for 
mycobacteria under conditions that allow maximum efflux (incubation at 37ºC, in the 
presence of glucose and absence of efflux inhibitor) against the data from the control 
tube that contains the EtBr-loaded cells under conditions that inhibit efflux (presence of 
an efflux inhibitor and no glucose). Thus, the relative fluorescence corresponds to the 
ratio of fluorescence that remains per unit of time relative to the EtBr-loaded cells 
(Rodrigues L. et al, 2008; Viveiros M. et al, 2008a; Viveiros M. et al, 2010a). Each 
experiment was conducted at least three times and the results obtained did not vary 
qualitatively.  
 
 [14C]-Erythromycin accumulation assay 
MAC cultures were grown in 7H9/OADC at 37ºC until an OD600 of 0.8. Cells were 
harvested by centrifugation at 13 000 rpm for 3 minutes, washed once with PBS and 
the pellet was re-suspended in the same buffer. The OD600 was adjusted to 0.4 with 
PBS containing glucose at a final concentration of 0.4% and 10 µM of [14C]-
erythromycin (specific activity 50 mCi/mmol) was added. The bacterial suspension 
containing radiolabelled erythromycin was split into two replicate sets: one set of 
triplicate tubes received 0.05 mL of an efflux inhibitor at ½ the MIC, whilst the other set 
of triplicate tubes received an equal volume of PBS. Following incubation at 37ºC for 
16 hours, 1.0 mL aliquots were filtered on Whatman GF/C filters. The filters were 
washed twice with 3.0 mL of cold 100 mM lithium chloride – 50 mM potassium 
phosphate buffer (pH 7.0), dried overnight at 37ºC and transferred to scintillation vials 
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containing the liquid scintillation cocktail ULTIMA GOLD F. The counts per minute 
(CPM) of each triplicate tube of the replicate sets corresponding to [14C]-erythromycin 
that remained inside the cells were obtained with the aid of a Beckman LS6500 
scintillation counter (Beckman Coulter, Fullerton, CA). The data presented are the 
average CPM per replicate set of three tubes.  
 
Screening for mutations in the 23S rRNA gene associated with macrolide 
resistance 
Mycobacterial genomic DNA was extracted using a QIAamp DNA Mini Kit (QIAGEN 
GmbH, Hilden, Germany) according to the manufacturer’s instructions. A 420 bp DNA 
fragment, spanning positions 1886–2305 of domain V of the 23S rRNA gene, was 
amplified by polymerase chain reaction (PCR) using primers 23S FI 
(TTTAAGCCCCAGTAAACGGC) and 23S RIII (GTCCAGGTTGAGGGAACCTT) as 
described previously (Jamal M.A. et al, 2002). The reaction mixture (50 µL) contained 
2.5U of Taq polymerase (Fermentas Inc., Ontario, Canada), 1× Taq buffer (Fermentas 
Inc.), 20 pmol of each primer, 200 mM dNTP and 1.75 mM MgCl2. PCR was conducted 
in a Mastercycler personal 5332 thermocycler (Eppendorf AG, Hamburg, Germany) 
and amplification conditions were as follows: DNA denaturation at 94ºC for 4 minutes; 
35 cycles of denaturation at 94ºC for 1 minute, annealing at 55ºC for 1 minute and 
extension at 72ºC for 1 minute; and a final extension at 72ºC for 10 minutes. 
Amplification products were visualised in 1% agarose gels, purified and sequenced in 
both strands. Sequences were analysed and aligned using the programs BioEdit 
version 7.0.9, and ClustalW, respectively, with reference to the 23S rRNA gene of the 
M. avium 104 genome (GenBank accession no. CP000479.1). 
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Contribution of efflux activity to isoniazid resistance in  
M. tuberculosis complex 
 
VI.1 Summary 
In this work we have induced INH susceptible M. tuberculosis H37Rv (ATCC27294) 
reference strain, M. tuberculosis clinical isolates and M. bovis BCG to high-level 
resistance to INH, by gradual exposure to increasing concentrations of this drug. We 
have used the methodologies developed in the previous chapters to characterize these 
strains with respect to their efflux pump activity and its contribution to INH resistance. 
In particular, M. tuberculosis strains and M. bovis BCG induced to INH resistance were 
evaluated for their susceptibility to this drug in the presence and absence of the efflux 
inhibitors thioridazine, chlorpromazine, verapamil and reserpine, using the BACTECTM 
MGITTM 960 system. The efflux activity was assessed by the semi-automated 
fluorometric method and the expression level of genes coding for efflux pumps was 
quantified by real-time qRT-PCR. It was demonstrated that the efflux inhibitors 
decreased INH resistance in the induced strains, namely, verapamil promoted reversal 
of resistance to susceptibility levels for some of the strains tested. The same efflux 
inhibitors were able to reduce real-time EtBr efflux. Finally, compared to the non-
induced controls, the INH-induced strains showed overexpression of genes coding for 
efflux pumps. Altogether, these results correlate efflux activity with INH resistance in M. 
tuberculosis. The work presented in this last chapter demonstrates that efflux pumps 
play an important role in INH resistance and, ultimately, on the emergence of MDRTB, 
the final goal of this PhD thesis, providing information concerning the role of efflux 
pumps in the development of INH resistance in M. tuberculosis complex. Compounds 
that inhibit efflux activity may prevent the development of this resistance and provide 
the basis for new anti-mycobacterial compounds. 
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VI.2 Introduction 
As already discussed in Chapter I Introduction, TB is still a major public health problem 
accounting for eight million new cases and two million deaths each year (WHO, 2009). 
The emergence of MDRTB and XDRTB has increased the concern of public health 
authorities around the world. MDRTB is defined by the WHO as TB caused by M. 
tuberculosis resistant to at least INH and RIF, whereas XDRTB is resistant not only to 
INH and RIF, but also to any fluoroquinolone and to at least one of the three injectable 
drugs amikacin, kanamycin and capreomycin (WHO, 2008). INH is one of the most 
effective first-line drugs against M. tuberculosis (Bernstein J. et al, 1952), having MICs 
that range from 0.02 to 0.06 mg/L (Youatt J. 1969). The mechanism of action of INH 
has been studied since the 1950’s and several studies demonstrate that this drug 
inhibits the synthesis of the mycolic acids by targeting the enzyme InhA (Vilchèze C. et 
al, 2007; Slayden R.A. et al, 2000). Resistance to anti-TB drugs is often due to the 
occurrence of spontaneous mutations in target genes or regulatory domains, followed 
by selection of the resulting resistant mutants by subsequent treatment with anti-TB 
drugs for which the mutants are resistant (Ramaswamy S. et al, 1998 Louw G.E. et al, 
2009). In the particular case of INH, resistance has been associated with mutations 
located in: (i) katG, the calase-peroxidase responsible for the convertion of INH into its 
active form; (ii) inhA, coding for the target enzyme InhA; (iii) kasA, encoding KasA, a β-
ketoacyl ACP synthase; (iv) oxyR-ahpC, an intergenic region responsible for oxidative 
stress response; and (v) ndh that codes for NADH dehydrogenase (Vilchèze C.  et al, 
2007; Louw G.E. et al, 2009). However, the described mutations do not explain all the 
cases of INH resistance, in fact, approximately 20-30% of clinical resistant M. 
tuberculosis isolates do not have mutations in any of the known genes associated with 
INH resistance (Louw G.E. et al, 2009; Ramaswamy S. et al, 1998; Ramaswamy S. et 
al, 2003). This suggests that other mechanism(s) are involved in the development of 
drug resistance, one of which could be the presence of active efflux pump systems that 
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extrude the anti-TB agent to the exterior of the cell, preventing access to its target 
(Nikaido H., 2001). 
 
In previous studies, we have induced INH susceptible clinical M. tuberculosis isolates, 
as well as the H37Rv (ATCC27294) reference strain, to high-level resistance to INH by 
gradual exposure to increasing concentrations of this drug (Viveiros M. et al, 2002). 
The induced strains were resistant to an INH concentration of 20 mg/L and the transfer 
of these strains to drug-free medium, followed by repeated passages in that medium, 
yielded organisms whose susceptibility to INH was identical to that of the original 
strains. Moreover, this induced high-level resistance to INH could be reduced with a 
subinhibitory concentration of reserpine, a known efflux inhibitor.  
In this chapter, we have continued the work started in 2002, now equipped with the 
rational and technical approaches developed and tested in the previous chapters of this 
thesis, and characterized these strains with respect to their efflux pump activity using 
the following approach: (i) M. tuberculosis strains (reference strain H37Rv and 2 clinical 
isolates) and M. bovis BCG induced to high-level resistance to INH were evaluated for 
their susceptibility to INH in the presence and absence of the efflux inhibitors 
thioridazine, chlorpromazine, verapamil and reserpine; (ii) efflux pump activity in the 
induced strains was detected using the semi-automated fluorometric method; and (iii) 
the  expression level of genes coding for efflux pumps was quantified by real-time qRT-
PCR.  
 
VI.3 Results 
 
VI.3.1 Inducement of resistance to INH in M. tuberculosis complex 
The process of inducement of INH resistance in M. tuberculosis complex was 
previously described and is represented in Figure VI.1 using M. tuberculosis H37Rv as 
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an example (Viveiros M. et al, 2002). The antibiotic susceptibility assay, performed with 
the BACTECTM 460TB and BACTECTM MGITTM 960 systems, for M. tuberculosis 
H37Rv (ATTC27294), two M. tuberculosis clinical strains and M. bovis BCG strain 
Pasteur indicated that each of these strains was susceptible to 0.1 mg/L of INH as well 
as to RIF, PZA, STR and EMB. These cultures remained inside the BACTEC 
instrument for an extended period of time that exceeded the completion of the antibiotic 
susceptibility assay until they yielded evidence of growth. By the end of 28 days after 
the beginning of the INH susceptibility  assay, the growth in all of the cultures with 
initially susceptible isolates reached a level comparable to that for the individual 
controls grown in drug-free medium (Figure VI.1).  
 
Figure VI.1 Induction and reversal of resistance to INH of M. tuberculosis H37Rv reference 
strain (Viveiros M. et al, 2002). The strain (original MIC of 0.05 mg/L) was incubated in medium 
containing 0.1 mg/L of INH for a period of time beyond that required for antibiotic susceptibility 
testing. Growth was observed after 28 days and the strain presented a MIC of 0.2 mg/L, being 
thus designated as having induced INH resistance (induction level 1, IL1). The mycobacteria 
were then exposed to INH at concentrations that corresponded to the MIC for the previous 
passage and after 21 days the resulting cells presented an MIC of 0.5 mg/L (IL2). This process 
was repeated until IL7, at which time the strain was able to grow in the presence of 20 mg/L of 
INH (MIC 40 mg/L). After this point, the strain was repeatedly transferred to drug-free medium 
and the MICs gradually decreased (IL8, IL9, and IL10), reaching the MIC for the initial strain 
(0.05 mg/L) at IL11. The other strains tested were subjected to the same induction procedure, 
with little difference in the amount of time required for the manifestation of induced resistance at 
each induction level.  
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The determination of the MICs for INH showed that these strains presented a higher 
MIC (0.2 mg/L) than the parental INH susceptible strains (0.05 mg/L) and were defined 
as having induced INH resistance (induction level 1, IL1). Aliquots of these cultures at 
IL1 were transferred to fresh BACTEC vials containing a concentration of INH that 
corresponded to the new MIC (0.2 mg/L). These cultures reached full growth by the 
end of 10 to 21 days and were subjected to MIC determination, after which time they 
served as inoculum for the next passage in medium containing a concentration of INH 
that corresponded to the new INH MIC for the strains in the previous passage. This 
process was repeated for five additional serial passages, with each succeeding 
passage containing a concentration of INH that corresponded to the previous MIC for 
the strain with INH induced resistance at IL2, IL3, IL4, IL5, IL6, and IL7. These 
passages were also conducted with solid medium containing equivalent concentrations 
of INH and the plates were evaluated for the numbers of colony forming units (CFUs). 
This procedure yielded strains that were capable of growing in liquid or solid medium 
containing 20 mg/L of INH.  
 
Direct examination of the contents of each vial by the use of identification probes 
indicated that all of the organisms were M. tuberculosis complex. However, unlike the 
parental strains, which were all positive by staining with the Ziehl-Neelsen stain, the 
cells from any given INH containing vial presented variations in acid-fast staining, 
ranging from negative to positive staining status. This variation in acid-fast staining 
could be due to some inhibition of cell-wall mycolic acid synthesis (Vilchèze C. et al, 
2007). The possibility that the potency of INH in the vials had been affected by 
prolonged incubation was ruled out since the medium, when filtered free of cells, was 
as effective as freshly made INH containing medium against M. tuberculosis isolates 
with proven INH susceptibility (data not shown).  
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After reaching IL7 induction point at which the INH induced strains were capable of 
growing at 20 mg/L of INH (MIC 40 mg/L), the strains were repeatedly transferred to 
drug-free medium. This promoted a gradual decrease of the MIC for INH (IL8, IL9, and 
IL10), reaching the MIC for the original parent strains (0.05 mg/L) at IL11.  
 
VI.3.2 Detection of efflux activity in INH induced M. tuberculosis complex strains  
The efflux activity of M. bovis BCG INH induced strain (M. bovis BCGINH) was assessed 
by the semi-automated fluorometric method and compared with the parental non-
induced strain. This was only determined for M. bovis BCG due to the biosafety 
requirements concerning M. tuberculosis (biosafety level III). By this manner, all the 
real-time fluorometric assays for the detection of efflux activity were performed using 
M. bovis BCG (biosafety level II) as a model for M. tuberculosis. The accumulation of 
increasing concentrations of EtBr by M. bovis BCG and M. bovis BCGINH is presented 
in Figure VI.2. As already demonstrated in previous studies, this assay allows the 
selection of the highest concentration of EtBr that does not cause accumulation of EtBr 
and defines the baseline transport equilibrium between influx and efflux of EtBr, as 
explained in Chapter III of this thesis (Paixão L. et al, 2009; Rodrigues L. et al, 2008; 
Viveiros M. et al, 2008a). In this case, accumulation of EtBr under conditions that are 
considered to maximize efflux, i.e., presence of glucose and 37ºC, begins to take place 
at a concentration of 0.125 mg/L of EtBr for the M. bovis BCG non-induced strain, 
whereas for M. bovis BCGINH accumulation of EtBr starts only at 0.25 mg/L. Moreover, 
the INH induced strain shows decreased accumulation even at higher EtBr 
concentrations when compared to the non-induced strain (Figure VI.2. - Compare the 
accumulation curves for the same EtBr concentration, between the two strains). This 
increased ability of M. bovis BCGINH to handle higher concentrations of EtBr further 
supports the hypothesis that the INH induction process renders the bacteria resistant to 
this drug by the overexpression of efflux system(s) and our assumption that EtBr and 
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INH are substrates of the same panel of efflux pumps. These results are in accordance 
with the MICs of EtBr determined for these strains (Table VI.1). Moreover, the 
accumulation of EtBr, used at the above concentrations, increased in the presence of 
the efflux inhibitors verapamil, thioridazine and chlorpromazine, but only marginally with 
reserpine. It is important to note that, as previously explained, each efflux inhibitor was 
used at ½ of the MICs determined for test their inhibitory potential. From the analysis of 
Figure VI.4, it is possible to conclude that the increase in accumulation of EtBr seen in 
Figure VI.3 is due to the inhibition of efflux pumps. Efflux of EtBr is observed at 37ºC in 
the presence of glucose and is inhibited in the presence of the same efflux inhibitors. 
These results suggest the presence of an intrinsic efflux system in M. bovis BCG that 
extrudes EtBr and is inhibited by thioridazine, chlorpromazine and verapamil. In M. 
bovis BCGINH this efflux system(s) present an increased activity that enables the 
bacteria to extrude higher concentrations of EtBr than the parental strain.  
 
Chapter VI - Contribution of efflux activity to isoniazid resistance in M. tuberculosis complex 
____________________________________________________________________________________ 
 
_____________________________________________________________________________ 
 
158 
 
0
10
20
30
40
50
60
70
80
90
100
0 10 20 30 40 50
Time (min)
Fl
u
o
re
sc
en
ce
 
(ar
bi
tr
ar
y 
u
n
its
) 8 mg/L EtBr
4 mg/L EtBr
2 mg/L EtBr
1 mg/L EtBr
0.5 mg/L EtBr
0.25 mg/L EtBr
0.125 mg/L EtBr
0.0625 mg/L EtBr
A
B
0
10
20
30
40
50
60
70
80
90
100
0 10 20 30 40 50
Time (min)
Fl
u
o
re
sc
en
ce
 
(ar
bi
tr
ar
y 
u
n
its
)
8 mg/L EtBr
4 mg/L EtBr
2 mg/L EtBr
1 mg/L EtBr
0.5 mg/L EtBr
0.25 mg/L EtBr
0.125 mg/L EtBr
0.0625 mg/L EtBr
Fl
u
o
re
sc
en
ce
 
(ar
bi
tr
ar
y 
u
n
its
)
Fl
u
o
re
sc
en
ce
 
(ar
bi
tr
ar
y 
u
n
its
)
 
Figure VI.2. Accumulation of increasing concentrations of EtBr (0.0625 – 8 mg/L) by (A) M. 
bovis BCG and (B) M. bovis BCGINH. 
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Figure VI.3. Effect of verapamil (VP), thioridazine (TZ), chlorpromazine (CPZ) and reserpine 
(RES) in the accumulation of EtBr by (A) M. bovis BCG (0.125 mg/L EtBr) and (B) M. bovis 
BCGINH (0.25 mg/L EtBr). 
. 
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Figure VI.4. Efflux of EtBr by by (A) M. bovis BCG and (B) M. bovis BCGINH. M. bovis BCG was 
loaded with 0.125 mg/L of EtBr, whereas the INH induced strain was loaded with 1 mg/L of 
EtBr, both in the presence of verapamil at ½ MIC. Efflux of EtBr took place at 37ºC in the 
presence of glucose and was inhibited by the efflux inhibitors used at ½ MIC.  
EPI, efflux pump inhibitor; CPZ, chlorpromazine; RES, reserpine; TZ, thioridazine; VP, 
verapamil.  
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VI.3.3 Evaluation of gene expression in INH induced M. tuberculosis complex 
strains  
The quantification of the expression of selected genes coding for efflux pumps M. 
tuberculosis complex by qRT-PCR analysis was performed for the M. bovis BCG and 
M. tuberculosis strains induced to INH. As shown in Figure VI.4, exposure to INH 
promoted the over-expression of mmr, mmpL7, tap, efpA and p55 in M. tuberculosis 
H37RvINH, 737/99INH and 711/99INH, although at a lesser extent in the latter. In the 
particular case of M. bovis BCGINH, only p55, mmpL7 and mmr showed 
overexpression. It is important to stress the absolute level of overexpression (20-40 
times) reached at certain measurements once compared to their non-induced 
counterparts in the absence of INH. It clearly demonstrates that overexpression of 
efflux pumps is an intrinsic mechanism of resistance that M. tuberculosis uses to 
reduce the level of INH that reaches the activation process inside the mycobacterial 
cell and further on inhibits the mycolic acid synthesis. 
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Figure VI.5. Relative expression of genes coding for efflux pumps in M. tuberculosis H37Rv and 
clinical strains and M. bovis BCG induced to INH compared with their non-induced counter parts 
in the absence of INH. A ratio of 1 corresponds to no alterations in expression compared with 
untreated control cells. 
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The efflux pumps MmpL7, Tap and EfpA have been associated with INH efflux in other 
studies (Doran J.L. et al, 1997; Pasca M.R. et al, 2005; Siddiqi N. et al, 2004). In the 
case of P55 although no study until now has demonstrated its association with INH 
extrusion, this pump is responsible for efflux-mediated resistance to other compounds 
such as aminoglycosides, TET and RIF (Ramon-Garcia S. et al, 2009; Silva P.E. et al, 
2001). Concerning Mmr, a recent study based in microarray analysis has reported the 
overexpression of mmr along with other genes coding for efflux pumps after exposure 
to a combination of INH and EMB. Moreover, this pump has been associated with 
resistance to TPP, EtBr, ERY and acriflavine (De Rossi E. et al, 1998b). In summary, 
these results further demonstrate that the INH induced strains present an increased 
efflux activity that is associated with INH resistance. 
 
VI.3.4 Effect of efflux inhibitors in INH resistance of INH induced M. tuberculosis 
complex strains  
Since the induction of resistance to INH may be due to the activation or induction of an 
efflux mechanism(s), the MICs of INH for the induced strains at 20.0 mg/L of INH were 
also determined in the presence of the efflux inhibitors thioridazine, chlorpromazine, 
verapamil and reserpine. These inhibitors were used at ½ the MIC (Table VI.1) in order 
to ensure bacterial viability and their effect of the MIC of INH for these strains is 
summarized by Table VI.2. The efflux inhibitor verapamil promoted a significantly 
reduction (at least a 4-fold reduction) of the MIC of INH in all of the strains tested. 
Moreover, it caused the reversal of resistance to INH to a level similar to the fully INH 
susceptible wild-type counterparts of the induced H37RvINH and BCGINH. Concerning 
the other inhibitors tested, chlorpromazine only had a significant effect in the case of 
BCGINH, whereas reserpine and thioridazine caused only a marginal reduction (one 
dilution factor) of the MIC for all of the strains tested. The lower inhibitory activity 
detected in this study for the efflux inhibitor reserpine, compared with the studies of 
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2002 (Viveiros M. et al, 2002), might be explained by the use in this study of a different 
and much more accurate growth system, the BACTECTM MGITTM 960 system equipped 
with the Epicenter V5.53A software and the TB eXIST module.  
 
Table VI.1 MICs for thioridazine, chlorpromazine, verapamil, reserpine and EtBr against M. 
tuberculosis H37Rv and clinical strains induced to resistance to INH. 
Strains 
MICs (mg/L) 
TZ CPZ VP RES EtBr 
M. tuberculosis  
H37Rv – 711/99 – 737/99 
10 20 320 320 0.5 
M. tuberculosis H37RvINH 10 20 320 320 4 
M. tuberculosis 711/99INH 10 20 320 320 4 
M. tuberculosis 737/99INH 10 20 320 320 4 
M. bovis BCG 10 20 320 320 0.5 
M. bovis BCGINH 20 20 320 320 4 
EtBr, ethidium bromide; CPZ, chlorpromazine; RES, reserpine; TZ, thioridazine; VP, verapamil. 
 
Table VI.2 MICs for INH in the presence and absence of thioridazine, chlorpromazine, 
verapamil and reserpine against M. tuberculosis H37Rv and clinical strains and M. bovis BCG 
induced to resistance to INH. 
Strains 
MICs (mg/L) 
INH INH + TZ INH + CPZ INH + VP INH + RES 
M. tuberculosis  
H37Rv – 711/99 – 737/99 
0.05 0.05 0.05 0.05 0.05 
M. tuberculosis H37RvINH 40 20 20 0.0625 20 
M. tuberculosis 711/99INH 40 20 20 1.25 20 
M. tuberculosis 737/99INH 40 20 20 1.25 20 
M. bovis BCG 0.05 0.05 0.05 0.05 0.05 
M. bovis BCGINH 40 20 10 0.0625 20 
CPZ, chlorpromazine; INH, isoniazid; RES, reserpine; TZ, thioridazine; VP, verapamil. Data in bold represents at least a 
4-fold reduction, considered to denote significant synergistic effect between the antibiotic and the EPI. 
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VI.4 Conclusions 
The process of in vitro inducement of INH resistance by exposure to INH may 
reproduce what occurs during anti-TB therapy using INH and may account for the 
remainder of the INH resistance that is not caused by mutations. In fact, only about 70 
to 80% of INH resistant M. tuberculosis isolates present mutations in any of the genes 
associated with INH resistance, which suggests that other mechanisms, such as efflux 
activity, can be responsible for the emergence of resistance to this drug.  
The results presented in this chapter show that when INH susceptible M. tuberculosis 
complex strains are gradually exposed to increasing concentration of this drug for a 
prolonged period of time, they can become resistant to 20 mg/L of INH (MIC 40 mg/L). 
This induced resistance to INH occurs via a mechanism that does not involve 
mutations in any of the genes associated with INH resistance, but by an efflux system 
that is sensitive to efflux inhibitors. This induced resistance can also be reversed by 
consecutive passage of the induced strains in drug-free medium.  
The use of the semi-automated fluorometric method applied to M. bovis BCG (as a 
model for M. tuberculosis) allowed the detection of an increased efflux of EtBr in the 
INH induced strains, which was inhibited in the presence of thioridazine, 
chlorpromazine and verapamil. The same inhibitors also reduced the MIC of INH in the 
induced strains and, in particular, verapamil caused reversal of resistance in some of 
the strains tested. These results were further supported by the quantification of the 
expression level of genes coding for efflux pumps that showed overexpression of mmr, 
p55, mmpL7, tap and efpA for the tested strains relatively to the non-induced parental 
strains. 
In conclusion, efflux is an important factor in the development of INH resistance in M. 
tuberculosis complex that creates conditions for the survival of distinct elements of the 
M. tuberculosis population infecting the patient, those that are able to overexpress 
efflux pumps and resist due to this mechanism. This response stresses the need for 
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compliance of the multidrug regimen against TB, especially at the first 2 months. If this 
subpopulation survives the initial treatment there will be an increased possibility of 
emergence of genetic mutants to INH that can progress to acquire mutations to other 
anti-TB drug, namely RIF, and thus establish MDRTB. 
With the increase of MDRTB strains and the emergence of XDRTB, there are fewer 
alternatives left to treat the most serious cases of TB. Thus, the identification and 
development of efflux inhibitors that can restore the antimicrobial activity of the 
antibiotic subject to efflux, is an approach that can be useful in order to prevent the 
emergence of this resistance and for the development of new effective anti-TB drugs.  
The results and conclusions obtained in this chapter are presently being object of 
compilation for publication. 
 
VII.5 Materials and Methods 
 
Materials 
Middlebrook 7H9 broth and OADC supplement were purchased from Difco (Detroit, 
MI., U.S.A.). INH, EtBr, glucose, PBS, Tris base, ethylenediaminetetraacetic acid 
(EDTA), chlorpromazine, thioridazine, verapamil and reserpine were purchased from 
Sigma-Aldrich Química SA (Madrid, Spain). All solutions were prepared on the day of 
the experiment.  Materials and equipment used to test the antibiotic susceptibilities of 
the M. bovis BCG and M. tuberculosis strains tested with the BACTECTM 460TB and 
BACTECTM MGITTM 960 systems were purchased from Becton Dickinson Diagnostic 
Instrument Systems (Sparks, Md., U.S.A.) and were prepared according to the 
recommendations of the manufacturer. 
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Bacteria 
M. tuberculosis H37Rv (ATCC27294) and two M. tuberculosis clinical strains, isolated 
from untreated patients and shown to be susceptible to INH, RIF, STR and EMB, were 
previously induced to high-level resistance to INH by consecutive passages of the 
mycobacteria into media containing increasing concentrations of the antibiotic (Viveiros 
M. et al, 2002). M. bovis BCG strain Pasteur was also induced to high-level resistance 
to INH in the present study. 
 
Determination of minimum inhibitory concentrations in the BACTECTM MGITTM 
960 system 
The MIC for the efflux inhibitors thioridazine, chlorpromazine, verapamil and reserpine 
and for INH in the presence and absence of an efflux inhibitor was determined by the 
BACTECTM MGITTM 960 system equipped with the Epicenter V5.53A software and the 
TB eXIST module (Springer B. et al, 2009). Briefly, the mycobacteria were grown in 
MGIT tubes containing Middlebrook 7H9 broth until the growth index (GI) reached 100-
200 and used as the inocula. MGIT tubes were prepared with serial dilutions of each 
compound. All of the drug-containing vials were inoculated with 0.5 mL of the bacterial 
suspensions prepared as described above. Two drug-free controls were included with 
each test; one inoculated with 0.5 mL of the suspension and the other inoculated with 
0.5 mL of a 1:100 dilution of the suspension. The vials were incubated at 37°C and 
read in a BACTECTM 960 reader every day until the GI in the control diluted 1:100 
reached 100-200. MIC was defined as the lowest dilution that was negative in drug-
containing tubes when the control diluted 1:100 turned positive.  
 
Inducement of resistance to isoniazid 
The induction of M. tuberculosis H37Rv (ATCC27294) reference strain and four clinical 
strains to a high-level of INH resistance (20 mg/L) was performed in a BACTECTM 
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460TB (Becton Dickinson), as previously described (Viveiros M. et al, 2001). Briefly, 
the susceptibilities of the strains to INH were determined by the BACTECTM 460TB 
system and the vials retained in the incubator for an additional period of time. By the 
end of 28-34 days, all of the vials yielded evidence of growth and a new MIC 
determination was performed. Aliquots of 0.1 mL from cultures growing at an INH 
concentration just below the MIC were inoculated into fresh vials containing the lowest 
INH concentration that had completely inhibited the growth of the previous population. 
This process was repeated for five additional consecutive passages, with each 
passage containing a stepwise increase in the concentration of INH corresponding to 
the lowest concentration that had inhibited growth in the previous passage. This 
process yielded M. tuberculosis isolates that were capable of growing in medium 
containing 20 mg/L of INH.  
In this study we have also induced M. bovis BCG strain Pasteur to INH resistance (20 
mg/L) using the BACTECTM MGIT 960. Briefly, the susceptibility of the strain to INH 
was determined by the BACTECTM MGITTM 960 system and the MGIT tube (containing 
0.1 mg/L of INH) was retained in the BACTEC instrument for an additional period of 34 
days, after which a GI of 75 was reached indicating evidence of growth. The MIC for 
INH was determined and aliquots of 0.1 mL from cultures growing at an INH 
concentration just below the MIC were inoculated into new MGIT tubes containing the 
lowest INH concentration that had completely inhibited the growth. This procedure was 
repeated for seven consecutive passages, each containing a stepwise increase in the 
INH concentration corresponding to the lowest concentration that had inhibited growth 
in the previous passage. At the end of this process, the M. bovis BCG strain Pasteur 
with an original MIC for INH of 0.05 mg/L was capable of growing in medium containing 
20 mg/L of INH (MIC 40 mg/mL).  
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Semi-automated fluorometric method 
The semi-automated fluorometric method was used for the detection and quantification 
of efflux pump activity in the studied mycobacterial strains.  
(i) Accumulation assay. Mycobacterial cultures at mid-log phase (O.D.600 of 0.8) were 
centrifuged at 13000 rpm for 3 minutes, the supernatant discarded and the pellet 
washed and resuspended in PBS. After adjusting the O.D.600 to 0.4, glucose at 0.4% 
was added and, in order to determine the lowest concentration of EtBr that caused 
accumulation, aliquots of 0.005 mL were transferred from stock solutions of EtBr to 
yield final concentrations of EtBr that ranged from 0.0625 to 10 mg/L. Aliquots of 0.1 
mL were distributed to replicate sets of 0.2 mL PCR microtubes, which were placed 
into a 36-well rotor in the Rotor-GeneTM 3000, and the fluorescence measured using 
the 530 nm band-pass and the 585 nm high-pass filters as the excitation and detection 
wavelengths, respectively. Fluorescence data was acquired every 60 seconds for 60-
90 minutes. After the selection of the highest EtBr concentration that did not cause 
accumulation, the effect of the efflux inhibitors thioridazine, chlorpromazine, verapamil 
and reserpine on the accumulation of EtBr was evaluated at 37ºC, in the presence or 
absence of glucose.  
(ii) Efflux assay. The mycobacteria were loaded with EtBr using the conditions that 
promoted accumulation: accumulation of EtBr in the presence of the most effective 
efflux inhibitor; absence of glucose; and incubation at 25ºC for 60 minutes (Rodrigues 
L., 2008; Viveiros M., 2008). In the M. tuberculosis strains tested in this work the most 
effective EPI was verapamil (Figure VI.3). Subsequently, the EtBr-loaded cells were 
centrifuged at 13000 rpm for 3 minutes and resuspended in EtBr-free PBS with or 
without 0.4% glucose. After adjusting the O.D.600 to 0.4, aliquots of 0.095 mL were 
transferred to 0.2 mL microtubes and the efflux inhibitors added to the respective 
tubes. The fluorescence emitted was measured on a real-time basis, as described for 
the accumulation assay. The efflux activity was quantified by comparing the data 
Chapter VI - Contribution of efflux activity to isoniazid resistance in M. tuberculosis complex 
____________________________________________________________________________________ 
 
_____________________________________________________________________________ 
 
169 
 
obtained under optimum efflux conditions (incubation at 37ºC, presence of glucose and 
absence of efflux inhibitor) with the data relative to the EtBr-loaded cells in conditions 
that minimize efflux (presence of efflux inhibitor and no glucose). Thus, the relative 
fluorescence corresponds to the ratio of fluorescence that remains per unit of time, 
relative to the EtBr-loaded cells. 
 
Quantification of gene expression by real-time qRT-PCR 
The quantification of the expression level of genes coding for efflux pumps by real-time 
qRT-PCR was carried out by comparing the mRNA levels extracted from the strains 
induced to resistance to INH with the mRNA extracted from the susceptible non-
induced counterparts (normalised against a reference gene). Total RNA was isolated in 
an RNase-free environment with the aid of the RNeasy Mini Kit (QIAGEN, Hilden, 
Germany), according to the manufacturer’s instructions. Mycobacteria were grown in 
the BACTECTM MGITTM 960 system until the GI reached 100-200. Aliquots of 0.5 mL 
were taken from the cultures and added to 1 mL of RNA Protect Bacteria Reagent. 
After 5 minutes of incubation at room temperature, the bacteria were harvested at 9000 
rpm for 10 minutes, the bacterial pellet ressuspended in 0.1 mL of TE buffer (10 mM 
Tris-HCl, 1 mM EDTA pH 8.0) and incubated for 10 minutes at 95ºC. The tubes were 
cooled at room temperature and lysozyme at a final concentration of 3 mg/mL was 
added. After an incubation period of 10 minutes at room temperature, buffer RLT + 1% 
β-mercaptoethanol (0.350 mL) was added and the tubes sonicated for 15 minutes at 
room temperature. After sonication, the samples remained for 15 minutes at room 
temperature, followed by centrifugation at 13000 rpm for 2 minutes. The supernatant 
was transferred to a new microcentrifuge tube and 0.250 mL of ethanol was added. 
The sample was applied to an RNeasy mini column (placed in a 2 mL collection tube) 
and the RNA extracted with the RNeasy mini kit (QIAGEN), according to the 
manufacturers instructions. Digestion of contaminant DNA with DNAse I was carried 
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out for 2 hours at room temperature. Purified RNA was stored in RNase-free water and 
maintained at -20ºC until quantification was performed. 
The primers (table VI.3) were designed using Primer Express 1.5 Software (Applied 
Biosystems, CA, USA) based on the sequence entries in the GenBank for M. 
tuberculosis H37Rv complete genome (accession number NC_000962). 
 
Table VI.3: Primers used in this study 
Gene  Primer sequence (5’-3’) 
Length of 
amplicon 
Ref. 
16S rDNA 
Fw_CAAGGCTAAAACTCAAAGGA 
Rv_GGACTTAACCCAACATCTCA 
197 This study 
rv2942 (mmpL7) 
Fw_TACCCAAGCTGGAAACAA 
Rv_CCGTCAGAATAGAGGAACAG 
214 This study 
rv1258c (tap) 
Fw_AGTTATAGATCGGCTGGATG 
Rv_GTGCTGTTCCCGAAATAC 
268 This study 
rv1410c (p55) 
Fw_AGTGGGAAATAAGCCAGTAA 
Rv_TGGTTGATGTCGAGCTGT 
198 This study 
rv2846c (efpA) 
Fw_ATGGTAATGCCTGACATCC 
Rv_CTACGGGAAACCAACAAAG 
131 This study 
rv3065 (mmr) 
Fw_AACCAGCCTGCTCAAAAG 
Rv_CAACCACCTTCATCACAGA 
221 This study 
 
The assay was performed in a Rotor-GeneTM 3000 thermocycler (Corbett Research) 
strictly adhering to manufacturer recommendations of the QuantiTect SYBR Green RT-
PCR Kit (QIAGEN, Hilden, Germany). Briefly, each 0.2 ml microfuge tube contained 10 
µL of the 2x QuantiTect SYBR Green RT-PCR master mix, 0.2 µL of 10x QuantiTect 
RT mix, 5 pmol of each primer, approximately 20 ng of total RNA and RNase-free 
water to complete a final volume of 20 µL. Thermal cycling conditions were as follows: 
reverse transcription for 30 minutes at 50ºC; Initial activation step of 15 minute at 95ºC; 
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40 cycles of denaturation at 94ºC for 30 seconds, annealing at 52ºC for 30 seconds 
and extension at 72ºC for 30 seconds; a final extension step at 72ºC for 5 minutes; and 
an additional step at 52ºC for 15 seconds followed by melt analysis (50-99ºC). The 
relative quantities of the mRNA of each gene of interest were determined by the use of 
the comparative threshold cycle (CT) method (Livak K.J. et al, 2001). 
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Final Conclusions and Future Perspectives 
 
VII.1 Final Conclusions 
This thesis focused on the study of the contribution of efflux systems to the 
development of bacterial drug resistance, with the final objective consisting in the 
evaluation of the role of efflux activity in the resistance of M. tuberculosis to INH. In 
order to detect efflux activity and to evaluate its contribution to the development of drug 
resistance, several techniques had to be developed and optimized using experimental 
models like E. coli, M. smegmatis and M. avium complex prior to their application to M. 
tuberculosis. This approach had to do with the limitations associated with M. 
tuberculosis manipulation in the laboratory: this organism is not only a biosafety level III 
pathogen, but also presents a very slow growth rate (replication cycle of 24 hours). 
Using experimental models it is possible to develop and optimize the basic 
experimental conditions in a shorter period of time, thus minimizing the time consuming 
aspect of working with M. tuberculosis. At the same time, the use of E. coli, M. 
smegmatis and M. avium complex as models allowed to gain more insight of their 
efflux-mediated resistance mechanisms that was expected to be fairly similar to what 
occurs in M. tuberculosis.  
 
The development of a qRT-PCR protocol in E. coli provided the basis for the later 
application of this methodology to M. tuberculosis, but also allowed further insight into 
the mechanisms that are responsible for the interplay between efflux activity and 
permeability of the cell envelope that occur after exposure of E. coli to TET. By this 
manner, it was possible to create a model showing the sequence of events regarding 
the regulation process that increase the expression of efflux pumps and decrease the 
porin content of the cell wall. The model shows that there is an early stress response to 
exposure to non-lethal concentrations of TET that promotes the activation of global 
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regulators like MarA, SoxS and Rob and of periplasmic proteases that regulate the two 
major outer membrane proteins OmpC and OmpF. This is followed by a long-term 
adaptative response caused by the increase of MarA that is responsible for (i) the 
overexpression of AcrAB-TolC and other efflux systems and (ii) the overexpression of 
MicF and OmpX, downregulators of OmpC and OmpF. This process results in a 
reduced permeability due to a decreased porin content and in an increased efflux 
activity, thus establishing the basis for the development of an MDR phenotype (Viveiros 
M. et al, 2007). 
The other method that was developed through the course of this thesis was the semi-
automated fluorometric method, which allowed the correlation of the results of gene 
expression quantification with the real-time detection of efflux activity. This method 
allows not only the detection of efflux of EtBr, but also the screening of compounds for 
activity against efflux pumps (Viveiros M. et al, 2008a, Viveiros M. et al, 2008b, 
Viveiros M. et al, 2010a). Moreover, this method was also used to develop a 
mathematical model that quantifies efflux activity, using EtBr as a substrate. The use of 
E. coli as a model allowed the standardization of the experimental conditions, but also 
showed the method’s ability to detect differences in the EtBr efflux activity between 
strains that differ in their efflux pump expression (Paixão L. et al, 2009). Moreover, the 
use of the semi-automated method applied to M. smegmatis strains that differ in their 
porin content or efflux activity, demonstrated the main pathways for entry and extrusion 
of EtBr from these mycobacteria (Rodrigues L. et al, 2010). In particular, the role of 
MspA was put in evidence as being extremely important for EtBr entry into the cell, 
whereas the efflux pump LfrA was shown to be highly associated with EtBr extrusion, 
as already reported by other studies (Li X.Z. et al, 2004).  
Encouraged by the previous results, the work evolved towards more pathogenic 
mycobacterial species, in this case M. avium as a pathogenic model for M. 
tuberculosis. The study of the role of efflux pumps in antimicrobial resistance in M. 
avium complex provided evidence that efflux plays a role in drug resistance in this 
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clinical relevant mycobacteria (Rodrigues L. et al, 2008; Rodrigues L. et al, 2009). In 
particular, this efflux-mediated resistance was demonstrated in M. avium complex 
clinical isolates resistant to macrolides, such as clarithromycin and erythromycin 
(Rodrigues L. et al, 2009). In this study, the semi-automated method coupled with the 
determination of MICs in the presence and absence of efflux inhibitors allowed the 
detection of an increased efflux activity in M. avium complex clinical isolates and that 
was inhibited in the presence of efflux inhibitors. Moreover, the efflux assays 
highlighted the efflux activity in four high-level resistant M. avium complex strains (two 
M. avium and two M. intracellulare), demonstrating that besides the presence of 
mutations in the 23S rRNA gene in three of these strains, this high-level resistance also 
results from efflux activity, as already suggested by the reduction of MICs for 
clarithromycin and erythromycin in the presence of the efflux inhibitors. Furthermore, 
the tested inhibitors also caused an increased retention of radiolabelled erythromycin 
inside the mycobacterial cell, further supporting the presence of active efflux pump 
system(s) (Rodrigues L. et al, 2008; Rodrigues L. et al, 2009). Based on their activity in 
the reduction of resistance of M. avium complex to macrolides, these efflux inhibitors 
were selected for further studies in M. tuberculosis. 
 
The final goal of this thesis was the application of the developed methodologies to the 
study of the contribution of efflux pumps to INH resistance in M. tuberculosis complex. 
M. bovis BCG strain Pasteur and M. tuberculosis reference and clinical strains were 
induced to resistance to INH by a step-wise increase of antibiotic concentration over a 
prolonged period of time until they became resistant to 20 mg/L of INH (Viveiros M. et 
al, 2002). The evaluation of efflux pump activity in the M. bovis BCG INH induced strain 
by the semi-automated fluorometric method demonstrated an increased efflux of EtBr 
that was inhibited in the presence of thioridazine, chlorpromazine and verapamil. These 
inhibitors also promoted the reduction of the MIC of INH in the induced strains. In 
particular, verapamil was responsible for the reversal of resistance in some of the 
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strains tested. Moreover, qRT-PCR analysis showed that the INH resistance 
inducement process caused the overexpression of genes coding for the efflux pumps 
mmr, p55, mmpL7, tap and efpA in the induced strains relatively to their non-induced 
counterparts. Altogether, these results suggest that efflux pumps are involved in the 
development of INH resistance and that efflux inhibitors can be used to prevent this 
resistance and, ultimately, the emergence of MDRTB (Rodrigues L. et al, unpublished 
data). 
 
In conclusion, the main objective of this thesis was the demonstration that efflux 
mechanisms are involved in the development of multidrug resistance in M. tuberculosis 
and how phenotypic resistance, mediated by efflux pumps, correlates with genetic 
resistance. This objective was achieved and the tools developed and optimized in this 
thesis connected with molecular modelling can lead to the development of new anti-TB 
drugs or enhancers of the activity of the already existing anti-TB drugs, as well as new 
methods for the in vitro testing of putative efflux inhibitors. These non-antibiotic 
inhibitors would restore the activity of the antibiotic subject to efflux, by acting directly 
upon the protein structure of the pump or by a decrease in the level of activity and 
expression of the efflux pump, and therefore provide an easy way to enhance the 
activity of already existent anti-TB drugs. 
 
As a corollary of this work, we have also been able to demonstrate the fact that 
increased activity of efflux pumps can occur in response to prolonged exposure to 
subinhibitory concentrations of anti-TB compounds, a common situation that results 
from inadequate TB therapy, which allows the survival of a population increasingly 
resistant to the anti-TB compound and might be the basis for the maintenance of an 
increased mycobacterial population in the patient undergoing therapy. 
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VII.2 Future perspectives 
The results gathered in this thesis demonstrate that induced resistance of M. 
tuberculosis to INH is not due to the selection of a mutation that bestows INH 
resistance, but rather to the inducement of efflux activity by some efflux pump which 
extrudes the antibiotic prior to its reaching its intended target. 
The primary and most obvious perspective to expand this work will be the genetic 
characterization and the description of the mode of action of the M. tuberculosis efflux 
pumps we have been able to demonstrate are connected with INH resistance.  
Secondly, because efflux inhibitors have the ability to reverse the induced INH 
resistance, further proven by others (Rossi E. et al, 2006; Gumbo et al, 2007), the 
potential use of efflux inhibitors as helper-compounds in the anti-TB standard therapy 
to improve the compliance and the outcome, as well as to decrease the probability of 
emergence of acquired resistance, is the obvious perspective to be explored in the 
future. The in vitro situations simulated in this thesis are considered to mimic what 
takes place in the patient who receives an anti-TB drug for a long period of time and 
each time at a dose level that allows the survival of the bacteria. The demonstration of 
extrusion of a large variety of agents by phenotypically MDR bacteria has fostered a 
search for agents that can inhibit efflux pumps and, hence, render ineffective antibiotics 
effective again.  
 
Thirdly, and because efflux pumps of prokaryotic and eukaryotic cells share a high 
degree of functional homology (Amaral L. et al, 2007), efflux inhibitors will also affect 
the efflux pumps present in eukaryotic cells and in recent studies it has been 
demonstrated that many of these compounds, like verapamil or the phenothiazines, 
inhibit the transport of Ca2+ and K+ by eukaryotic efflux pumps and, when used at 
therapeutically dosages, cause non-killing macrophages to kill phagocytosed bacteria 
by this double effect on the bacteria cell and on the host cell (Martins M. et al, 2009, 
Amaral L. et al, 2010, Viveiros M. et al, 2010b). Therefore, since pulmonary TB is 
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mainly an intracellular infection of the alveolar macrophage, a cell that has little killing 
activity of its own, M. tuberculosis can reside in a viable state within its phagosome 
prison for many years. If a compound is to be effective for the therapy of a TB patient, 
the activity of the compound against the M. tuberculosis strain isolated from the patient 
would be best evaluated if the macrophage that is to phagocytose the organism is 
obtained from that same patient. Employing this approach should result in the best 
predictive situation for the selection of effective anti-TB agents. This approach requires 
the preparation of human non-killing macrophages obtained from the MDRTB/XDRTB 
infected patient’s peripheral blood prior to the patient receiving any therapy, allowing 
the rapid screening of new anti-TB drugs, the evaluation of effectiveness of combined 
therapies and the patient’s directed selection of the most effective therapy against TB 
and/or MDRTB/XDRTB (Viveiros M. et al, 2010b).  
Finally, it’s our future perspective to contribute to the enormous task of controlling and 
preventing the spread of drug resistant TB. 
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